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ABSTRACT 
Nodal is a potent embryonic morphogen belonging to the TGF-beta superfamily. 
Typically, it binds to the Alk4/ActRIIB receptor complex in the presence of the 
co-receptor Cripto-1. Nodal expression is physiologically restricted to 
embryonic tissues and human embryonic stem cells and is absent in normal cells, 
including melanocytes. However it re-emerges in a number of human cancers, 
including melanoma, breast and colon cancer. Recent studies indicate that Nodal 
expression correlates with melanoma tumor progression toward a metastatic 
phenotype, indeed inhibition of the Nodal pathway also blocks the tumorigenic 
capacity and the plasticity of aggressive human melanoma cells. Recently, also 
Cripto-1 expression has been correlated to the pathogenesis and progression of 
human melanoma tumor. These findings suggest the hypothesis that inhibition of 
the Nodal-Cripto-1 signaling, which is supported by a direct binding between the 
two proteins, is a valid therapeutic approach against melanoma and increases the 
interest for Nodal as both a diagnostic or prognostic marker and as a potential 
new target for therapeutic intervention against melanoma. With the aim to 
produce molecules able to recognize Nodal and to block the signaling by 
preventing the association with Cripto-1, we have generated and screened a set 
of monoclonal antibodies targeting a major CBR (Cripto-Binding-Region) site 
which encompasses residues around Glu49 and Glu50 of human Nodal involved 
in the interaction with Cripto-1. 
With this approach, we have selected one, named 3D1, which strongly associates 
(KD about 1.4 nM) with full-length rhNodal. The selected mAb has been 
successfully tested for its ability to recognize endogenous Nodal protein in a 
panel of melanoma cell lines by both western blot and FACS analyses. 
Furthermore, the antibody inhibits the binding of Nodal to Cripto-1, as 
demonstrated by competitive SPR assays and, most importantly, blocks the 
Nodal-dependent activation of Smad2/3 in melanoma cancer cells. Notably, the 
antibody also blocks the Cripto-independent Nodal signalling converging on the 
MAPKs, as demonstrated by the concomitant effective blocking of MAPK 
activation. Given the autocrine mechanism of activation of Nodal (Smad2/3 
regulate through Smad4 the expression of Nodal itself), the antibody also has the 
ability to reduce Nodal expression in the supernatants of C8161 cells. In 
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addition, it is also effective in reducing the C8161 clonogenicity and the typical 
vasculature-like phenotype induced by Nodal (vasculogenic mimicry). 
Remarkably, 3D1 in vivo strongly reduces lung colonization induced by C8161 
metastatic cells, injected in mice. Moreover, immunohistochemical analyses 
revealed the ability of the 3D1 to affect the progression of the cell cycle by 
reducing Cyclin B1 and concurrently increasing p27 expression.   
The data accumulated on the 3D1 anti-Nodal mAb are all supportive of a huge 
diagnostic and therapeutic potential of this reagent. Next steps are therefore 
devoted to antibody affinity maturation to increase binding and selectivity and to 
humanization, to pave the way to in vivo experiments on human cells and 
tissues. 
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                                           I 1. INTRODUCTION 
 
  
1.1 THE SUPERFAMILY OF THE TRANSFORMING GROWTH 
FACTOR-BETA (TGF-β) 
The transforming growth factor-β (TGF-β) superfamily comprises many 
structurally related ubiquitous cytokines that exerts several regulatory functions 
in cell processes, including development, cell-cycle progression, cell 
differentiation, reproductive function, adhesion, motility, bone morphogenesis, 
neuronal growth, wound healing and immune surveillance
 [1-5]
. The ligands of 
this family are highly conserved across the species, denoting their importance 
during the evolution, indeed TGF-β orthologs are found from Caenorhabditis 
elegans through humans with equally conserved cell surface receptors and 
signaling co-receptors.  
In mammals, the TGF-β superfamily is composed of more than 30 factors that in 
turn can be grouped into two sub-families; one family branch includes factors 
such as Activin, Lefty, Myostatin, Nodal and TGF-β, while bone morphogenetic 
proteins (BMPs), anti-muellerian hormone (AMH, also known as MIS), and 
growth and differentiation factors (GDFs) belong to the other branch 
[6-8]
 . 
Human Activins, AMH/MIS, AMH/MIS, BMPs, GDFs and Nodals are key 
regulators of embryonic stem cell differentiation, body axis formation, left-right 
symmetry and organogenesis. In addition to these functions, in adult organism 
BMPs are involved in bone growth and repair, Myostatin in inhibition of muscle 
development and Activins and GDF9 in regulation of gonadal function 
[7]
. 
In normal and premalignant cells, TGF-β promotes homeostasis and suppresses 
tumor progression directly through cell-autonomous tumor-suppressive effects 
such as cytostasis, differentiation and apoptosis, or indirectly through effects on 
the stroma (suppression of inflammation and stroma-derived mitogens). 
However, when cancer cells lose TGF-β tumor-suppressive responses, they can 
use TGF-β to initiate immune evasion, growth factor production, differentiation 
into an invasive phenotype and metastatic dissemination or to establish and 
expand metastatic colonies 
[9]
. 
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                                         Figure 1.1: A summary of biological responses to TGFβ family signalling [10]. 
 
Members of the TGF-β superfamily consist of both homodimers and 
heterodimers, characterized by seven cysteine residues, six of these residues 
form three intrasubunit disulfide bonds crucial for structural integrity, whereas 
the remaining cysteine residue forms a disulfide bond with the other subunit so 
as to stabilize the dimer interface 
[11]
.  
The monomeric TGF-β exhibits a general structure that involves two pairs of 
antiparallel β-strands forming a flattened surface, projecting away from a long α-
helix. Of interest, one of the disulfide bonds of the core traverses through a ring 
formed by two other disulfide bonds generating the “cysteine knot” motif [11]. 
The monomer has been described as a four-digit hand, where each β-strand is 
linked to a finger. At the N-terminus, fingers 1 and 2 are antiparallel, with finger 
2 leading to a general helix ‘wrist’ region, followed by antiparallel fingers 3 and 
4 and the C-terminus. The dimeric active form of TGF-β is stabilized by 
hydrophobic interactions and is usually further strengthened by an intersubunit 
disulfide bridge 
[11-13]
.  
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                                                   Figure 1.2: The TGF-β fold [11]. 
 
TGF-βs exert their functions through an endocrine, paracrine and autocrine 
mechanism 
[11]
. 
Cellular responses to most TGF-β ligands are transduced through interactions 
with the two single transmembrane-spanning serine–threonine kinase receptors, 
termed type I and type II receptors 
[14]
. Type I and type II receptors are 
glycoproteins of approximately 55 and 70 kDa respectively, which interact upon 
ligands binding. All type I receptors possess a highly conserved TTSGSGSG 
motif in their cytoplasmic region, upstream from the kinase domains, termed the 
GS (Glycine-Serine) domain, required to regulate their kinase activity. In the 
absence of ligand, type II and type I receptors exist as homodimers at the cell 
surface 
[14]
. TGF-β signalling is triggered by binding to and bringing together 
type I and type II receptors on the cell surface to form a ternary holo-complex 
[15,16]
. After holo-complex formation, the type II receptor, via its active kinase 
domain, transphosphorylates the GS domain of type I receptor, which in turn 
phosphorylates Smads proteins. Smads are intracellular mediators of 
transcriptional activation, grouped into three functional classes: the receptor-
regulated Smad (R-Smad), the co-mediator Smad (co-Smad) and the inhibitory 
Smad (I-Smad) 
[17]
.  
R-Smads (Smad1, Smad5, and Smad8 for BMP and Smad2 and Smad3 for other 
TGF-β ligands) are directly phosphorylated and activated by type I receptor 
kinases. Subsequently they undergo homotrimerization and form hetero-
11 
 
complexes with the co-Smad, Smad4 (Fig. 1.3). The activated Smad complexes 
translocate into the nucleus where, in association with nuclear cofactors, regulate 
the transcription of target genes. By contrast, the I-Smads (Smad6 and Smad7) 
negatively regulate TGF-β signaling through competition with R-Smads for 
receptor or co-Smad interaction and by targeting the receptors for degradation. 
On the basis of their downstream signaling, TGF-β ligands act as tumor 
suppressors in early stages of cancer, while they promote tumor cell proliferation 
at later stages of carcinogenesis 
[18]
. In fact, while TGF-β Smad-2/3 dependent 
signaling is related to an increased cell proliferation, Smad-7 activation results in 
decreased cell proliferation 
[19]
. In addition, in normal and premalignant tissues 
TGF-βs act as anti-oncogenic factor, mediating cell cycle arrest in G1 phase; by 
contrast, TGF-βs secreted from tumours or stroma cells surrounding tumours 
enhance invasion and metastasis 
[20-22]
 and they also control tumour development 
influencing apoptotic pathways. In addition to Smad-mediated transcription, 
TGF-βs can activate further signalling cascades (Fig. 1.3), such as Erk 
(extracellular signal-regulated kinase), JNK (JUN N-terminal kinase), B-RAF, 
RAS, PI3K–AKT and p38 MAPK (mitogen-activated protein kinase) pathways. 
Cellular responses to TGF-β are affected by the balance between cooperativity 
and counteraction of Smad and MAPK pathways. However, the mechanisms of 
Erk, JNK or p38 MAPK activation by TGF-β and their biological consequences 
are still unclear 
[23]
.  
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                                Figure 1.3: Canonical and non-canonical TGF-β signalling [24]. 
                   1.2 NODAL LIGANDS 
Nodal ligands were initially identified through forward genetic screens in mouse 
and zebrafish. Whereas there is a single Nodal ligand in mouse, human and 
chick, multiple Nodal-related ligands are found in frogs (encoded by six xNr 
genes) and zebrafish [cyclops (cyc; ndr2 – Zebrafish Information Network), 
squint (sqt; ndr1 – Zebrafish Information Network) and southpaw (spw)][25].  
Like most members of the TGF-β superfamily, Nodal proteins are synthesized 
and secreted as homodimeric precursors with a hydrophobic leader sequence 
(15-25 aa), an N-terminal pro-domain (50-375 aa) and a mature C-terminal 
domain of 110-140 aminoacids. Removal of the prodomain through extracellular 
proteolytic processing, involving subtilisin-like proprotein convertases 
Spc1/Furin and Spc4/Pace4, is required to produce the mature functional form of 
the Nodal dimer 
[26-28]
. Convertases are not simply housekeeping proteases that 
allow Nodal processing, they also regulate the spatial and temporal distribution 
of active Nodal ligands. Recent data suggest that the EGF (Epidermal growth 
factor) - CFC (colony-forming cell) superfamily members are involved in the 
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maturation process of Nodal by recruiting PACE-4/Furin and Nodal in proximity 
to the Nodal receptors on the cell membrane, increasing both efficiency of Nodal 
processing and availability of the its final active form 
[29]
.  
It appears that the cleavage of the prodomain allows Nodal ligands to trigger 
signal transduction and promotes their turnover through endocytosis
[28]
. 
Moreover the removal of the prodomain reduces Nodal stability and promotes 
local autocrine signaling, whereas glycosylation stabilizes the mature form of 
Nodal and increases its ability for paracrine signaling 
[28]
. Of interest, although 
Nodal precursors are more stable than the mature forms 
[28]
, they exhibit weak 
induction activity 
[26,27]
. 
  1.3 HUMAN NODAL PROTEIN                 
                   1.3.1 Structure 
Human Nodal is synthesized as pre-pro-Nodal (55 kDa), that is proteolytically 
processed by the subtilisin-like proprotein convertases PACE-4 and Furin, 
leading to the active intermediate pro-Nodal (37 kDa) and eventually active 
Nodal (22 kDa). 
The mature form of Nodal is a homodimeric protein of 220 amino acids and 
each Nodal monomer (110 aa) adopts the canonical, symmetric and elongated 
TGF-β arrangement (Fig. 1.4). The structure involves two antiparallel β-sheets 
(β1 and β2) forming a flattened surface, composed by two and four strands, a 
short turn linking the first two strands and an amphipathic α-helix (H3) 
perpendicular to the β-sheets. One of the disulfide bonds of the core crosses a 
ring formed by the two other disulfide bonds, generating the so called ‘‘cysteine 
knot” motif  [11]. The overall monomer folding has been described as a hand with 
the helix mimicking the wrist, the cysteine knot core the palm, and the β-sheets 
the fingers 
[30]
. The convex surface of the fingers corresponds to the “knuckle 
epitope” while the helix corresponds to the “wrist epitope”; these regions usually 
bind to the type II and type I receptors, respectively
 [31]
. The monomer core with 
β-sheets and the cysteine knot is conserved across the different members of 
TGF-β superfamily. The Nodal monomers are covalently linked by a single 
disulfide bond (Cys76 from both monomers) and intermonomer contacts occur 
by interactions of the helix H3 with the β-sheets of the neighboring molecule [11]. 
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Figure 1.4: Ribbon representation of Nodal dimer model built by Modeller6v2. The color code 
is based on the sequence of secondary structure elements. The interchain disulfide bridges are 
shown as yellow sticks, whereas the interchain one as a green stick 
[33]
. 
Docking studies performed to investigate the interaction between Nodal and the 
EGF-like domain of the co-receptor Cripto 
[32] 
revealed that, unlike the other 
TGF-β [11], the H3 wrist helix of Nodal doesn’t interact with this domain but it 
exert only a structural role, contributing to the proper orientation of Nodal 
regions – the pre-helix loop and the finger tips - directly involved in Cripto 
binding 
[32]
. 
Residues of human Nodal required for the binding to the EGF-like domain of 
Cripto-1 are E49, E50, Y58, N79 and T81. In particular, the glutammic acids, 
E49 and E50, located in the pre-helix loop play a relevant role in the Cripto 
recognition; in fact, when these residues are mutated to A, affinity for Cripto is 
remarkably reduced 
[32]
. Moreover, the Nodal Y58 can pocket in a polar groove 
that G87 and T88 residues of the Cripto-1 EGF-like domain form together with 
the Nodal N79, T81, and G92 residues. The EGF-like domain T88 residue, 
normally O-fucosyled and well exposed on the surface so that the fucose can be 
easily accommodated 
[32]
, is required for Cripto to facilitate Nodal signaling, 
indeed, when this threonine is replaced by D and/or E residues in Cripto 
mutants, the affinity for Nodal drastically decreases compared to the wild-type 
protein 
[33]
. Furthermore, T88 is close to Nodal E49 so that its replacement with 
acidic residues can cause electrostatic repulsions 
[33]
. In addition, favorable 
electrostatic contacts between Nodal E49 and EGF-like R80 are established. 
Moreover, EGF-like R104, another residue important for Nodal binding, can 
establish electrostatic interactions at the binding interface with Nodal D97 and 
H3 H3
b2
b1
b2
turn
turn
b1pre-helix loop
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D90 and even cation-π interactions with Nodal Y88 and W27 [34]. Finally, 
favorable aromatic interactions between Nodal W27 and EGF-like F94 occur 
[32]
.  
So far it has been reported that Nodal can bind to ALK4 only in the presence of 
the co-receptor Cripto, while it binds directly to ALK7 without Cripto 
[35-37]
. The 
amino acids crucial for the interaction are mostly hydrophobic and located in the 
“wrist epitope” and on the N-terminal region of the ligand and span the entire 
region that includes loop 23 of the receptor 
[38]
.  
Of interest, very recent biochemical assays have revealed that Nodal is able to 
bind to ALK4 without the presence of Cripto 
[39]
 but this results need to be 
further investigated in biological systems. 
 
              
Figure 1.5: Ribbon representation of the proposed model for the interaction between Nodal 
(purple) and the EGF-like domain of hCripto-1 (green). 
E49 
E50 
Y58 
T81 
N79 
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Figure 1.6: Ribbon representation of the proposed model for the interaction between Nodal 
(purple) and ALK7 (cyan). 
 
                   1.3.2  Biological functions 
 
Nodal is a potent morphogen and regulator of cell fate in both embryological and 
adult systems 
[40,25]
. Like many other members of the TGF-β superfamily, it is 
involved in cell differentiation in early embryogenesis playing a key role in 
signal transfer from the node, in the anterior primitive streak and to lateral plate 
mesoderm (LPM) 
[41,42]
. 
Furthermore, it was demonstrated that the TGF-β/activin/Nodal signaling is 
involved in maintaining pluripotency in human embryonic stem (ES) cells since 
disruption of this signaling pathway results in their differentiation 
[43,44]
. In 
addition, Nodal has been demonstrated to inhibit differentiation of human ES 
cells along the neuroectodermal differentiation pathway, further supporting a 
role for Nodal in the maintenance of pluripotency in human ES cells 
[44]
, 
whereas  in mouse ES cells TGF-β signaling is active but not required for 
stemness 
[43]
, suggesting that there are differences in the regulatory pathways 
involved during the maintenance of pluripotency between human and mouse ES 
cells.  
Nodal signaling plays a dual role in neural development, its inhibition is required 
to generate the anterior neural tissue while the subsequent maintenance and 
patterning of neural tissue depends upon axial mesendoderm generated in 
response to Nodal signaling 
[45]
. 
E49
E50
Y58
N79
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Nodal can also regulate mesoderm and endoderm formation, establishment of 
the left–right (LR) axis and subsequent asymmetric development and positioning 
of visceral organs 
[25,44,46]
. 
Although most genes in the Nodal pathway are rarely espressed during later 
development and adulthood, it was found that pathway activity is upregulated in 
many human cancers. 
 
                   1.3.3 Signaling 
Nodal signaling is triggered by its binding to heteromultimeric complexes 
consisting of the EGF-like domain of the co-receptor Cripto-1 and type I (ALK 
4/7) and type II (ActRIIB) activin-like serine-threonine kinase receptors; this 
event leads to the phosphorylation and activation of ALK 4/7 by ActRIIB and 
subsequent ALK 4/7-mediated phosphorylation of Smad-2 and Smad-3 
[47]
. 
Phosphorylated Smad-2/3 associate with the common mediator (co-Smad) 
Smad-4 and translocate to the nucleus where, together with transcription factors 
such as FoxH1, Mixer and p53, regulate expression of target genes, such as 
Nodal itself and Lefty, its natural inhibitor. Indeed Nodal activates its own 
transcription via a positive feedback loop. However, it still remains unclear how 
essential is the role of Cripto-1 for Nodal signaling, since recent studies have 
demonstrated that the Nodal precursor can bind to ALK 4 in a Cripto-1-
independent manner, allowing the expression of Nodal-responsive genes 
[48]
. 
While Nodal is able to bind directly to ALK7 without Cripto-1, the latter is 
required as co-receptor for Nodal binding to ALK4. However, Cripto-1 is still 
able to enhance the responsiveness of the ALK7/ActRIIB complex to Nodal, 
suggesting that both ALK7 and ALK4 cooperate with Cripto-1 in modulating 
Nodal signaling 
[49,50]
.  
Furthermore, Nodal can activate other important signaling proteins through 
Smad-independent pathways, such as MAPK (ras/raf/mitogen-actived protein 
kinase) and PI3K–AKT [47].  
1.3.4 Internalization of Nodal ligand-receptor complexes 
Nodal signal transduction during embryonic development can be regulated by 
receptor internalization and degradation. The formation of ligand-receptor 
complexes on the plasma membrane are usually followed by internalization of 
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the complexes, that can result in switching off receptor-mediated signaling or 
propagation of the signal 
[51]
. TGF-β receptors are internalized through clathrin-
coated pits, which facilitate signaling, or through lipid raft-caveolae, which 
promote proteasomal degradation of the receptors 
[52]
.
 
                                              
                                        
                                                  Figure 1.7: Schematic outline of the Nodal signaling pathway 
[53] 
 
1.3.5 Inhibitors  
Since Nodal is a key regulator of vertebrate embryological development, its 
signaling requires a tight spatial and temporal control. However only a few 
Nodal inhibitors have been identified 
[54] 
(see Table 1).  
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Lefty-A and –B, two highly divergent members of the TGF-β superfamily, act 
as specific antagonists of Nodal signaling by directly binding to Nodal or to 
Cripto-1 preventing the formation of a more active signaling complex between 
Nodal, the type I and II Activin receptors 
[55]
. This restriction of Nodal signaling 
can occur in the extracellular microenvironment where Nodal and Cripto-1 are 
present, as well as at the cell surface. Notably, the Lefty proteins are not 
competitive inhibitors of the ALK receptor complex since they fail to bind 
ALK4 or ActRIIB. Furthermore, in embryological systems, the Lefty genes are 
often downstream targets of Nodal signaling, which provides a powerful 
negative-feedback loop for this pathway 
[25,56]
.  
Cerberus, a member of the cysteine-knot superfamily, directly binds and blocks 
Nodal signaling 
[57]
,
 
but it was not expressed as abundantly as the Lefty proteins 
by human ES cells.  
Finally, Tomoregulin (TMEFF1), a transmembrane protein containing two 
follistatin domains and an EGF motif, indirectly inhibits Nodal signaling in 
binding to the CFC domain of Cripto-1 and sequestering it from the ALK4 
receptor, thus preventing Cripto-1 from functioning as a coreceptor for Nodal 
[56]
.  
Deregulation of the expression of key players involved during proper 
development, such as the morphogen Nodal, results in embryonic lethality or 
even diseases in adults, such as cancer.  
Table 1. Summary of Nodal antagonists [54]
Factors Types Antagonist mechanisms
Lefty proteins secreted proteins inhibit the Nodal signal transduction by binding to the
Nodal coreceptors EGF-CFCs as well as the Nodal
ligands
Cerberus/ Dan family members secreted proteins binds to the Nodal proteins preventing their signal
transduction
Tomoregulin-1 transmembrane
proteins
binds to egf-cfcs to prevent the Nodal signal
transduction
Bmp3/Bmp7 secreted proteins form heterodimers with Nodal proteins and result in
mutual inhibition
Nicalin/Nomo endoplasmatic
reticulum
membrane proteins
probably modifies or traps the Nodal signalling
components
Dapper 2 endosomalproteins promotes degradation of Nodal receptors
Drap 1 transcriptional
repressor
binds to the DNA binding domain of FoxH1
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Nodal was identified in several human cancers and it plays a key role during the 
growth and spread of cancer cells. Therefore, a better understanding of the 
regulatory processes involved in Nodal expression and function may contribute 
to develop novel treatment strategies for targeting Nodal in human malignant 
diseases 
[58]
. 
 
 
1.4 CUTANEOUS MELANOMA 
The incidence and mortality rates of melanoma have been increasing over the 
last few decades. American Cancer Society estimated that the incidence of  
lifetime risk of developing melanoma is approximately 1 in 50 for Caucasians. 
Overall it is the 6th most common cancer in men and 7th most common in 
women. While melanoma related deaths also continue to increase, some 
significant breakthroughs in the understanding of the pathobiology of melanoma 
have resulted in promising new therapies. Risk factors for developing melanoma 
comprise prolonged exposure to ultraviolet radiation (UVR), increased number 
of melanocytic nevi, a family history of melanoma or a history of previous 
melanoma 
[59]
.  
Melanomas are categorized into subgroups with similar clinical, epidemiologic 
and molecular features, which may be sensitive to distinct targeted therapy. 
Several models have been proposed describing melanoma as a linear process 
evolving from hyperplastic and dysplastic nevi to early and late stage melanoma. 
Recently, new methods have been proposed for improving the diagnosis of 
melanoma, as to discriminate benign lesions from melanoma, for instance, 
multiple tissue marker arrays or fluorescence in situ hybridization DNA.  
Current therapies for advanced stage of melanoma employing cytotoxic agents 
are often associated with serious side effects and with relatively low percentages 
of response rates 
[59]
. Initially, anti-cancer drugs exert their effect, killing of the 
majority of cancer cells sensitive to the chemotherapeutic agent. 
However, many factors lead to chemoresistance such as increased signaling of 
cell survival pathways, enhanced DNA repair mechanisms or mutations of 
molecular targets in melanoma cells. Similarly, molecular redundancy and cross-
talk between multiple signaling pathways reduce the efficacy in instances of 
targeted molecular biotherapy. Continuous efforts are dedicated to improving 
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detection and quantification of chemoresistance, not only to define the molecular 
mechanisms involved in drug resistance in melanoma, but also to help those 
patients which present resistance to standard treatments and who may otherwise 
benefit from a more aggressive or alternative approach. Studies continue to 
increase the understanding of the biological processes of melanoma and offer the 
potential for improving current methods for diagnosis and therapy 
[59]
 . 
1.4.1 Expression of Nodal in human melanoma 
Several studies in human cancers revealed a key role of Nodal and/or its 
coreceptors in the growth and spread of malignant cells, however it was 
demonstrated that Cripto-1 co-receptor also activate a common cancer-related 
pathway Nodal-independent 
[60]
, such as the c-Src–MAPK–AKT signaling. 
Recent data indicate that Nodal is over-expressed with its co-receptor Cripto and 
appears to play a predominant role in the growth of several human cancers, 
including prostate 
[61]
, testicular 
[62]
, endometrial 
[63]
, ovarian 
[64]
, breast 
[65,66]
, 
brain 
[67]
, pancreatic 
[68,69]
, colon 
[70]
, hepatocellular carcinoma 
[71]
 and melanoma 
[72]
. Interestingly, in some of these reports, Nodal expression was detected in the 
context of veery low Cripto-1 levels, indeed it remains still unclear how Cripto-1 
and Nodal can exert their tumorigenic activity independently of each other 
[73]
. 
Notably, it less than 5% of aggressive human melanoma cell lines were found to 
be Cripto-1 positive; therefore, it seems unlikely that the growth and metastatic 
potential of melanoma would be entirely dependent on the capability of less than 
5% of an entire melanoma population to bind Nodal and induce the 
protumorigenic activity 
[58]
. Studies are in progress to elucidate the role of 
Cripto-1 and Nodal in human cancer, in particular in melanoma.  
Expression studies revealed that the presence of Nodal is restricted to embryonic 
tissues, hESCs (human embryonic stem cells) and cancer cells, whereas it is 
absent in normal cells, such as melanocytes 
[74]
; indeed, Nodal expression is 
largely restricted to very early progenitor and reproductive cell types and re-
emerges during tumorigenesis 
[58]
.  
In addition, several studies indicate that Nodal expression positively correlates 
with melanoma tumor progression toward a metastatic phenotype 
[72]
, thus, 
metastatic melanoma cell lines (C8161, WM278 and 1205Lu) express high 
levels of Nodal, while Nodal is weakly expressed or absent in non-metastatic 
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melanoma cells (C81–61) [72]. Furthermore, Nodal expression positively 
correlates with melanoma progression clinically; indeed Nodal protein is absent 
in normal skin, is weakly expressed or absent in primary melanomas and it is 
only rarely observed in poorly invasive RGP melanomas, in contrast to invasive 
VGP melanomas and melanoma metastases, where Nodal expression is 
detectable in up to 60% of cases 
[72]
. All these studies indicate that Nodal may be 
considered a useful biomarker of melanoma progression, from a treatable RGP 
disease to a more aggressive VGP disease, to the presence of metastases.  
In addition to serving as a useful biomarker for melanoma progression, Nodal 
plays a key role in melanoma plasticity, invasiveness and tumorigenicity 
[72]
. 
Several studies have demonstrated that aggressive melanoma cells exhibit a 
functional plasticity characterized by the expression of genes from different cell 
types, as well as a reduction in the expression of melanocyte-associated genes. 
For instance, aggressive melanoma cells express proteins, such as VE-Cadherin, 
which are characteristically associated with endothelial cells and keratins and 
vimentins, which are intermediate filaments normally associated with epithelial 
and mesenchymal cells, respectively 
[75]
. Collectively, this gene-expression 
pattern confers a functional plasticity upon aggressive melanoma cells that 
enables them to escape normal physiological control and regulation. For 
example, VE-Cadherin expression by melanoma cells is essential for the 
formation of tumor-derived vascular networks and provides rapidly growing 
tumors with a paravascular perfusion pathway, while the expression of keratins 
is associated with enhanced invasion and metastasis 
[76,77]
.  
Altogether, these findings suggest that Nodal may prove to be not only a 
diagnostic or prognostic marker but also a potential novel therapeutic target in 
melanoma. 
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1.5 MONOCLONAL ANTIBODIES  
 
1.5.1 Antibody structure  
Antibodies (immunoglobulin) are roughly Y-shaped glycosylated proteins. Each 
antibody consists of two identical heavy (H) chains (50 kDa) linked to two 
identical light (L) chains (25 kDa), giving an antibody molecule two 
identical antigen-binding sites and thus the ability to bind simultaneously to two 
identical structures. Each light chain pairs with a heavy chain, and each heavy 
chain pairs with another heavy chain; the chains are linked by covalent 
interchain disulfide bonds and noncovalent interactions. Each chain has a 
tandem series of repeating homology units approximately 110 amino acid 
residues in length called Immunoglobulin domains (Ig-like domain), which fold 
independently into a compact globular structure. All proteins that exhibit this 
structural motif belong to the immunoglobulin gene superfamily. An antibody 
molecule is composed of three major fragments: the two Fabs (Fragment 
antigen- binding), which are identical and each of which contains the light chain 
and the first two domains of the heavy chain, and the Fc (Fragment 
crystallizable), which contains the C-terminal constant domains of the two heavy 
chains. The Fabs are linked to the Fc by the “hinge region” (located between the 
CH1 and CH2 domains) which allows them to swing and varies in length and 
flexibility in the different antibody classes and isotypes. The antigen binding 
sites (paratopes) are located at the tips of the Fabs 
[78]
.  
A representation of human IgG1 antibody is shown in Fig. 1.7. 
Antibody structure consists of two regions: the variable (V) region and the 
constant (C) region. The variable (V) regions are the sections that constitute the 
tips of the Y’s arms, defining antigen binding properties, vary greatly from one 
antibody to another, creating a pocket uniquely shaped to enfold a specific 
antigen epitope. The stem, or constant (C) region, of the Y allow the antibody to 
bind other components of the immune response; the stem is identical in all 
antibodies of the same class. The light chain of IgG has two domains called VL 
and CL while the heavy chain has four domains: one VH and three in the CH 
region (CH1, CH2, and CH3 or Cg1, Cg2, and Cg3). The heavy-chain V unit is 
similar to the V part of the light chain, while the three C-region units exhibit 
strong homology to each other and to the C region of the light chain.  
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Each V domain contain three regions (CDR1, CDR2 and CDR3) exhibiting high 
variability of the amino acid sequence, called hypervariable regions or 
complementarity-determining regions (CDRs) 
[75]
, because these segments 
mark the antibody combining site; the differences in structure are almost entirely 
confined to these regions. Usually, each CDR is about 10 amino acid residues in 
length. Intervening sequences between the CDRs have restricted variability and 
show little difference in amino acid sequence between chains. These invariant 
segments make up the framework residues (FR1, FR2, FR3, and FR4) 
[75]
, 
which compose about 85% of the V region. Framework residues define the 
positioning of the CDRs. When the light and heavy chains are joined, the CDRs 
of the chains form a cleft that serves as the antigen-binding site of an 
immunoglobulin. Because the amino acid sequences of the CDRs determine the 
shape and ionic properties of the antigen-binding site, the CDRs define the 
specificity of the antibody.
[78-80] 
                                 
           
                       Figure 1.8: Typical structure of an immunoglobulin G1 (IgG1) 
[81]
. 
 
Immunoglobulins can be grouped into five different classes IgA, IgD, IgE, IgM, 
and IgG on the basis of the kind of heavy chain they bear, respectively 
designated as α, δ, є μ and γ. IgGs are further divided into several subclasses 
(isotypes) — IgG1, IgG2, IgG3, and IgG4 (in order of relative abundance in 
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human plasma), with different heavy chains, named γ1, γ2, γ3, and γ4, 
respectively. 
All immunoglobulins share the same pool of light chains; there are two types of 
light chains, kappa (κ) and lambda (λ). The structural differences among these 
subtypes are the number and location of interchain disulfide bonds and the 
length of the hinge region. The two heavy chains are connected in the hinge 
region by a variable number of disulfide bonds: 2 for IgG1 and IgG4, 4 for IgG2 
and 11 for IgG3. The light chain of the IgG1 is connected to the heavy chain by 
a disulfide bond between the last cysteine residue of the light chain and the fifth 
cysteine residue of the heavy chain. However, for IgG2, IgG3 and IgG4, the 
light chain is linked to the heavy chain by a disulfide bond between the last 
cysteine residue of the light chain and the third cysteine residue of the heavy 
chain. 
Cysteine residues that form inter-chain disulfide bonds are located in the hinge 
region with the exception of the third cysteine residue of the heavy chain in 
IgG2, IgG3 and IgG4, which is located between the interface of VH and CH1 
domains. On the other hand, intra-chain disulfide bonds are buried between the 
two layers of anti-parallel β-sheet structures within each domain [78].  
Compared to the other classes of immunoglobulines, IgGs are the most abundant 
and widely used for therapeutic purposes, thus they are currently the class of 
choice for the development of therapeutic antibodies, because they show more 
favourable features, although the IgG3 are not employed in therapy because of 
their shorter half-life and their long hinge region, that is easily accessible to 
proteolysis 
[82]
. 
1.5.2 Monoclonal antibodies in cancer therapy  
A century ago, Paul Ehrlich hypothesized that a ‘magic bullet’ could be 
developed to selectively target disease. This vision became practical with the 
development of hybridoma technology by Kohler and Milstein, which provided 
murine mAbs able to recognize with hight specificity their antigens 
[83]
. The 
limitations of the first generation of mAbs evaluated in the clinic phase were 
their immunogenicity and poor ability to recruit immune effector mechanisms, 
due to their murine nature 
[84]
. Indeed, to overcome these issues, new enginereed 
antibodies were generated, by maintaining the human Fc domains and by 
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grafting either the entire murine variable regions (chimeric antibodies) or the 
murine complementarity-determining regions (humanized antibodies) into the 
human IgG framework as to retain targeting specificity 
[84]
. Modifications to 
render mAbs more “human” reducing the foreign nature of these proteins have 
provided more efficient interaction with the Fc receptors expressed on immune 
human effector cells. The transition to human IgG backbones has allowed 
customization of the IgG for desired functions. Most therapeutic mAbs with 
human backbones are IgG1 isotype, which effectively mediates Fc domain–
based functions, such as antibody-dependent cellular cytotoxicity (ADCC) and 
complement fixation. Other isotypes, such as human IgG2, can be also used 
when the mechanism of action of mAb is to block a soluble target for example 
the anti–epidermal growth factor receptor (EGFR) antibody, panitumumab 
(ABX-EGF) 
[83]
.  
Although most of the mAbs approved by the US Food and Drug Administration 
(FDA) for cancer therapy are still classical humanized or chimeric antibodies, 
the next generation of mAbs currently under development incorporates 
additional beneficial modifications, such as alterations in glycosylation and 
sequence that enhance ADCC or modifications in size and antigen-binding 
affinity that increase the ability of the mAb to penetrate solid tumors 
[83]
. 
Antibody-based therapeutics have emerged as important components of 
therapies for an increasing number of human malignancies. Trastuzumab, an 
unconjugated anti-HER2/neu antibody, is broadly used alone and in combination 
with chemotherapy agents in breast cancer. Antibodies directed against the 
extracellular domain of the EGFR exhibit activity in advanced cancer, and one 
(cetuximab) has been approved for for the treatment of the colorectal cancer 
[85,86]
. Unconjugated mAbs directed against the B-cell idiotype, against CD20 
[87,88] 
and against CD22 
[89]
 are useful in treatment of  lymphomas as well as an 
anti-CD20 antibody, rituximab (Rituxan). Radioimmunoconjugates, such as 
ibritumomab tiuxetan (Zevalin) and tositumomab plus 131I tositumomab 
(Bexxar; a mixture of radiolabeled and unconjugated antibody) directed against 
CD20 show substantial anti-tumor activity 
[90,91]
 and have entered standard 
clinical practice for lymphoma therapy. Campath-1H (alemtuzumab), an anti-
CD52 antibody that efficiently mediates complement fixation, has been 
approved for use in chemotherapy-refractory chronic lymphocytic leukemia 
[92]
. 
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An immunoconjugate containing an anti-CD33 antibody and calicheamicin has 
been approved for use in refractory acute-myeloidleukemia 
[93]
; indeed, 
immunotoxins consisting of recombinant antibody fragments conjugated to 
catalytic toxins exerts anti-tumor activity as well 
[94]
.  
Ipilimumab, an anti-CTLA-4 (cytotoxic T-lymphocyte-associated antigen 4) 
antibody 
 
and anti-PD-1 (programmed cell death protein 1) mAbs, 
pembrolizumab
 
and the most recently approved nivolumab, are used for the 
immune-based therapy of metastatic melanoma 
[95,96]
.  
The safety and efficacy of therapeutic mAbs in oncology depend on the nature of 
the target antigen. Ideally, the target antigen should be abundant and accessible 
and it should be expressed homogeneously, consistently and exclusively on the 
surface of cancer cells. Antigen secretion should be minimal, as secreted 
antigens can bind the antibody in the circulation and could prevent sufficient 
antibody from binding to the tumour. If the desired mechanism of action is 
ADCC or CDC, then it is desirable that the antigen–mAb complex should not be 
rapidly internalized so as to maximize the availability of the Fc region to 
immune effector cells and complement proteins, respectively. By contrast, good 
internalization is desirable for antibodies or proteins that deliver toxins into the 
cancer cell and for antibodies the action of which is primarily based on the 
downregulation of cell surface receptors 
[97]
. 
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1.5.3 Mechanism of action of therapeutic antibodies 
Available clinically useful mAbs typically use a combination of mechanisms in 
directing cytotoxic effects on tumor cells. Most interact with components of the 
immune system through antibody-dependent cellular cytotoxicity (ADCC) or 
complement dependent cytotoxicity (CDC) and other alter signal transduction 
within the tumor cell or act to eliminate a critical cell-surface antigen. 
Monoclonal antibodies can also be used to delivery payloads (e.g., radioisotopes, 
drugs or toxins) to directly kill tumor cells or to activate prodrugs specifically 
within the tumor (antibody-directed enzyme prodrug therapy, ADEPT). Finally, 
mAbs can be employed in combination with traditional chemotherapeutic 
agents, attacking tumors through complementary mechanisms of action that may 
Table 2. FDA-approved mAbs for use in oncology [98]
Name Marketed by Class Target First approved indication Reported mechanisms of 
action
Approval 
year
Rituximab
(RituxanTM)
Biogen Idec/
Genentech
Chimeric IgG1 CD20 Non-Hodgkin’s Lymphoma ADCC, CDC, Induction of 
apoptosis
1997
Trastuzumab
(Herceptin®)
Genentech Humanized IgG1 HER2 Breast cancer Signal inhibition, ADCC 1998
Alemtuzumab
(Campath®)
Sanofi-Aventis Humanized IgG1 CD52 B cell chronic lymphocytic 
leukemia
CDC, Induction of apoptosis 2001
Ibritumomab
tiuxetan
(Zevalin®)
Biogen Idec Murine IgG1 CD20 Non-Hodgkin’s Lymphoma Radioisotope delivery (90Y) 2002
Tositumomab
(Bexxar®)
GlaxoSmithkline Murine IgG2a CD20 Non-Hodgkin’s Lymphoma Radioisotope delivery (131I), 
ADCC, CDC, Induction of 
apoptosis
2003
Cetuximab
(ErbituxTM)
Bristol-Myers
Squibb/Eli Lilly
Chimeric IgG1 EGFR Squamous cell carcinoma of 
the head and neck
Signal inhibition, ADCC 2004
Bevacizumab
(AvastinTM)
Genentech Humanized IgG1 VEGF Colorectal cancer Signal inhibition 2004
Panitumumab
(VectibixTM)
Amgen Human IgG2 EGFR Colorectal cancer Signal inhibition, ADCC 2006
Ofatumumab
(Arzerra®)
Genmab/GSK Human IgG1 CD20 Chronic lymphocytic 
leukemia
ADCC, CDC 2009
Denosumab
(Xgeva®)
Amgen Human IgG2 RANKL Bone metastases Signal inhibition 2010
Ipilimumab
(Yervoy®)
Bristol-Myers
Squibb
Human IgG1 CTLA-4 Metastatic melanoma Signal inhibition 2011
Brentuximab
vedotin
(Adcetris®)
Seattle Genetics Chimeric IgG1 CD30 Hodgkin Lymphoma ADC 2011
Pertuzumab
(Perjeta®)
Genentech Humanized IgG1 HER2 Breast cancer Signal inhibition, ADCC 2012
Trastuzumab
emtansine
(Kadcyla®)
Genentech Humanized IgG1 HER2 Breast cancer ADC, Signal inhibition, 
ADCC
2013
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include anti-tumor immune responses that may have been compromised owing 
to a chemotherapeutic’s cytotoxic side effects on T lymphocytes [83]. 
The most important cell-killing mechanisms of mAbs action are described 
below. 
 
a. Antibody-dependent cellular cytotoxicity 
ADCC occurs when antibodies bind to antigens on tumor cells and the antibody 
Fc domains engage Fc receptors (FcR) on the surface of immune effector cells 
[99]
. Several families of Fc receptors have been identified and specific cell 
populations characteristically express defined Fc receptors 
[100]
. For example, 
neutrophils commonly express human FcγRI (CD64), FcγRII (CD32) and the B 
(lipid-anchored) isoform of FcγRIII (CD16). In contrast, human natural killer 
(NK) cells express only the A (transmembrane) isoform of CD16. This structure 
facilitates recruitment of adaptor proteins and activation of natural killer cells by 
antibody engagement of CD16 
[101]
. 
 
b. Complement-dependent cytotoxicity 
Although IgM is the most effective isotype for complement activation, it is not 
widely used in clinical oncology because IgM does not readily extravasate from 
vascular structures. IgG1 and IgG3 are both very effective for triggering CDC 
[102]
 via the classical complement-activation pathway. In this cascade, the 
formation of antigen-antibody complexes leads to the uncloaking of multiple 
C1q binding sites in close proximity on the CH2 domains of IgGs (C1q is one of 
three subcomponents of complement C1). These uncloaked C1q binding sites 
convert the previously low-affinity C1q–IgG interaction to one of high avidity, 
which triggers a cascade of events involving a series of other complement 
proteins and leads to the proteolytic release of the effector-cell 
chemotactic/activating agents C3a and C5a. The complement cascade ultimately 
leads to the formation of a membrane attack complex, which creates pores in the 
cell membrane permitting free passage of water and solutes into and out of the 
cell 
[83]
. 
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c. Signal transduction changes 
Some of the most commonly targeted tumor-associated antigens are growth 
factor receptors, which are overexpressed in several malignancies. Since their 
activation under normal conditions induces a mitogenic response and promotes 
cellular survival, it follows that their overexpression promotes tumor cell growth 
and resistance to chemotherapeutic agents. By decreasing signaling through 
these receptors, mAbs can normalize growth rates and resensitize cells to 
cytotoxic agents 
[83]
. Antibodies that target members of the EGFR family are the 
most potent inhibitors of signal transduction. Some, such as cetuximab and 
panitumumab, act by physically blocking the interaction between the receptor 
and its activating ligand 
[103]
 and by sterically preventing the receptor from 
assuming the extended conformation required for dimerization 
[104]
. Others, such 
as pertuzumab (2C4), allow ligand binding to occur but sterically inhibit the 
subsequent receptor heterodimerization required for signal transduction 
[105]
. 
Virtually every clinically effective, unconjugated mAb perturbs the signaling 
that promotes the proliferation and survival of the targeted cell population.  
Therapy with mAbs often has the effect of reducing the density of target antigen 
expression. Examples include the reduction in concentration of a critical growth 
factor receptor, such as EGFR, from the surface of a tumor cell 
[106]
 or the 
clearance of a ligand, such as vascular endothelial growth factor (VEGF), that 
promotes tumor or vascular growth. However, some mAbs, such as trastuzumab, 
enter into the cell and are then passively recycled back to the cell surface along 
with their target antigen 
[107]
.  
 
d. Tumour antigens as antibody targets 
The safety and efficacy of therapeutic mAbs in oncology depend on the nature of 
the target antigen. The ideal target antigen should be abundant and accessible 
and should be expressed homogeneously, consistently and exclusively on the 
surface of cancer cells. Antigen secretion should be minimal, as secreted 
antigens can bind the antibody in the circulation and could prevent sufficient 
antibody from binding to the tumour 
[108]
. If the desired mechanism of action is 
ADCC or CDC, then it is desirable that the antigen–mAb complex should not be 
rapidly internalized so as to maximize the availability of the Fc region to 
immune effector cells and complement proteins, respectively. By contrast, good 
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internalization is desirable for antibodies or proteins that are designed to deliver 
toxins into the cancer cell and for antibodies whose action is primarily based on 
the downregulation of cell surface receptors 
[108]
. 
                                                  
                           
                       Figure 1.8: Mechanisms of action of therapeutic antibodies 
[109]
. 
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1.6 Antibody fragments generated by enzymatic digestion  
Monoclonal antibodies (mAbs) have been widely used for nearly three decades 
for purposes including imaging and therapy because their selectivity for specific 
targets. 
While intact monoclonal antibody molecules are still most commonly used, they 
may not necessarily be the most efficient or desired molecular form depending 
on the application. Because of their relatively large size (approximately 150 
kDa), intact mAbs exhibit unfavorable imaging kinetics, relatively poor tumor 
penetration and present with the potential for eliciting host antibody responses 
[110]
. These limitations were overcome by the reduction of the size of intact 
antibodies to smaller forms or monovalent and bivalent fragments, achieved 
either through enzymatic cleavage or by genetic engineering. The latter requires 
a serious commitment of time and resources while the enzymatic strategy is 
affordable and easily achievable. Proteolytic fragments of mouse antibodies are 
widely used as immunochemical, diagnostic and therapeutic tools due to their 
more advantageous pharmacokinetic properties than those of the intact 
molecules 
[110]
. Indeed, the smaller size results in clearing faster from the 
circulation and tumor localization patterns, in better tissue penetration and less 
steric hindrance leading to more sensitive antigen detection. The removal of the 
Fc portion avoid the potential of binding with Fc receptors thus reducing non-
specific interactions and distribution in vivo of the mAb via the Fc receptors 
found on normal cells and in addition it  reduces the immunogenicity in vivo 
[102]
. The most widely proteolytic enzyme used to obtain IgG fragments - Fab, 
F(ab’)2 and/or Fc - of a variety of animal species 
[111] 
are papain and pepsin, 
which split immunoglobulin G (IgG) molecules preferentially in the hinge 
region.  
The typical IgG fragments are summarized below. 
F(ab')2 (110 kDa) fragment consists of two antigen-binding regions joined at the 
hinge through disulfides. This fragment may contain a small portion of the Fc 
region 
[112]
. 
Fab' (55 kDa) can be obtained by the reduction of F(ab')2 fragments. The Fab' 
fragment contains a free sulfhydryl group that may be alkylated or utilized for 
the conjugation with an enzyme, toxin or other protein of interest. Since it is 
derived from F(ab')2, it may contain a small portion of Fc 
[112]
. 
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Fab (50 kDa) is a monovalent fragment that is produced from IgG and IgM, 
consisting of the VH, CH1 and VL, CL regions, linked by an intramolecular 
disulfide bond. 
Fc (50 kDa) fragment contains the CH2 and CH3 region of the heavy chain and 
part of the hinge region held together by one or more disulfides and noncovalent 
interactions 
[112]
. Fc (Fc-alpha) and Fcµ fragments are produced from proteolytic 
cleavage of IgG and IgM, respectively. The term Fc is derived from the ability 
of these antibody fragments to crystallize; these fragments cannot bind antigen, 
but they are responsible for the effector functions of antibodies, such as 
complement fixation 
[102]
. 
                                       
                           
                 Figure 1.9: Enzymatic digestion of IgG antibodies with papain and pepsin 
[113]
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1.7 AIM OF THE PROJECT  
The purpose of this project is the development of novel monoclonal antibodies 
and their functional fragments such as Fab or F(ab’)2 able to bind with high 
affinity and selectivity the growth factor Nodal and to inhibit its interaction with 
the co-receptor Cripto-1. Nodal binds Cripto-1 on the EGF-like domain, whereas 
the site of binding on Nodal comprises the region 43-69, termed CBR (Cripto-
Binding Region). Such region encompasses the pre-helix loop and the H3-helix 
and contains two glutammic acid, E49 and E50, crucial for the recognition and 
stabilization of the binding of Nodal to the EGF-like domain of Cripto. Within 
the same region, Y58 has been recently identified as participating to the 
interaction. Given the relevance of this interaction for several mechanisms 
associated to tumour growth, Nodal-Cripto-1 inhibitors have the potential to 
block Nodal-Cripto dependent cellular proliferation. Moreover, since Nodal 
expression correlates with the progression of melanoma toward a metastatic 
phenotype, Nodal protein can be considered as a novel diagnostic and prognostic 
marker in this context, indeed the Nodal binders may be used as diagnostic tools 
for the specific detection of the protein in tumoral tissues with different degree 
of aggressiveness and in human biological fluids. 
On this bases, we  will explore the possibility of developing new monoclonal 
antibodies specifically targeting the CBR of Nodal with the perspective to inhibit 
the interaction with Cripto-1 and block the Nodal-associated tumorigenesis. The 
antibodies can be also potentially used for the selective and sensitive detection 
of the protein in the biological fluids of individuals overexpressing Nodal to 
predict the risks of tumour development. The high affinity and selectivity 
potentially achievable with monoclonal antibodies and the selective expression 
of the protein in the tumoral compartments, especially in melanoma, provide a 
robust scientific and technological background for the successful application of 
this strategy. They will also pave the way for the development of new 
biotherapeutics that could help to overcome the limitation associated to the 
currently mAb-based immunotherapy in metastatic melanoma [ Ipilimumab anti-
CTL4 antibody) and the most recently approved anti-PD1 Nivolumab and 
Pembrolizumab]. 
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                      I 2. MATERIALS AND METHODS 
 
2.1 MATERIALS AND CHEMICALS 
 
Protected amino acids for peptide synthesis were purchased from GL-Biochem 
(Shanghai, PRC) and IRIS Biotech GmbH (Marktrewitz, DE). The RINK amide 
resin was from Novabiochem. Coupling agents were from GL-Biochem 
(Shanghai, PRC). Solvents for peptide synthesis and purification, including 
acetonitrile (ACN), dimethylformammide (DMF), dichloromethane (DCM), 
methanol (MeOH) were from Romil (Dublin, Ireland). Other reagents for 
peptide synthesis, BSA and glutaraldehyde were from Sigma-Aldrich (Milano, 
Italy). KLH (Keyhole Lympet Hemocyanin) was from Pierce-ThermoFisher 
(Milano, Italy). Freund's complete and incomplete adjuvant, and all media 
including Dulbecco's modified Eagle's medium (DMEM), OPTI-MEM and 
serum were purchased from GIBCO (Life Technologies, Italia) and Sigma-
Aldrich (Milan, Italy). HiTrap protein G and Superdex200 10/300 columns, 
AKTA FPLC, all reagents for SPR analyses and the Biacore3000 system were 
provided by GE Healthcare. Pierce Rapid mouse antibody isotyping kit was 
purchased from Thermo Scientific (RocKford, IL, USA). All chemicals used for 
ELISA assays were provided by Sigma-Aldrich (Milano, Italia). Nunc MaxiSorp 
96 multi-well plates were purchased from Thermo Scientific (Denmark). APS 
and TEMED were purchased from Sigma-Aldrich (Milano, Italia); all the 
reagents used for electrophoresis analyses, including the ladder proteins and the 
buffers, were supplied by Biorad. Recombinant proteins were purchased from 
R&D System (Minnesota, USA). 
All the enzymes used to cleave the 3D1 antibody and all the reagents used 
throughout the digestion were supplied by Sigma-Aldrich (Milano, Italia). 
Protein purifications were performed on AKTA-FPLC system. For analytical 
HPLCs an Agilent 1100 system was used. All the reagents used to perform SDS-
PAGE and Western blot analyses were purchased from Biorad.  
The RPMI 1640 medium, containing 10% Fetal Bovine Serum (FBS) and 1% 
Penicillin, Streptomycin and Glutamine (PSG) was used for maintaining 
myeloma cells. The RPMI-GM medium contained RPMI 1640 with added 1% 
non-essential amino acids (NEAA). For the fusion of splenocytes and myeloma 
36 
 
cells we used an RPMI 1640 medium supplemented with 15% FBS, 2% HAT 
(Hypoxantine-Aminoipterine-Thymine), 1% PSG and 10% HES (Hybridoma 
enhancing supplement). The medium for clone selection was RPMI 1640 
supplemented with 15% FBS, 2% HAT, 1% PSG.  
 
2.2 SOLID-PHASE PEPTIDE SYNTHESIS, PURIFICATION AND 
IDENTIFICATION 
2.2.1 Peptide synthesis 
The chemical synthesis of each peptide was performed by using an automatic 
SYRO system (MultiSynTech, Germany). 
The wild-type hNodal[43-69] peptide and its variants were prepared as 
acetylated and amidated derivatives by stepwise solid-phase synthesis following 
standard fluorenylmethoxycarbonyl (Fmoc) chemistry protocols. A Rink- amide 
MBHA resin (Sigma-Aldrich, Milano, Italy) with a substitution grade of 0.57 
mmol/g and amino acid derivatives with standard protections were used in all 
syntheses. The syntheses were performed under canonical conditions of peptide 
synthesis, for each coupling reaction (HATU/DIEA pre-activation, 5-fold excess 
of Fmoc-protected amino acids). Coupling and deprotection times were kept at 
30 and 20 minutes, respectively. Standard side-chain protection groups for Fmoc 
chemistry were used for all residues. N-terminal acetylation was performed on 
the resin using acetic anhydride at 0.5 M in DMF with 5% DIEA, 20 minutes at 
room temperature. The cleavage of peptides from the solid support was 
performed by treatment with a trifluoroacetic acid (TFA)/tri-
isopropylsilane/water (90:5:5, v/v/v) mixture for 90 min at room temperature. 
Crude peptides were precipitated in cold ether, dissolved in a water/acetonitrile 
(1:1, v/v) mixture and lyophilized.  
 
2.2.2 Peptide purification 
After lyophilisation, peptides were dissolved in a solution of H2O/CH3CN 95/5 
v/v, containing 0.1% TFA and were purified by reverse-phase HPLC (RP-
HPLC) on a Shimadzu LC-8A instrument (Shimadzu Corporation, Milan, Italy) 
using a semi-preparative 5×1 cm ID C18 monolythic Onyx column 
(Phenomenex), applying a linear gradient of 0.05% TFA in acetonitrile from 5% 
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to 70% over 10 min at a flow rate of 15 mL/min, monitoring the absorbance at 
214 nm. The collected fractions were lyophilized. 
 
2.2.3 Peptide identification by LC-MS 
Peptides purity and identity were confirmed by liquid chromatography–mass 
spectrometry analysis (LC-MS), analyses were carried out on a LCQ DECA XP 
ion Trap mass spectrometer (ThermoFisher) equipped with an OPTON ESI 
source and with a complete Surveyor HPLC system. 
 
2.3 IMMUNOGEN PREPARATION : CONJUGATION OF THE 
IMMUNOGEN PEPTIDE TO KLH AND BSA  
The conjugation reaction of the antigen to carrier proteins was carried out using 
a w/w ratio of peptide:protein 1:3. 1 mg of hNodal[43-69] non acetylated peptide 
was dissolved in 1 mL of 50 mM  phosphate buffer pH 7.0 and 3 mg of carrier 
protein Keyhole Limpet Hemocyanin (KLH, Pierce & Co., Rockford, Illinois) 
were dissolved in 1 mL of 50 mM  phosphate buffer pH 7.0. The two separate 
solutions were mixed and glutaraldehyde at final concentration of 0.2% was 
added. The mixture was incubated at room temperature under stirring; after 2 
hours, the reaction was stopped by adding 2 mL of 0.5 M Glycine. Finally, the 
reaction mixture, placed in a 10 kDa MWCO dialysis membrane, was dialyzed 
over night at 4° C against 2 liters of PBS buffer, pH 7.4,  performing a dialysis 
buffer-exchanging after 1 hour and after 4 hours. The amount of peptide-protein 
conjugated was determined by the method of Bradford using the BIORAD kit 
(Biorad). The same procedure was used to prepare the BSA-peptide conjugated 
and the glutaraldehyde self-conjugated BSA (BSA2), omitting the addition of the 
peptide solution. The KLH-conjugated peptide was used for the effective 
immunization of Balb/c mice and for the generation of monoclonal antibodies 
specific for the 43-69 region of hNodal protein; the BSA-conjugated peptide was 
used to screen hybridoma cell culture supernatants. 
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2.4 GENERATION AND PRODUCTION OF ANTI-NODAL 
MONOCLONAL ANTIBODIES BY HYBRIDOMA TECHNOLOGY 
Murine monoclonal antibodies tested in this research project were generated in 
the laboratory of Prof. Antonio Leonardi at the University of Naples “Federico 
II”, Department of Molecular and Cellular Biology and Pathology. 
BALB/c mice were housed and handled according to the institutional guidelines. 
Four-five weeks old Balb/c mice (Jackson Lab) were immunized with 50 μL of 
suspension containing about 100 μg of adjuvant-emulsified KLH-conjugated 
hNodal[43-69] peptide mixture. Two independent injections were carried out 
sub-cutaneously with 25 μL of immunogen. Before immunization, 250 µL blood 
samples were taken from each mouse from the caudal vein and used as the pre-
immune control (T0 samples). Mice were again immunized with the same 
amount of immunogen at day 30 after the first immunization (T = 30d), at day 
40 (T = 40d) and at day 60 (T = 60d); blood samples were taken from the caudal 
vein (250 µL) before every subsequent immunization and tested by ELISA to 
monitor the increase of antibody titer compared to the pre-immune serum. Mice 
showing the highest antibody titer were sacrificed and splenectomised. 
These immunizations were administered subcutaneously with incomplete 
Freund's adjuvant (TiterMax Gold Adjuvant, Sigma-Aldrich). A final antigen 
boost was administered intravenously 20 days before animals were sacrificed 
and splenectomized. Three days after the boost, spleen cells were collected by 
surgery from an immunized mouse sacrificed by CO2 inhalation and for which 
all efforts were taken to reduce animal suffering; the spleen cells were then fused 
with myeloma SP2/0 cells in 50% polyethylene glycol (pH 7.4) fusion solution 
to generate mAb hybridomas. The splenocytes were fused at a ratio of 5:1 with 
the mouse plasmacytoma cell line SP2/0 (ATCC) using RPMI-GM containing 
polyethylene glycol 1300-1600 (Hybri-Max, Sigma-Aldrich, Milano) and 7.5% 
DMSO (Sigma-Aldrich, Milano), following the standard procedure described by 
Köhler 
[114]
. The fused hybridoma cells were re-suspended in 30 mL of selection 
medium consisting of RPMI–GM medium containing PEG 1300-1600, 10% 
FBS, 100 U/mL penicillin, 100 μg/mL streptomycin, 100 μM hypoxanthine, 
16 μM thymidine and 400 nM aminopterin (RPMI-HAT Sigma-Aldrich, 
Milano). The cell suspension (100 μL) was dispensed into 96-well plates and 
incubated at 37 °C in a 5% CO2 atmosphere. After 12 hours, an additional 
39 
 
volume of 100 μL of selection medium was added to each well. After 24 h, half 
the medium from each well was removed, and fresh selection medium was 
added. Every 2 or 3 days, medium was replaced with fresh selection medium. 
After 10 days, aminopterin was omitted from the medium. Between the 12th and 
14th day, supernatants from the 96-well plates were collected and screened by 
ELISA assay. Hybridoma clones with strong reactivity versus the hNodal[43-69] 
peptide were re-cloned twice by limiting dilution, and their reactivity was re-
confirmed by ELISA assay. Sub-cloned hybridoma cells were cultured in OPTI-
MEM medium containing 10% FBS, adapted gradually to serum-free cell 
medium and then transferred to the Bioreactor (INTEGRA Biosciences AG, CH-
7000 Chur) for large scale production. 
2.5 ISOTYPIZATION 
Isotype of the anti-Nodal antibodies produced by the selected clones was 
determined by using the commercial kit specific for murine antibodies, in 
accordance to the manufacturer’s instructions (Pierce Rapid Mouse antibody 
Isotyping kit, Thermo scientific). 
 
2.6 ENZYME-LINKED IMMUNOSORBENT ASSSAYS (ELISA) 
2.6.1 Antibody titration in mouse sera 
To determine the antibody titer in mouse sera, 96-well ELISA plates were coated 
with 100 µL of the BSA-conjugated hNodal[43-69] 0.5 μg/mL in PBS and with 
BSA2 as negative control overnight at 4 °C. The plate was then triple-washed 
three times with PBS containing 0.05% Tween 20 (PBS-T). Non-specific sites of 
the plate were blocked with 2% BSA and incubated at 37 ºC for 60 minutes. 
Wells were then washed 3 times again and ascitic fluid was added to the wells in 
three fold serial dilutions starting from 1:100 to 1:100000. The plate was 
incubated at 37 °C for 1 hour and washed again with PBS-T. Then, 100 μL of a 
1:1000 dilution of HRP-conjugated rabbit anti-mouse Ig (1.0 mg/mL, Biorad, 
Milano) were added to the wells and incubation was carried out for 1 h at 37 °C. 
After washing, 100 μL of 2,2-Azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) 
(ABTS) substrate solution was added to each well. After 15 min, the reaction 
was stopped by adding 100 μL of 1% SDS solution in water to each well. The 
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Optical Density (OD) was measured at 415 nm by a microplate reader (BioTek, 
Winooski, VT, USA).  
Antibody titers were evaluated sufficiently high when the average absorbance 
values from triplicate wells incubated with immune sera dilutions at 1:10000 
were at least thrice those determined on wells incubated with the pre-immune 
serum. After generation, hybridomas were screened for their ability to secrete 
specific mAbs for the hNodal antigen. For this purpose, supernatants were tested 
as described above, by coating plates with both BSA-hNodal[43-69] and BSA2 
as control to exclude clones producing antibodies recognizing the BSA-linked 
glutaraldehyde. Positive clones were stabilized by 3 sequential rounds of cloning 
performed by the method of limited dilution. At every round, cells were counted 
and diluted up to about 3 cells/mL; 20 mL of this solution were plated in two 96-
well plates, dispensing 100 µL/well, thus reaching about 0.3 cells/well. Cells 
were incubated for 2 weeks at 37 °C under 5% CO2, then supernatants from each 
well were tested again for the presence of antibodies against the antigen peptide. 
Supernatants showing the highest antibody titer were isolated and again cloned 
thrice by limited dilution, always testing by ELISA the presence of specific 
antibodies.  
To obtain secreted monoclonal antibodies in absence of serum-derived bovine 
antibodies, selected clones were adapted to grow in serum-free medium. Thus, 
medium was first changed to OPTIMEM (Sigma-Aldrich, Milano, Italy) 
supplemented with 10% FBS, then FBS was progressively reduced and finally 
removed over a time period of about 4 weeks. Productivity was always 
monitored by ELISA assays.  
 
2.6.2 Screening of the hybridoma supernatants 
hNodal[43-69] peptide and hNodal[43-69]E49A-E50A, its mutated variant, in 
which the glutamic acids 49 and 50 were substituted with two Alanine residues, 
were coated at 330 nM diluted in PBS on polystyrene conical shaped flat bottom 
96-well plates, (Nunc MaxiSorp
TM
, Roskilde, Denmark) at 4°C overnight (100 
µL/well). After incubation, the coated wells were washed three times with PBS 
containing 0.005% Tween-20 (PBS-T) and non-specific binding sites were 
blocked by incubating with 1% BSA in PBS (300 µL/well) for 1 hour at 37° C. 
After washing three times with PBS-T, supernatants of hybridomas diluted in 
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PBS at 33 nM were incubated for 1 hour at 37° C (100 µL/well). After 
incubation, plates were washed three times with PBS-T and goat anti-mouse 
HRP-conjugated antibody (1 mg/mL, Blotting Grade Affinity Purified Goat 
Anti-Mouse IgG (H+L) diluted 1:1000 in PBS was added as secondary antibody 
(100 µL/well) and incubated for 1 hour at 37° C. After incubation and washes 
with PBS-T, bound supernatants were detected by adding 100 µL/well of freshly 
prepared ortho-phenylenediamine (0.4 mg/mL) containing H2O2 (0.4 mg/mL) in 
0.1 M citrate buffer (pH 5.2) (SIGMAFAST™ OPD tablet Sigma Aldrich). The 
peroxidase reaction was stopped after 5 minutes with 50 µL/well of 2.5 M 
H2SO4 and the optical density was measured at 490 nm, using a multiwall plate 
reader (BioTek, Winooski, VT, USA). 
2.6.3 Mapping of the 3D1 epitope 
The following peptides were used for the epitope mapping : wild type [43-69], 
[43-69]E49-E50, [43-67], [44-67], [44-67]E49A-E50A, [43-67]P46A-V47A, 
[44-67]P46A-V47A and the shorter variants [43-56], [52-60] and [56-67]. 
Peptides were coated at 1 µg/mL; 3D1 mAb, dissolved in PBS, was used as 
primary antibody at 1 µg/mL. 
 
2.6.4 Specificity of the 3D1 mAb 
hNodal[43-56], hNodal[1-38], hNodal[39-75], hNodal[76-100], hGDF5/6[43-
56] and hGDF7[43-56] peptides, stock solution in water, were coated at 1 µg/mL 
(diluted in PBS) on polystyrene 96-well plates at 4° C overnight (100 µL/well). 
The ELISA assay was carried out following the procedure alrready described. 
3D1 monoclonal antibody, dissolved in PBS, was used as primary antibody at 1 
µg/mL. 
 
2.6.5 Detection of rhNodal 
A sandwich ELISA assay was developed to set up the optimal conditions to 
detect Nodal in biological human samples. 3D1 antibody was coated at 100 
ng/mL on black and clear bottom polystyrene 96-well plates, to capture rhNodal 
(recombinant human Nodal) at 4° C overnight. After the incubation, the coated 
wells were washed three times with PBS containing 0.005% Tween-20 (PBS-T) 
and non-specific binding sites were blocked by incubating with 1% BSA in PBS 
(300 µL/well) for 1 hour at 37°C. After washing three times with PBS-T, 
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rhNodal at scaling concentrations were incubated for 1 hour at 37° C (100 
µL/well). After incubation, plates were washed three times with PBS-T and anti-
Nodal anti-rabbit monoclonal antibody (EP2058Y, Epitomics) diluted 1:1000 in 
PBS was added to detect the captured rhNodal (100 µL/well) and incubated for 1 
hour at 37° C. After incubation and three washes with PBS-T, an HRP-
conjugated anti-rabbit antibody diluted 1:5000 in PBS was added (100 µL/well) 
and incubated for 1 hour at 37° C. After three washes with PBS, the resulting 
captured rhNodal-antibody complex was detected with a QuantaRed™  
Enhanced Chemifluorescent HRP substrate (Thermo scientific), mixing 50 
volumes QuantaRed Enhancer Solution with 50 volumes QuantaRed Stable 
Peroxide and 1 volume of the QuantaRed ADHP Concentrate. 100 μL of 
QuantaRed Working Solution were added to each plate well and incubated for 
15 minutes at room temperature. Peroxidase activity was stopped by adding 10 
μL of QuantaRed Stop Solution. The enzymatic activity was immediately 
stopped. The plate was shacked for 10-30 seconds and Relative Fluorescence 
Units (RFU) of each well were measured using a plate reader. The excitation and 
emission maxima for QuantaRed Substrate are 570 nm and 585 nm, respectively.  
 
2.7 MONOCLONAL ANTIBODIES PURIFICATION 
 
2.7.1 Protein G affinity chromatography 
Antibodies were purified by standard procedures. After centrifugation at 4000 
rpm for 20 minutes at 4° C, hybridoma cell-culture supernatants, containing 
monoclonal IgGs, were filtered on a 0.22 μm filter and loaded onto a HiTrapTM 
Protein G HP column (GE Healthcare). Purifications were performed on an 
ÄKTA FPLC™ instrument (GE Healthcare) at a flow rate of 0.6 mL/min, 
monitoring the absorbance at 280 nm. After washing away the unbound material 
using PBS (pH 7.4) as loading buffer, the bound antibodies were recovered by 
changing drastically the pH conditions using 100 mM Glycine pH 2.7 as elution 
buffer. The eluted antibodies were quickly neutralized by adding 1/10 volume 2 
M TRIS pH 9.0. To ensure the stability of purified mAbs, the antibodies were 
buffer-exchanged into PBS (pH 7.4), using an Amicon® Ultra MWCO 50000 
centrifugal filter (Millipore); mAbs were then concentrated, using the same 
filter. mAbs concentrations were estimated by UV spectrophotometry using the 
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Bradford assay. Purity of concentrated mAbs was evaluated by 10% SDS-PAGE 
gel and Coomassie blue staining. 
2.7.2 Size-exclusion chromatography 
Size-exclusion chromatography purifications were performed on a Superdex
™
 
200 HR 10/30 (GE Healthcare, Piscataway, NJ) gel filtration column, using PBS 
pH 7.4 as running buffer, at a constant flow rate of 0.5 ml/min, with a volume of 
elution of 25 mL and monitoring the absorbance at 280 nm. The final purified 
product was concentrated using an Amicon® Ultra MWCO 50000 centrifugal 
filter (Millipore) at 4000 rpm at 4°C.  
After concentration, the purified IgGs were quantified by Bradford assay and 
analyzed by SDS-PAGE on 10% polyacrylamide gel; all the samples were 
loaded onto the gel under non-reducing conditions. Gel staining was achieved 
using by Coomassie Brilliant Blue. 
2.8 SPR ANALYSES 
All real-time binding analyses were performed on a Biacore 3000 instrument 
from GE Healthcare at 25° C, using certified HBS-EP as running buffer (10 mM 
HEPES, 150 mM NaCl, 3 mM EDTA, 0.005% Biacore surfactant P20, pH 7.4).  
Before each immobilization, the optimal immobilization level of the ligand, 
expressed as RU (Response Unit), was calculated on the basis of the following 
formula: 
Rmax = MW analyte/MW ligand x Immobilized amount x Stoichiometric 
ratio 
2.8.1 Binding of purified mAbs to rhNodal protein 
For this purpose we used the recombinant human Nodal protein provided by 
R&D Systems (Minneapolis, Minnesota, USA), E. coli-derived, His238-Leu347, 
with an N-terminal Met. The lyophilized protein was reconstituted at 100 µg/mL 
in sterile 4 mM HCl, according to the datasheet instructions.  
RhNodal protein was covalently immobilized at 5 µg/mL in 10 mM Sodium 
Acetate buffer pH 4.5 at a flow rate of 5 µL/min by standard amine coupling 
onto a CM5 sensor, using EDC/NHS chemistry, exposing the primary amine 
groups or other nucleophilic groups to the reactive succinimide esters and 
allowing a covalent binding to the dextran matrix. Indeed, before 
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immobilization, a 50/50 mixture composed by 0.4 M EDC and 0.1 M NHS was 
used to activate free carboxyl groups on the dextran matrix. The amount of 
immobilized ligand corresponded to about 4100 response units (RU). Residual 
reactive groups on the sensor chip surface were deactivated by addition of 1M 
ethanolamine hydrochloride, pH 8.5. A 10 mM NaOH solution was used as 
regeneration solution to wash away non-specific linked molecules. 
A control channel, prepared by activating with EDC/NHS and deactivating with 
1M ethanolamine-HCl, indicated as control blank, was used as reference. 
Real-time binding analyses were performed at a flow rate of 20 µL/min, using 
HBS-EP as running buffer, injecting a constant volume of 60 µL.  
Stock solutions of purified antibodies in PBS were diluted in HBS-EP and tested 
at 100 nM; dissociations were monitored for at least 500 s. 
After the single-dose screening, dose-dependent binding analyses were carried 
out with the two antibodies able to bind to rhNodal protein, 3D1 and 5F10. For 
the 3D1 mAb binding experiments were carried out at concentrations ranging 
between 6 nM and 100 nM. For 5F10 higher concentrations were used (100, 
250, 500 and 750 nM). Dissociations were monitored for at least 500 s. 
 
2.8.2 Competition assay  
RhCripto-1 protein, supplied by R&D System (Minneapolis, Minnesota, USA), 
was covalently immobilized at 5 µg/mL in 10 mM Sodium Acetate buffer pH 
4.5 at a flow rate of 5 µL/min onto a CM5 sensor, by standard amine coupling, 
using EDC/NHS chemistry, reaching an immobilization level of 600 RU. 
RhNodal was used at the fixed concentration of 5nM, while the 3D1 was used at 
increasing concentrations providing a final molar ratio of antigen to antibody 
1:0.25, 1:0.5 and 1:1. Each Nodal-3D1 mixture was incubated for 30 min at 
room temperature, before passing on the sensor chip.  
 
2.8.3 Mapping of the 3D1 epitope  
To define the epitope of the anti-Nodal 3D1 mAb, an epitope mapping study was 
carried out using hNodal [43-67] peptide variants.  
The whole antibody was immobilized at 5 µg/mL in 10 mM NaAc buffer pH 5 at 
a flow rate of 5 µL/min by standard amine coupling chemistry on a CM5 sensor 
chip. The immobilization level reached with the mAb was about 5350 RU. On 
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another channel of the same sensor chip, the 3D1 Fab’ was immobilized at 10 
µg/mL in 10 mM NaAc buffer pH 4.5 at a flow rate of 5 µL/min, following the 
standard amine coupling chemistry. The amount of immobilized Fab’ was about 
2570 RU. Residual reactive groups were deactivated by 1M ethanolamine 
hydrochloride, pH 8.5. The blank channel was prepared also already described. 
Real-time binding analyses were performed at a flow rate of 20 µL/min, using 
HBS-EP buffer, injecting a constant volume of 60 µL of sample. 5 mM stock 
solutions of peptides in water were opportunely diluted in HBS-EP buffer and 
injected at the following concentrations: 0.5, 1, 2.5, 5, 10 and 20 µM. 
Dissociations were monitored for at least 500 s; the regeneration solution was 5 
mM NaOH.  
Experimental sensorgrams from every analysis were aligned, subtracted of blank 
signal and overlapped. All mathematical manipulations and fitting were 
performed using the BIAevaluation software, version 4.1 from GE Healthcare. 
 
2.9 ANTIBODY DEGLYCOSYLATION 
To improve the splitting of the 3D1 antibody by pepsin to get functional 
fragments, the antibody was first subjected to a deglycosylation reaction. 
Peptide-N-Glycosidase F, also known as PNGase F, supplied by New England 
Biolabs (Beverly, MA), was used for this purpose. This enzyme is an amidase 
that cleaves between the innermost GlcNAc and asparagine residues of high 
mannose, hybrid and complex oligosaccharides from N-linked 
[115]
. We used the 
PNGase to remove the single conserved N-linked glycan at Asn
297
 on each CH2 
domain of the two heavy chains of the IgG1. A first preliminary small-scale 
deglycosylation reaction was performed to set up the optimal conditions. The 
large-scale deglycosylation reaction was performed incubating 1.5 mg of the 
mAb, diluted in PBS (pH 7.4), with 11 units of PNGase F at 37° C for 24-48 
hours. The time for optimal deglycosylation was fixed at 48 hours. 
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2.10 ENZYMATIC DIGESTION OF 3D1 WITH A PANEL OF 
PROTEASES 
Small-scale pilot experiments were performed to assess the best reaction 
conditions to obtain the maximum yield of Fab fragments. To determine the 
optimal conditions, both the concentration of enzyme (enzyme:mAb ratio) and 
the reaction time were varied. The reaction was monitored after 2, 4, 6 hours and 
overnight. After terminating the digestions, fragments were analyzed by SDS-
PAGE under reducing and non-reducing conditions. The reduced samples were 
shortly boiled in a dry block heater for 5 min in the presence of 10% (v/v) β-
mercaptoethanol.  
 
2.10.1 Papain digestion 
Papain is a cysteine protease of the peptidase C1 family, consisting of a single 
polypeptide chain with three disulfide bridges and a sulfhydryl group necessary 
for activity of the enzyme; it exhibits broad specificity, cleaving peptide bonds 
of basic amino acids (preferably arginine and lysine), leucine, or glycine and it 
also hydrolyzes esters and amides 
[116]
. 
Papain (Sigma-Aldrich, Saint Louis, Missouri, USA, catalog number P3125) 
was activated in digestion buffer (phosphate buffer saline, pH 7.4) in the 
presence of 5 mM L-Cysteine hydrochloride and incubating for 10 min at room 
temperature. To enhance the enzyme activity, 2 mM EDTA (heavy-metal 
chelator) was added. 3D1 (3-4 mg/ml), was used at a final w/w ratio of papain to 
mAb of 1:100. The mAb was mixed with the activated papain at pH 7.4 and the 
reaction was incubated in a 37° C water bath for 6 hours.  
The reaction was stopped by incubating the digestion mixture with 25 mM 
Iodoacetamide for 20 min in the dark at room temperature to irreversibly 
inactivate papain. 
 
2.10.2 Ficin digestion 
Ficin is a thiol protease, containing a single reactive cysteine at its active site. 
The amino acid homology of the active site is similar to that of papain. This 
enzyme hydrolyses the peptide bonds where the carbonyl group is from 
phenylalanine or tyrosine 
[117]
. 
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Ficin (Sigma-Aldrich, Saint Louis, Missouri, USA, catalog number 1987) was 
activated in digestion buffer (PBS, pH 7.4) containing 10 mM L-Cysteine 
hydrocloridre by incubation for 10 min at room temperature. Enzyme activity 
was enhanced by adding 2 mM EDTA; the enzyme to mAb 3D1 ratio (w/w) was 
1:30. The digestion mixture was incubated for 5 hours in a 37° C water bath. 
The reaction was stopped by adding 5 mM IAM, mixing carefully and 
incubating the ficin digest for 20 min in the dark at room temperature. 
 
                2.10.3 Pepsinolysis 
Pepsin, a member of the Peptidase A1 family, unlike some other endopeptidases, 
hydrolyzes only peptide bonds; it does not hydrolyze non-peptide amide or ester 
linkages 
[118]
. 
After the deglycosylation reaction, prior to digestion, the 3D1 antibody was 
buffer-exchanged into 20 mM sodium acetate buffer (pH 4.0) using an Amicon® 
Ultra MWCO 50000 centrifugal filter (Millipore). PNGase F was not removed 
before proceeding to pepsinolysis. Small-scale pilot digestions were conducted 
on the deglycosylated 3D1 antibody to select the most appropriate conditions for 
the large-scale production of F(ab’)2. In these experiments the optimum 
concentration of pepsin (Sigma-Aldrich, Saint Louis, Missouri, USA, catalog 
number P6887), digestion time and pH were examined. In preliminary 
experiments 20 mM sodium acetate buffer was used at pH 4.5, but at this pH the 
pepsin proteolytic activity was greatly reduced. The antibody digestion was 
completed using an equal volume of a pepsin solution prepared in the same 
buffer and providing a final w/w ratio of pepsin to antibody 1:25. The resultant 
enzyme/antibody mixture was incubated for 3 to 6 hours and overnight in a 37° 
C water bath. At different time intervals, aliquots were removed and the enzyme 
reaction was stopped by adjusting the reaction pH to neutrality with 2M Tris pH 
9. Samples were analyzed on a 12% SDS-PAGE gel under reducing and non-
reducing conditions to determine the best digestion conditions, which were then 
used to produce F(ab’)2 on a large scale. Conditions for large scale production 
were as follows: 2 mg/mL 3D1 mAb, 20 mM NaAc, pH 4.0, enzyme/antibody 
ratio 1:25 w/w and incubation in a 37° C water bath for 6 hours. 
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2.11 PURIFICATION OF Fab/F(ab’)2 /Fab’ FRAGMENTS 
Following the large-scale digestion, to separate the Fab fragments from the Fc 
portions and other eventual side products of degradation or intact mAb, the 
digestion mixture containing the deglycosylated Fab/F(ab’)2 fragments were 
loaded onto a HiTrap
TM
 Protein G HP column (GE Healthcare), equilibrated 
with PBS, connected to ÄKTA FPLC instrument. Purification was carried out at 
a flow rate of 0.6 mL/min, monitoring the absorbance at 280 nm. The column 
was washed with PBS and the Fab fragment was collected in the flow through, 
using PBS (pH 7.4) as loading buffer; the Fc fragment and intact mAb were 
eluted from the column with 100 mM glycine, pH 2.7. When the pepsin digest 
was passed through the column, F(ab’)2 fragments were eluted using 100 mM 
glycine pH 2.7 and then neutralized using 2 M TRIS, pH 9. The relevant eluted 
fractions were collected, buffer-exchanged into PBS and concentrated using an 
Amicon® Ultra MWCO 10000 centrifugal filter (Millipore). The purity of Fab 
and F(ab’)2 fractions was detected by SDS-PAGE which was performed on a 
12% gel under reducing and non-reducing conditions according to the method of 
Laemmli. Samples were treated with loading buffer in the absence and presence 
of β-mercaptoethanol (boiled at 100° C for 2 min) and stained with Comassie 
Brilliant Blue. After digestion samples were stored at -20°C. 
Fab and F(ab’)2 fragments were further purified by size-exclusion 
chromatography to check for high molecular weight aggregates. SEC was 
performed on a Superdex™ 200 10/300 GL column (GE Healthcare), connected 
to ÄKTA FPLC system. The column was eluted at a flow rate of 0.5 mL/min, 
using PBS as running buffer and the column effluent was monitored at 280 nm. 
The eluted final products were concentrated, using an Amicon® Ultra MWCO 
10000 centrifugal filter (Millipore) and analyzed by 12% SDS-PAGE gel under 
reducing and non-reducing conditions. 
 
2.12 REDUCTION OF THE F(ab’)2 TO Fab’ AND Fab’ ALKYLATION 
Fab' fragments were produced by reducing selectively the hinge-region disulfide 
bonds of F(ab’)2 using 5 mM 2-Mercaptoethylamine (Thermo Scientific Pierce), 
that is a mild reductant. To promote the activity of the 2-MEA, 20 mM sodium 
acetate buffer pH 4.0 was added to the F(ab’)2 fragments dissolved in PBS pH 
7.4 to adjust the pH at 6.0. 2 mM EDTA was also added. The mixture was 
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incubated for 1 hour at 37° C. After the incubation, PBS was added to the 
mixture to adjust the pH to neutrality. Reduction of F(ab’)2 to Fab’ fragments 
was checked and confirmed by 12% SDS-PAGE gel under reducing and non-
reducing conditions.  
After reduction, Fab’ fragments were incubated with 25 mM IAM for 30 min at 
room temperature in the dark to alkylate the free cysteine residues of the 
interchain disulfide bonds in the hinge region to block their reformation. 
 
2.13 DOT BLOT ANALYSIS 
Increasing amounts of rhNodal (50, 100, 150 and 200 ng) were spotted through 
circular templates  directly onto a polyvinylidene difluoride (PVDF) membrane 
(Millipore). PVDF membranes was previously soaked in methanol 100% for 5 
min. The blot was blocked with 5% milk (NFDM) in Tris-buffered saline 
containing 0.1% Tween-20 (TBS-T) for 1 h at room temperature under shaking; 
next, the membrane was probed overnight at 4° C with 3D1 mAb as primary 
antibody at 2 µg/mL in 2.5% NFDM in TBS-T under shaking. The membrane 
was then triple-washed with TBS-T and incubated with GAM-HRP as secondary 
antibody diluted 1:1000 in TBS-T for 1 h at room temperature under agitation. 
The target protein was detected using the enhanced Chemi-luminescent 
Substrate method with the SuperSignal West Pico kit provided by Pierce 
Chemical Co. (Rockford, IL USA), following the manufacturer’s instructions. 
Signals were acquired with the ChemiDoc™ XRS video densitometer (Bio-Rad, 
Hercules, CA), using the Quantity One® software (Bio-Rad), that was used to 
performed the densitometer analysis as well. 
 
2.14 WESTERN BLOT ANALYSES 
Protein lysates of the cell lines were collected, quantified and subjected to SDS-
PAGE gel electrophoresis and Western blot using standard protocols. 
 
2.14.1 Detection of recombinant human Nodal 
Increasing amounts of rhNodal (50, 100 and 200 ng) were loaded under reducing 
and denaturing conditions onto a 15% SDS-PAGE gel; after electrophoresis, 
proteins were transferred onto a PVDF) membrane, previously soaked in 
methanol 100% for 5 min, then equilibrated in transfer buffer (10 mM Tris base, 
100 mM Glycine, 10% Methanol and 0.5% SDS) for at least 3 minutes. The 
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semi-dry electrophoretic transfer was performed at 18 eV for 40 min, using a 
Trans-Blot® SD (Bio-Rad) instrument. The western blot analysis was performed 
following the protocol previously described in the section 2.13. 
 
                2.14.2 Detection of endogenous Nodal protein in human melanoma cell lines 
Western blot analyses for the detection of endogenous Nodal protein were 
performed using the following human skin malignant melanoma cell lines: PES, 
A-375, SK-MEL, WM 266 and LCM. HEK-293 cells and 100 ng of rhNodal 
protein were used as positive controls. Cells were lysed using a lysis buffer (50 
mM Tris-HCl pH 7.5, 500 mM NaCl, 1% NP, 10 mM EDTA, 1 mM MgCl2, 1 
mM CaCl2, 10% Glycerol), with added a cocktail of protease inhibitors (Roche, 
Switzerland) and PMSF (Phenyl-MethaneSulfonylFluoride), a serine protease 
inhibitor, performing three freeze/thaw cycles. Samples were quickly frozen 
using a dry ice/ethanol bath and subsequently thawed at room temperature. 
Cycles of freezing and thawing caused cells to swell and break. Cell lysates were 
cleared by centrifugation at 12,000 for 20 min at 4° C and the supernatants 
containing all protein whole lysates were quantified by Bradford assay.  
50 µg of cell lysate from each sample were applied to a 15% SDS-PAGE gel 
under reducing conditions and electrophoresed for 3 h at 80 V. Separated 
proteins were transferred onto a PVDF membrane. The western blot analysis 
was performed following the protocol previously described. 
  
2.14.3 Competition between 3D1 antigen peptide and endogenous Nodal 
protein 
Thirty micrograms of H9 and H14 human embryonic stem cell total protein 
lysates, obtained as previously described, were separated on a 15% SDS-PAGE 
gel under reducing conditions and the resolved proteins were transferred onto a 
PVDF membrane. 50 ng of rhNodal protein were used as positive control. The 
western blotting procedure was as previously described. The membranes were 
blocked, then probed with the 3D1 alone at 4 µg/mL in 2.5% NFDM in TBS-T 
and with the 3D1 mAb at 4 µg/mL pre-incubated with its antigen, the CH[43-56] 
peptide at 10 µg/mL. The blots were probed with GAM-HRP as secondary 
antibody and detected as already described.  
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2.14.4 Effects on Nodal expression  
Twenty-five micrograms of total C8161 cell lysates were loaded per lane. 
Western blot analyses were performed following the protocol previously 
described. The blot was probed for detection of Nodal protein using anti-Nodal 
anti-rabbit monoclonal antibody (EP2058Y, Epitomics). The blot was then 
stripped and probed for β-Actin to determine equal loading using a mous anti-β-
Actin antibody (β-Actin (C4): sc-47778 Santa Cruz). Densitometric values for 
Pro-Nodal [39 kDa] were corrected by values determined for β-Actin. 
 
2.14.5 Detection of Phospho-Smad, Phospho-MAPK, Cyclin B1 and p27 
Thirty micrograms of total protein lysates (C8161) were loaded per lane on a 
15% SDS-PAGE gel under reducing conditions. Western blot analyses were 
carried out using the procedure previously described. The membranes were 
probed with a rabbit polyclonal anti-Cyclin B1 (cyclin B1 antibody (H-20) sc-
594, Santa Cruz Biotechnology), anti-p27 (p27 antibody (C-19) sc-528, Santa 
Cruz Biotechnology), anti Phospho-Smad (MBS617171, My Biosource) and 
anti-Phospho-MAPK antibody ( MBS835580, My Biosource). 
 
2.15 CELL CULTURE AND ANTIBODY TREATMENT 
All human cell lines were purchased from ATCC (American Type Culture 
Collection) and cultured in T175 flasks at  37° C, in a humidified (90 %) and 
CO2 (5 %) containing atmosphere.  
HEK293 cells (immortalized human embryonic kidney cells, adherent), the 
following human aggressive melanoma cell lines, PES, A-375, SK-MEL, WM 
266, LCM and LCP and  the human embryonic stem cells, H9 and H14, were 
cultured and maintained in complete DMEM-F12 medium (Dulbecco’s modified 
Eagle’s medium-F12) supplemented with 10% FCS, and 1% 
penicillin/streptomycin. The human cutaneous amelanotic melanoma C8161 
cells, characterized as highly aggressive, invasive and metastatic 
[119]
, were 
cultured and maintained in RPMI 1640 (Invitrogen, Carlsbad, CA) supplemented 
with 10% fetal calf serum (FCS, Gemini Bio-Products, Woodland, CA). 
Medium was changed routinely twice per week and cells were splitted into a 
new flask containing fresh medium, when they reached 80-90% confluence. 
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All cells were passaged every second or third day in proportion of 1:4 or 1:6, 
respectively. For passaging the cell culture, medium was removed and PBS 
(room temperature) was used to wash the cells. PBS was removed as well and 
cells were detached with about 2 mL of 0.05% trypsin/EDTA solution 
(Invitrogen). The flasks were placed in the incubator (37°C) for around 5 
minutes. With a Zeiss model 25 inverted microscope (Carl Zeiss, Inc.) cells were 
monitored for detachment and for assuming a round shape. Fresh medium was 
added to neutralize trypsin. 
The cell lines were genotyped by short tandem repeat (STR) PCR amplification 
and authentication confirmed.  C8161 cells were treated with the 3D1 anti-Nodal 
antibody at 4 μg/mL, whereas an IgG was used as control (Santa Cruz anti-
Nodal antibody).  
For most in vitro experiments, antibodies were diluted in complete RPMI and 
added to cells daily for a period of 72 hours. 
 
2.16 FLUORESCENCE-ACTIVATED CELL-SORTING (FACS) 
ANALYSES 
LCP, A375 and WM266 cells were collected by centrifugation. After aspiration 
of supernatant, the cells were resuspended in 500 µL of PBS and formaldehyde 
was added to obtain a final concentration of 4%. Cells were fixed for 10 min at 
room temperature. After fixation, cells were permeabilized by adding 500 µL of 
PBS-Tween 20. 
1x10
6
 cells were aliquoted into each vial; 1 ml of PBS (incubation buffer) was 
added to each vial and cells were washed by centrifugation at 4000 rpm for 5 
min at 4°C. Cells were resuspended in 100 µL of solution of 3D1 anti-Nodal 
antibody (primary antibody), diluted in PBS at the following concentrations: 0.1, 
0.5, 1 and 2 µg/mL. A standard IgG1 isotype was used as negative control. Cells 
were incubated with the primary antibody for 1 hour at 4°C under shaking. After 
incubation, cells were washed by centrifugation in 1 mL of PBS, resuspended 
and incubated with a FITC-conjugated anti-mouse antibody (secondary 
antibody), diluted 1:1000 (1µg/mL) in PBS , for 40 min at 4° C in the dark under 
stirring. Cells were washed by centrifugation with 1 mL of incubation buffer, re-
suspended in 500 µL of PBS and analyzed on flow cytometer. Fluorescence was 
evaluated using the BD FACScalibur
™
 System. 
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2.17 SOFT AGAR CLONOGENIC ASSSAY 
Colony forming assays were prepared in triplicate wells with C8161 melanoma 
cells. Briefly, for each well, 5.000 cells were suspended in 0.35% agarose in 
complete RPMI or in complete RPMI containing 3D1 anti-Nodal antibody at 4 
µg/mL or an IgG used as negative control. Suspensions were pipetted onto a 
solidified layer of 0.5% agarose in complete RPMI in six-well dishes. Cells were 
cultured for three weeks, then clusters of > 50 cells were scored and 
photographed using a Zeiss model 25 inverted microscope (Carl Zeiss, Inc.) and 
Hitachi HV-C20 CCD camera (Hitachi Denshi Ltd.,Woodbury, NY, USA). 
 
2.18 VASCULOGENIC MIMICRY ASSAY 
An aliquot of growth factor-reduced Matrigel (14 mg/ml; BD Biosciences) was 
warmed up at room temperature. Before completely thawed, it was transferred 
onto ice and its liquid was kept on ice for at least 10 min. Then 50 μL of 
Matrigel was plated to 96-well plates at a horizontal level that allows the 
Matrigel to distribute evenly and incubated for 30 min at 37° C. 
C8161 cell pellets (1-2 x 10
4
) were re-suspended with serum-free RPMI and 
loaded on the top of the Matrigel. The 3D1 mAb, the blocking anti-Nodal 
antibody (Santa Cruz) that was used as positive control and an IgG1 used as 
negative control were added at 3 µg/mL and at 4 µg/mL to the serum-free 
medium. Each conditional group contained 4-6 wells. Following incubation at 
37° C overnight, each well was analyzed directly under a microscope. 100 μL of 
10% formalin saline-based solution was gently added for the tubules fixation. 
Under a microscope with 10x phase contrast, tubules in each field were imaged 
and an average of tubules from 3-5 random fields in each well was counted. 
 
2.19 LUNG COLONIZATION IN MICE INDUCED BY C8161 CELLS 
250,000 C8161 metastatic human melanoma cells were injected retro-orbitally in 
16 nude mice and characteristically colonized first to the lung; lung colonization 
was established after 4 days. Following colonization, animals received by 
intraperitoneal delivery alternate injections of 100 µg of either of 3D1 
monoclonal antibody (N=8) or control IgG (N=8) over the next 10 days, every 
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other day (5 total injections). The mice were sacrificed on days 12 and their 
lungs were examined macroscopically and immunohistochemically. 
 
2.20 IMMUNOHISTOCHEMICAL ANALYSES 
Four-micron thick, formalin-fixed, paraffin-embedded lung mice tissue sections 
were prepared and immunohistochemistry was carried out on a Microm HMS 
710i autostainer (Thermo Scientific Lab Vision, Waltham, MA, USA). Briefly, 
following antigen retrieval and blocking steps, sections were incubated in Cyclin 
B1, p27 and P-Smad antibody at 5 μg/mL for 60 minutes, followed by 
biotinylated anti-mouse secondary antibody (Biocare Medical, LLC, Concord, 
CA, USA), and then streptavidin-horseradish peroxidase (Thermo Scientific Lab 
Vision). Colour was developed with 3,3’-diaminobenzidine substrate (Thermo 
Scientific Lab Vision) and sections were counterstained with hematoxylin 
(Biocare Medical, LLC). As a negative control, adjacent serial sections were 
incubated with ChromPure mouse Ig (Jackson Immunoresearch Labs, West 
Grove, PA, USA) at the same concentration. Cyclin B1, p27 and P-Smad 
staining was scored on a scale of 0 to 3 at 10 × and 63 × magnification to 
determine, respectively, percentage and intensity of Cyclinn B1, p27 and P-
Smad staining within the area of interest (0, no staining; 1 = < 10% or weak; 2 = 
10 to 50% or moderate; 3 = > 50% or strong). The two scores were then 
multiplied to obtain a Cyclin B1, p27 and P-Smad Scoring Index (SI).  
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                              I 3. RESULTS 
3.1 GENERATION AND CHARACTERIZATION OF ANTI-
NODAL MONOCLONAL ANTIBODIES  
 
3.1.1 ANTIGEN DESIGN 
On the basis of previous docking and binding studies 
[32]
, the region of human 
Nodal (Uniprot Q96S42) including the H3-wrist helix along with the pre-helix 
loop was chosen as hNodal-like antigen.  
As reported by Calvanese et al.
[32]
, the hNodal[43-69] peptide, referred to the 1-
110 residues numbering and corresponding to the mature form of the 
endogenous protein (238-347 aa), is involved in the binding with the co-receptor 
Cripto and it contains two glutamic residues, E49 and E50, which are crucial to 
stabilize the interaction. With the aim to select anti-Nodal antibodies able to 
recognize these two hot-spots residues, we devised a simple and new strategy of 
screening. After immunization and hybridoma generation, cell supernatants were 
screened using a mutated form, named hNodal[43-69]E49A-E50A peptide, in 
which E49 and E50 were replaced with two alanines. 
  
 
                             
              Figure 3.1:  Aminoacid sequence and secondary structure of the Nodal monomer.  
 
 
3.1.2 CHEMICAL SYNTHESIS, PURIFICATION AND 
IDENTIFICATION OF HUMAN NODAL AND GDF PEPTIDES  
hNodal[43-69] peptide and mutated variants were synthesized with either a free 
amino group at the N-terminus (used for conjugation with KLH and immunogen 
preparation), or acetylated and amidated to better mimic the peptide within the 
protein structure. 
A set of mutated variants of hNodal[43-69] peptide, reported in Table 1, were 
designed to define the epitope and to investigate the contribution of specific 
residues to the recognition with antibodies. Peptides 1 to 7 (Table 1) included 
pre-helix loop
H1HLPDRSQLCRKVKFQVDFNLIGWGSWIIYPKQYNAYRCEGEC43PN
b1
b4
b2
b3H3
PVGE49E50FHPTNHAYIQSLLKRYQPH69RVPSTCCAPVKTKPLSMLYVDNGRVLLDHHKDMIVEECGCL
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variants of hNodal[43-69] bearing doubly mutated residues, at the N-terminus; 
shorter peptides (entries from 8 to 10, Table 1) were used to confirm the epitope 
at N-terminus region. 
To confirm the specificity of recognition in the full-length protein, three peptides 
(entries from 11 to 13, Table 1) mimicking the N-terminal portion [1-38], the 
central region [39-75] and the C-terminal region [76-100] of the mature form of 
human Nodal 
[120]
 were tested. Peptides 14 and 15 in Table 2, reproducing the 
human GDF 5 and GDF6/7 region (GDF : Growth Differentiation Factors; GDFs 
are close structural homologs of Nodal 
[33]
) were tested to explore the selectivity 
of antibody among TGF-b family ligands. The sequence were chosen on the 
basis of multiple alignment of hNodal[43-69] peptide versus all TGF-b ligands 
performed by using the BLAST server (http://www.expasy.org/proteomics); 
alignments are reported in Fig. 3.2.  
All peptides were synthesized, purified and identified as described in the 
Methods section 2.1; they were obtained with an average yield of 50% and with 
a purity level above 95%, as determined by LC-MS analysis. (Table 1).  
 
 
 
                           
Table 1.  Nomenclature, aminoacidic sequence and MW of hNodal peptides 
hNodal peptides Sequence MW Theor. MW Exp.
1 [43-69] CPNPVGEEFHPTNHAYIQSLLKRYQPH 3217.592 amu 3216.6  amu
2 [43-69]E49A-E50A CPNPVGAAFHPTNHAYIQSLLKRYQPH 3100.56  amu 3100.6  amu
3 [43-67] CPNPVGEEFHPTNHAYIQSLLKRYQ 2983.335 amu 2982.3 amu
4 [44-67] PNPVGEEFHPTNHAYIQSLLKRYQ 2880.192 amu 2879.3 amu
5 [44-67]E49A-E50A PNPVGAAFHPTNHAYIQSLLKRYQ 2764.119 amu 2763.5 amu
6 [43-67]P46A-V47A CPNAAGEEFHPTNHAYIQSLLKRYQ 2929.244 amu 2928.6 amu
7 [44-67]P46A-V47A PNAAGEEFHPTNHAYIQSLLKRYQ 2826.101 amu 2825.5 amu
8 [43-56] CPNPVGEEFHPTNH 1618.728 amu 1617.8 amu
9 [52-60] HPTNHAYIQ 1121.202 amu 1121.2 amu
10 [56-69] AYIQSLLKRYQPH 1657.916 amu 1658.0 amu
11 [1-38] HHLPDRSQLCRKVKFQVDFNLIGWGSWIIYPKQYNR 4719.428 amu 4718.4 amu
12 [39-75] CEGECPNPVGEEFHPTNHAYIQSLLKRYQPHRVPSTC 4279.778 amu 4278.7 amu
13 [76-100] CAPVKTKPLSMLYVDNGRVLLDHHKDMIVEECGCL 3969.720 amu 3968.6 amu
Table 2. Nomenclature, aminoacidic sequence and MW of  hGDF peptides 
hGDF peptides Sequence MW Theor. MW Exp.
14 GDF5 CEFPLRSHLEPTNH 1720.908 amu 1719.8 amu
15 GDF 6/7     CDFPLRSHLEPTNH 1706.881 amu 1705.7 amu
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       Figure 3.2: Multiple alignment of TGF-b ligand versus hNodal[43-69] sequence. 
 
3.1.3 SCREENING OF HYDRIDOMA SUPERNATANTS AND EPITOPE 
IDENTIFICATION BY ELISA ASSAY 
An initial screening of hybridoma supernatants was carried out by ELISA assay 
coating the hNodal[43-69] BSA-conjugated peptide and detecting the bound 
antibodies using suitable anti-mouse antibodies (See Methods). By this 
preliminary test, 9 clones were positive, with binding signals above 1.5 
absorbance units. Following our strategy, the pre-selected hybridoma 
supernatants were next screened using hNodal[43-69] and its mutated variant 
hNodal[43-69]E49A-E50A peptides. The assay was performed coating the 
unconjugated peptides at 330 nM and testing the hybridoma supernatants at a 
total protein concentration of 5 µg/mL (33 nM). 
Data reported in Fig. 3.3 show that supernatants from 6 clones indicated as 9B9, 
3D1, 10B12, 5F10, 1B4 and 2D12, although to a different extent, recognized 
very well the immobilized antigen; clones 9F10, 1C8 and 8E3, showed a very 
weak signal, and were therefore discarded. Furthermore, clone named 3D1 
recognized the wild-type hNodal peptide much better than the mutated variant, 
suggesting that binding occurs close to the region encompassing the two 
glutamic residues crucial for the binding of Nodal to the co-receptor Cripto. 3D1 
clone was thereby identified as the most promising to show a neutralization 
activity for the interaction Nodal/Cripto.  
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Figure 3.3: ELISA-based screening assay of hybridoma supernatants. hNodal[43-69] and 
hNodal[43-69]E49A-E50A peptides were coated at 1µg/mL (330 nM). Hybridoma supernatants 
were tested at a concentration of 5µg/mL total protein (33 nM assuming the occurrence of 
purified antibodies). 
 
3.1.4 ISOLATION OF ANTI-NODAL mAbs FROM HYBRIDOMA 
SUPERNATANTS  
Supernatants from the six monoclonal antibodies (mAbs, 9B9, 3D1, 10B12, 
5F10, 1B4 and 2D12) showing the strongest signal for binding to Nodal 
peptides, were purified by Protein G affinity chromatography (Fig. 3.4A) and 
concentrated as described in the section of Methods. High yield and high purity 
were achieved for all the antibodies and, as expected, a band of 150 kDa was 
detected by 10% SDS-PAGE under non-reducing conditions (Fig. 3.4C).  
MAbs isolated from hybridoma supernatants were further purified by size-
exclusion chromatography to evaluate the presence and even to remove possible 
aggregates (Fig. 3.4B). All mAbs showed a similar gel filtration profile, with a 
retention volume of 11-12 ml, according to a protein molecular weight of 150 
kDa. As can be seen, no aggregates were detectable, as well as confirmed by 
10% SDS-PAGE under non-reducing conditions. All purified mAbs were 
identified as IgG1 isotype with kappa light chains. 
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Figure 3.4: (A) Representative chromatogram of Protein G affinity purification of a mAb from 
hybridoma supernatant, sharp peaks are due to the elution of the bound mAb with 100mM 
Glycine pH 2.7; (B) Representative SE chromatographic profile of an anti-Nodal  mAb; (C) 10% 
SDS-PAGE analysis of  two steps purified anti-Nodal mAbs.                                
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3.1.5 SPR BINDING ANALYSES OF mAbs TO rhNODAL PROTEIN  
 
After selection, the ability of the purified monoclonal antibodies to bind to the 
full-length recombinant human Nodal protein was evaluated and considered a 
pre-requisite for their use as diagnostic tool. This screening was carried out by 
SPR direct binding. MAbs were initially tested at 100 nM; at this concentration 
only two antibodies, 3D1 and 5F10, were able to bind to the full-length rhNodal 
protein. To determine their affinity constant, dose-dependent binding assays 
were next carried out. Analyses were performed injecting increasing 
concentrations of antibodies; association and dissociation rate constants were 
determined from each run. A global fitting of the data allowed the estimation of 
a KD value of 1.42 nM for the interaction between the 3D1 and the protein. A KD 
of 83 nM was instead measured for the interaction of the 5F10 antibody. The 
3D1 displayed rapid association (ka 6.95*10
5 
M
-1
s
-1
) and slow dissociation rate 
(kd 6.55*10
-4 
s
-1
) constants, resulting in a high binding affinity to the protein. 
The 5F10 mAb, compared to the 3D1, exhibited lower affinity, as result of 
slower association (ka 1.91*10
4 
M
-1
s
-1
) and quicker dissociation (kd 1.08*10
-3 
s
-1
) 
rates; moreover, it recognized the protein at higher concentrations, revealing a 
weak binding. 
                
 
Figure 3.5A: Overlay plot of SPR sensorgrams showing the interaction between 3D1 mAb and 
rhNodal immobilized on a CM5 sensor chip. The interaction was monitored at concentrations of 
mAb ranging between 6 and 100 nM, obtaining dose–dependent binding curves. 
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Figure 3.5B: Overlay plot of SPR sensorgrams showing the interaction between 5F10 mAb and 
hNodal immobilized on a CM5 sensor chip. The interaction was monitored at concentrations of 
mAb ranging between 100 and 750 nM, obtaining dose–dependent binding curves. 
 
                                        
                
 
       In light of these results, 3D1 was chosen for subsequent studies.  
  
Table 3. Association and dissociation rate constants and KD values
determined for the binding of the 3D1 mAb to rhNodal
functionalized sensor chip
3D1 mAb ka (1/Ms) kd (1/s) KD (M) SD
6 nM 1.28*106 6.29*10-4 4.91*10-10 0.0129
12 nM 9.79*105 6.30*10-4 6.98*10-10 0.0504
25 nM 6.42*105 6.20*10-4 9.68*10-10 0.165
50 nM 3.61*105 6.97*10-4 1.93*10-9 0.331
100 nM 2.12*105 6.44*10-4 3.03*10-9 1.07
average 6.95*105 6.55*10-4 1.42*10-9 0.326
Table 4. Association and dissociation rate constants and KD values
determined for the binding of the 5F10 mAb to rhNodal
functionalized sensor chip
5F10 mAb ka (1/Ms) kd (1/s) KD(M) SD
100 nM 2.60*104 8.16*10-4 3.14*10-8 0.0246
250 nM 1.81*104 1.08*10-3 5.97*10-8 0.0818
500 nM 1.31*104 1.33*10-3 1.02*10-7 0.148
750 nM 9.40*103 1.30*10-3 1.38*10-7 0.0286
average 1.91*104 1.08*10-3 8.28*10-8 0.0708
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                3.2 BIOCHEMICAL CHARACTERIZATION OF THE 3D1 
 
3.2.1 SPR COMPETITION ASSAY 
By SPR assay, after achieved dose-dependent binding between  rhNodal and its 
co-receptor rhCripto-1, a dose-dependent competition experiment using 3D1 
monoclonal antibody was carried out to evaluate the ability of the mAb to 
interfere in the binding of Nodal to Cripto. Data shown in Fig. 3.6 revealed that 
the antibody at 1:1 molar ratio was able to inhibit the binding of Nodal to Cripto-
1 by approximately 70%. This is a preliminary evidence that the 3D1 is able to 
block the formation of Nodal/Cripto-1 complex and this result supports the 
hypothesis that the 3D1 can be a neutralizing antibody for the upstream Nodal 
signaling.  
                           
Figure 3.6: Inhibition of rhNodal/rhCripto-1 complex by SPR concentration-dependent 
competiton assay. A plot of % of binding versus increasing antibody concentrations is reported. 
RhNodal was used at the fixed concentration of 5 nM. 
 
3.2.2 PRODUCTION AND PURIFICATION OF Fab/F(ab’)2/Fab’ 
FRAGMENTS 
In the attempt to produce smaller antibody fragments useful for crystallization 
studies, we tried to obtain 3D1-derived Fab fragments by enzymatic digestion. 
After unfruitful attempts to obtain the Fab under canonical conditions using 
several enzymes (not shown), we ended up with a protocol foreseeing 
deglycosylation of the antibody prior digestion 
[121]
. For this purpose 3D1 mAb 
was deglycosylated with the Peptide-N-glycosidase F (PNGase F) to remove a 
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single N-linked glycan at Asn
297
 on each CH2 domain of the two heavy chains. 
This was expected to render the IgG1 molecule more sensitive to proteases 
activity, because the glycan pattern reportedly affects antibody’s resistance to 
proteases digestion, especially by pepsin. After the deglycosylation reaction, the 
whole antibody was digested by using three different proteases: papain, ficin and 
pepsin. 
Papain and ficin were used to prepare the monovalent Fab fragment by splitting 
the antibody above the hinge region; instead, pepsin was used to produce the 
bivalent F(ab’)2 fragment by cleaving the antibody on the carboxyl side of 
cysteine residues within the hinge region, below the disulfide bond. 
All digestions were completed after 6 hours of incubation. SDS-PAGE analyses 
showed the disappearance of the 150 kDa band corresponding to the whole 
antibody under non reducing conditions and the disappearance of the 50 kDa 
band representing the intact heavy chain under reducing conditions. The reaction 
with papain led to the formation of a Fab with an apparent MW of about 40 kDa 
(non reducing conditions) or 25 kDa (reducing conditions), Fig. 3.7A. The 
treatment with ficin led to fragments with the same array of molecular weights 
(Fig. 3.7B). Remarkably, pepsin (Fig. 3.7C) converted 3D1 into F(ab’)2, MW 
about 100 kDa, without formation of other fragments. 
 
Figure 3.7: 12% SDS-PAGE analysis under non reducing (-) and reducing (+) conditions of 
products obtained following digestion of the 3D1 mAb with three different proteases – (A) 
Papain, (B) Ficin and (C) Pepsin- T0 : 3D1 antibody ; Dig : proteolytic digest of 3D1 after 6 
hours. 
 
Fab and F(ab’)2 fragments were isolated from the digestion mixture by a two-
step purification procedure, that included Protein G affinity chromatography to 
remove the Fc portions and possible intact antibody (uncut) and size-exclusion 
chromatography to both evaluate the presence and remove aggregates and to 
remove residual proteases. Integrity and purity of the products were confirmed 
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after each step by SDS-PAGE analysis under reducing and non-reducing 
conditions.        
In the chromatograms of the Protein G affinity purification reported below, the 
first peak corresponded to the Fab from papain (A), the Fab from ficin (B) and 
the Fc portion (C) degraded by pepsin into small sub-fragments, eluted in the 
flow through. By contrast, the second peak corresponded to the Fc portion from 
papain and ficin digestion, [(A) (B) respectively] and the F(ab’)2 (C) obtained 
from pepsin digestion. F(ab’)2, instead of Fab, was eluted with Glycine because 
it contained a small portion of Fc. 
     
 
Figure 3.8: Chromatograms of Protein G affinity purification and SDS-PAGE analysis of 
products obtained from papain (A), from ficin (B) and from pepsin digestion (C).  
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Fab and F(ab’)2 fragments partially purified by the affinity chromatography step 
were purified to homogeneity by size-exclusion chromatography.              
SE-chromatographic profiles showed absence of aggregates and presence of 
highly homogenous products; moreover, the elution volume of each single 
product was in agreement with the expected molecular weight: ~ 45 kDa for the 
Fab obtained with papain and ficin digestion, ~ 110 kDa for the F(ab’)2 obtained 
with pepsin. Purity estimated on 12% non-reducing and reducing SDS-PAGE 
was also higher than 99%. By SDS-PAGE analysis the identity of final products 
was confirmed as well; as expected, the F(ab’)2 fragment exhibited, under non 
reducing conditions, an homogenous band at approximately 110 kDa, while 
under reducing conditions, two separated bands with different mobility at around 
25 kDa, the slower one corresponded to the heavy chain, higher than the other 
one due to the presence of a small Fc portion, while the faster one corresponded 
to the light chain. 
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Figure 3.9: SEC profiles with the retention volume and SDS-PAGE analysis of  Fab obtained by 
papain digestion (A), Fab obtained by ficin digestion (B) and F(ab’)2 obtained by pepsin 
digestion (C). 
 
Next, Fab' fragment was obtained by reducing selectively the hinge-region 
disulfide bonds of F(ab’)2 using Mercaptoethylamine. The reaction was 
successfully achieved after 3 hours as shown by SDS-PAGE analysis under non 
reducing conditions (Fig. 3.10A) by the absence of the F(ab’)2 band at 110 kDa 
and the presence of the ~45 kDa band corresponding to the Fab’ fragment. 
Additional smaller bands approximately at 25 and 20 kDa were other 
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unimportant products of the reduction reaction. To carry out further analyses, the 
Fab’ was alkylated with 25 mM IAM to block the reformation of the hinge 
region disulfide bonds. Subsequently, Fab’ was purified by size-exclusion 
chromatography to confirm its identity and to evaluate the presence of eventual 
aggregates. As indicated by the presence of a single peak eluted at 13.65 ml 
(Fig. 3.10B), no aggregates were detected. 
         
 Figure 3.10: (A) 12% SDS-PAGE analysis under non reducing conditions of the F(ab’)2      
 reduced to Fab’; (B) SE-chromatographic profile of the Fab’. 
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3.2.3 SPR COMPARATIVE BINDING ANALYSES OF Fab/F(ab’)2/Fab’ 
FRAGMENTS 
The ability of the different purified antibodies fragments, obtained by proteolytic 
cleavage, to bind to rhNodal protein was assessed by a comparative binding 
assay carried out by SPR technique. Fragments were tested at a concentration up 
to 100 nM. Unfortunately, Fab fragments obtained by digestion with papain and 
ficin were unable to bind to the immobilized protein; a plausible explanation was 
that also the CDRs were multiply cleaved by the proteases leading to antibody 
inactivation. 
                                 
 
The 3D1 F(ab’)2 and Fab’fragments bound to the immobilized rhNodal, 
displaying similar association and dissociation rate constants and consequently 
the same affinity for rhNodal (KD=15 nM, See Fig. 3.11 and Fig. 3.12). This KD 
is 10-fold lower compared to that exhibited by the whole antibody (KD=1.4 nM); 
this effect was probably due to partial local unfolding resulting from the low pH 
treatment required for the pepsin digestion 
[122]
.                              
                    
 
Figure 3.11: Overlay plot of SPR sensorgrams showing the binding of the 3D1 (Fab’)2 to 
rhNodal immobilized on a CM5 sensor chip. The interaction was monitored at concentrations of 
F(ab’)2 ranging between 25 and 500 nM, obtaining dose–dependent binding curves. 
Table 5. Fab fragments tested by SPR
Sample Binding vs rhNodal
Fab from Papain -
Fab from Ficin -
F(ab)’2 from Pepsin +
Fab’ from F(ab’)2 +
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Figure 3.12: Overlay plot of SPR sensorgrams showing the binding of the 3D1 Fab’ to rhNodal 
immobilized on a CM5 sensor chip. The interaction was monitored at concentrations of Fab’ 
ranging between 25 and 200 nM, obtaining dose–dependent binding curves 
.             
                     
  
Table 6. Association and dissociation rate constants and KD
values determined for the binding of the F(ab’)2 to rhNodal
functionalized sensorchip
F(ab')2 ka (1/Ms) kd (1/s) KD (M) SD
25 nM 4.40*105 1.13*10-3 2.57*10-9 0.0214
50 nM 2.77*105 1.35*10-3 4.87*10-9 0.0578
100 nM 1.87*105 1.63*10-3 8.71*10-9 0.323
250 nM 8.21*104 1.67*10-3 2.03*10-9 0.446
500 nM 4.58*104 1.84*10-3 4.02*10-8 1.63
average 2.06*105 1.52*10-3 1.53*10-8 0.496
Table 7. Association and dissociation rate constants and KD
values determined for the binding of the Fab’ to rhNodal
functionalized sensor chip
Fab' ka (1/Ms) kd (1/s) KD (M) SD
25 nM 3.42*105 2.02*10-3 5.91*10-9 0.0347
50 nM 1.59*105 2.62*10-3 1.65*10-8 0.0245
75 nM 1.50*105 1.92*10-3 1.28*10-8 0.0949
100 nM 1.18*105 1.56*10-3 1.32*10-8 0.0909
200 nM 7.59*104 2.31*10-3 3.04*10-8 0.145
average 1.69*105 2.09*10-3 1.58*10-8 0.078
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3.2.4 EPITOPE MAPPING STUDY  
To finely delineate the epitope of the 3D1 antibody, a mapping of the original 
antigen was carried out. For this purpose, the antigen peptide and its mutated 
variants (see Table 1) were assayed by ELISA and by SPR.  
 
a. ELISA assay 
ELISA assays were carried out to by coating the different peptides, probing the 
binding with 3D1 and detecting with a secondary anti-mouse antibody. As 
shown in Fig. 3.13, the highest signal was detected with the short [43-56] 
peptide, whereas weaker signals were detected with variants bearing the mutated 
E49 and E50. No binding was observed with the variants in which P46 and V47 
were mutated to alanines, as well as with other shorter peptides. 
These data confirmed the high specificity of the 3D1 for N-terminal residues, 
specifically C43, P46, V47, E49 and E50.  
                                         
               
Figure 3.13: Mapping of 3D1mAb epitope; peptides were coated at 1µg/mL; absorbance values 
of each peptide was normalized to the [43-69] peptide, considered as 100% of signal. 
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b. SPR analyses    
SPR dose-response binding assays were performed with peptides [43-67], [44-
67] and [43-56] to extrapolate KD values. Sensorgrams are reported in Fig. 3.14. 
In Table 8 are reported the relevant data obtained by the analyses. These data 
suggest that region [43-56] is the epitope of the 3D1 mAb and that residues from 
46 to about 50 are the most crucial for the recognition. The region falls within 
the pre-helix loop, encompassing the two glutammic acid residues crucial for the 
binding of Nodal to Cripto. The 3D1 is not a conformational antibody because it 
mostly recognizes a linear epitope; in addition, this finding was confirmed by 
SPR analysis by the absence of binding with the other two smaller variants, [52-
60] and [56-69], even tested at very high concentrations (data not shown). 
Furthermore, C43, which seems to have a role in the binding to the antibody, 
likely only plays a conformational role, helping the peptide to adopt a structure 
more prone to antibody recognition.  
 
 
 
    
Table 8. hNodal peptides screened in the epitope mapping study and KD values determined for the binding of the 
positive peptides to 3D1 mAb/Fab’ functionalized sensor chip. No fitting means that fitting of binding and 
association curves did not converge to any value.
hNodal peptides 0.5-20 µM Sequence KD vs 3D1 mAb KD vs 3D1 Fab’
[43-67] CPNPVGEEFHPTNHAYIQSLLKRYQ 613 nM 590 nM
[44-67] PNPVGEEFHPTNHAYIQSLLKRYQ NO FITTING NO FITTING
[44-67]E49A-E50A PNPVGAAFHPTNHAYIQSLLKRYQ NO BINDING NO BINDING
[43-67]P46A-V47A CPNAAGEEFHPTNHAYIQSLLKRYQ NO BINDING NO BINDING
[43-56] CPNPVGEEFHPTNH 405 nM 371 nM
[52-60] HPTNHAYIQ NO BINDING NO BINDING
[56-69] AYIQSLLKRYQPH NO BINDING NO BINDING
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Figure 3.14A: Overlay plot of SPR sensorgrams showing the interaction between peptide [43-
67] and 3D1 mAb immobilized on a CM5 sensor chip. The interaction was monitored at 
concentrations of peptide ranging between 0.5 and 10 µM, obtaining dose–dependent binding 
curves. 
 
                                    
                   
               
 
Figure 3.14B: Overlay plot of SPR sensorgrams showing the interaction between hNodal[43-67] 
peptide and 3D1 Fab’ immobilized on a CM5 sensor chip. The interaction was monitored at 
peptide concentrations ranging between 1 and 10 µM, obtaining dose–dependent binding curves. 
 
Table 9. Association and dissociation rate constants and KD values
determined for the binding of hNodal[43-67] peptide to 3D1 mAb
functionalized sensorchip
[43-67] vs mAb ka (1/Ms) kd (1/s) KD (M) SD
0.5 µM 8.43*104 3.95*10-3 4.69*10-8 0.0167
1 µM 2.01*104 3.37*10-3 1.68*10-7 0.0277
2.5 µM 5.56*103 2.91*10-3 5.23*10-7 0.0564
5 µM 3.03*103 2.48*10-3 8.17*10-7 0.0731
10 µM 1.45*103 2.32*10-3 1.60*10-6 0.0999
average 2.29*104 3.01*10-3 6.31*10-7 0.0548
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Figure 3.15A: Overlay plot of SPR sensorgrams showing the interaction between hNodal[44-67] 
peptide and 3D1 mAb immobilized on a CM5 sensor chip. The interaction was monitored at 
peptide concentrations ranging between 1 and 20 µM, obtaining dose–dependent binding curves. 
 
                     
 
Figure 3.15B: Overlay plot of SPR sensorgrams showing the interaction between hNodal[44-67] 
peptide and 3D1 Fab’ immobilized on a CM5 sensor chip. The interaction was monitored at 
peptide concentrations ranging between 1 and 20 µM, obtaining dose–dependent binding curves. 
                       
 
 
Table 10. Association and dissociation rate constants and KD values
determined for the binding of hNodal[43-67] peptide to 3D1 Fab’
functionalized sensor chip
[43-67] vs Fab' ka (1/Ms) kd (1/s) KD (M) SD
1 µM 5.62*104 2.65*10-3 4.71*10-8 0.018
2.5 µM 1.05*104 2.67*10-3 2.55*10-7 0.0449
5 µM 4.27*103 2.26*10-3 5.29*10-7 0.0727
10 µM 1.70*103 2.60*10-3 1.53*10-6 0.0338
average 1.82*104 2.55*10-3 5.90*10-7 0.0424
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Figure 3.16A: Overlay plot of SPR sensorgrams showing the interaction between hNodal[43-56] 
peptide and 3D1 mAb immobilized on a CM5 sensor chip. The interaction was monitored at 
peptide concentrations ranging from 0.5 to 20 µM, obtaining dose–dependent binding curves. 
     
                                        
                
 
 
 
                       
      
 
Figure 3.16B: Overlay plot of SPR sensorgrams showing the interaction between hNodal[43-56] 
peptide and 3D1 Fab’ immobilized on a CM5 sensor chip. The interaction was monitored at 
peptide concentrations ranging from 1 to 20 µM, obtaining dose–dependent binding curves. 
 
Table 11. Association and dissociation rate constants and KD values
determined for the binding of hNodal[43-56] peptide to 3D1 mAb
functionalized sensor chip
[43-56] vs mAb ka (1/Ms) kd (1/s) KD (M) SD
0.5 µM 2.42*104 1.61*10-3 6.66*10-8 0.0316
1 µM 1.17*105 1.83*10-3 1.57*10-8 0.0867
2.5 µM 2.90*104 1.97*10-3 6.79*10-8 0.152
5 µM 6.51*103 1.58*10-3 2.43*10-7 0.0325
10 µM 3.22*103 1.62*10-3 5.04*10-7 0.0826
20 µM 1.21*103 1.86*10-3 1.53*10-6 0.0348
average 3,02*104 1.75*10-3 4.05*10-7 0.07
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3.2.5 SPECIFICITY ASSAY 
ELISA assays were performed to further assess the specificity of the 3D1 mAb 
for the region of Nodal [43-56], involved in the binding with the co-receptor 
Cripto. New Nodal peptides were therefore screened for binding to 3D1. These 
peptides came from a previous study (Saporito et al., PhD Thesis, 2009) and 
were: hNodal[1-38], mimicking the N-terminal portion, hNodal[39-75], 
mimicking the central region and hNodal[76-110] mimicking the C-terminal 
portion of the mature form of human Nodal. Other peptides mimicking the 
region of the TGF-β ligand GDF and matching the 43-69 region of Nodal [GDF5 
and GDF6/7, see Table 1 and Fig. 3.2 (Multiple alignment)] were also used for 
this purpose The specificity of 3D1 for Nodal was especially required given the 
presence of GDF ligands 
[123]
 in plasma and serum, and the proposed use of the 
antibody as diagnostic tool for detecting Nodal in human biological samples. 
Testing by SPR of these reagents was prevented by their poor solubility in HBS-
EP buffer. 
Table 12. Association and dissociation rate constants and KD values
determined for the binding of hNodal[43-56] peptide to 3D1 Fab’
functionalized sensorchip.
[43-56] vs Fab' ka (1/Ms) kd (1/s) KD (M) SD
5 µM 2.88*103 5.36*10-4 1.86*10-7 0.0325
10 µM 1.72*103 5.29*10-4 3.08*10-7 0.0826
20 µM 9.43*102 5.85*10-4 6.20*10-7 0.0348
average 1.85*103 5.50*10-4 3.71*10-7 0.05
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Figure 3.17: Bar graph representing the specificity of the 3D1 for the central region of human 
Nodal; peptides were coated at 1 µg/mL. hNodal[43-56] peptide was considered as 100% of 
signal. The signal was expressed as % of relative absorbance measured at 490nm and calculated 
as  B/B0*100. 
 
 
As shown in Fig. 3.17, only fragment [39-75] of Nodal, containing the region 
43-69 used to generate the antibody, did bind with similar efficiency 3D1, 
whereas the other peptides were essentially unreactive. This result confirmed the 
selectivity of the monoclonal antibody for the Nodal epitope and the poor or no 
recognition with proteins sharing similar sequences.  
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                     3.3 DETECTION OF HUMAN NODAL  
 
3.3.1 CALIBRATION CURVE FOR ELISA DETECTION OF rhNODAL 
PROTEIN  
To proof the principle that 3D1 can be used as a diagnostic tool, a fluorescence 
ELISA assay was set up to define the lowest amount of protein detectable in 
human biological samples, such as serum/plasma and urine. To enhance the 
sensitivity, we set up a capture assay that made use the 3D1 antibody in coating 
and a rabbit monoclonal antibody (EP2058Y, Epitomics) for the detection. By 
this assay, the lowest detected quantity of rhNodal, with a significative S/N 
ratio, was 50 pg (See Fig.3.18), as shown in the graph below, in which on x axis 
the ng of protein are reported as function of fluorescence intensity.  
 
                              
     
                         Figure 3.18: ELISA calibration curve of the detection of rhNodal. 
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3.3.2 PRELIMINARY IMMUNOBLOT ANALYSES 
A dose-response dot-blot analysis was performed to evaluate the ability of 3D1 
to recognize different amounts of native rhNodal spotted on a PVDF membrane. 
This analysis was carried out to preliminarily evaluate the minimum amount of 
hNodal detectable under these conditions. 
As shown in Fig.3.19, 3D1 could stain as less as 50 ng of protein. 
 
                     
Figure 3.19: (A) Dot blot analysis on Nodal protein. Nitrocellulose membrane was spotted with 
Nodal at 50, 100, 150 and 200 ng, and then probed with 3D1 at 2µg/mL. (B) Dot blot 
densitometric analysis. 
 
Before performing western blot analyses to detect endogenous Nodal in cell 
lysates, preliminary dose-response western blot analysis was carried out to check 
the ability of the 3D1 to recognize the human Nodal protein under reducing and 
denaturing conditions. As shown in Fig. 3.20, 3D1 was able to detect as low as 
50 ng of Nodal under these conditions.  
                                                      
 
Figure 3.20: Dose-response western blot analysis probed using the 3D1 mAb; rhNodal was 
loaded at increasing concentrations 50-200 ng under reducing conditions on 15%SDS-PAGE. 
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3.3.3 DETECTION OF ENDOGENOUS NODAL PROTEIN 
a. Western blot analysis 
To evaluate the use of the 3D1 as diagnostic tool, western blotting analyses were 
carried out to explore the ability of the mAb to recognize the endogenous forms 
of Nodal protein in human melanoma cells. As shown in Fig.3.21, 3D1 was able 
to detect the immature endogenous form pro-Nodal (approximately 37 kDa) in a 
panel of melanoma cell lines and in non-melanoma HEK-293 cells, used as 
positive control. The smaller mature form of Nodal, approximately 13 kDa, is 
only barely detected, suggesting it is likely highly unstable and/or cleaved 
predominantly outside the cell. 
  
        
Figure 3.21: Western blot analysis of melanoma cell lysates separated by 15% SDS-PAGE 
under reducing conditions. As positive control HEK-293 cells and 100 ng of rhNodal were 
loaded. 3D1 antibody was used at 2 µg/mL. Detection was achieved using GAM-HRP antibody 
and ECL as substrate. 
  
 
 
 
 
 
 
 
 
 
80 
 
b. FACS analyses 
The capability of the 3D1 to recognize the endogenous Nodal protein expressed 
in melanoma cell lines was also confirmed by cytometric analyses. 
FACS analyses (Fig. 3.22) showed that 3D1 was able to bind to native Nodal 
protein (non-reducing and non denaturing conditions) also in intact cells at very 
low concentrations (0.1 µg/mL) and in a dose-dependent manner, as 
demonstrated by the increase of the signal intensity with increasing antibody 
concentration, indicated by the shift in fluorescence intensity to the right. 
However it was not possible to determine which form of Nodal protein was 
detected in melanoma cancer cell lines by FACS analyses, since both species 
were detected by the 3D1 in western blot analysis. 
     
 
  Fig. 3.22: (A, B and C ) Cytofluorimetric analyses of human melanoma cell lines (LCP, A375 and   
  WM266), after fixation and  permeabilization; an isotype IgG1 antibody was used as negative control. 
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3.3.4 COMPETITION ASSAY BETWEEN 3D1 ANTIGEN PEPTIDE AND 
ENDOGENOUS NODAL PROTEIN                                    
To confirm the specificity of the binding of the 3D1 mAb to its antigen, a 
competition assay between the synthetic antigen peptide and endogenous Nodal 
protein expressed in human embryonic stem cells was performed probing the 
blots either with the 3D1 alone or following pre-incubation with the hNodal[43-
56] peptide, named here CH. As reported in Fig.3.23, both forms of endogenous 
Nodal were no longer detectable when the mAb was pre-incubated with the 
peptide, suggesting that 3D1 binds to the same region also on the native 
endogenous protein. 
                                                         
                                    
 
Figure 3.23: Competition assay between the CH peptide and endogenous human Nodal in 
human embryonic stem cells lysates. 3D1 was used at 4µg/mL and the CH peptide at 10µg/mL. 
 
 
  
82 
 
                   3.4 FUNCTIONAL STUDY OF THE 3D1 mAb 
 
Functional study of the 3D1 mAb was carried out in collaboration with the group 
of Dr. Mary Hendrix of the Ann and Robert H Lurie’s Children Hospital of 
Chicago. 
For this study C8161 human metastatic cutaneous melanoma cells were selected 
as highly aggressive melanoma cell model to investigate the effects of the 3D1 
antibody in vitro and in vivo on Nodal protein. 
 
3.4.1 TARGETING NODAL IN C8161 MELANOMA CELLS in vitro 
In order to evaluate the ability of the 3D1 anti-Nodal to act as a blocking 
antibody, the following functional in vitro assays were performed: 
a. Effects on Nodal signaling 
b. Clonogenic assay 
c. Vasculogenic mimicry assay 
 
a. Effects on Nodal signaling 
The effects of 3D1 mAb on the C8161 cells were firstly tested on the Nodal 
downstream signalling pathway. Cells were thus treated with the antibody at 4 
µg/mL and the Smad-dependent and  independent pathways (MAPKs activation) 
were monitored by determining the reduction of Smad and MAPK 
phosphorylation over time. As shown below in Fig.3.24, 3D1 was able to 
strongly and very rapidly inhibit protein phosphorylation in a very short time 
period (4 hours) and the effect was detectable also after three days.    
These results showed that 3D1 was able to potently inhibit both Smad-dependent 
and Smad-independent Nodal signalling.                      
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Figure 3.24: Western blot analysis of the total and activated forms of  (A) Smad and (B) MAPK 
in C8161 cells following treatment with 3D1 mAb at 4 µg/mL. 
 
A further relevant effect was observed on the expression of Nodal itself. C8161 
cells were treated with 3D1 at 4 µg/mL and the reduction of pro-Nodal 
expression was monitored by western blotting. As shown in Fig. 3.25, 3D1 was 
able to reduce Nodal expression by approximately 50% at the concentration used 
and the reduction was similar to that achieved with a commercially available 
Santa Cruz anti-Nodal blocking antibody (http://www.scbt.com/).  
Data clearly showed that 3D1 mAb was able to bind soluble Nodal protein and 
to inhibit its autoregulated expression and the binding to the co-receptor Cripto 
or to other interactors sharing the same interacting surface. This in turn inhibits 
the activation of Smad-dependent and Smad-independent (MAPK) Nodal 
pathways. 
 
                                        
84 
 
                              
Figure 3.25: Treatment of human melanoma cell line C8161 with 3D1 anti-Nodal antibody 
causes a reduction of Nodal expression. 
 
 
b. Clonogenic assay 
Colony formation assay or clonogenic assay is an in vitro cell survival assay 
based on the ability of a single cell to grow into a colony. This assay essentially 
tests the ability of every cell in the population to undergo unlimited division, 
thus it is the method of choice to determine cell reproductive death after 
treatment with cytotoxic agents and can also be used to assess their effectiveness 
[124]
. 
Clonogenic soft agar assay was performed to evaluate and measure the effect of 
3D1 antibody treatment on the ability of the C8161 aggressive human melanoma 
cells to form colonies. As can be appreciate by macroscopical observation and in 
the bar graph of Fig. 3.26, C8161 showed a decrease in their ability to form non-
adherent spheroidal clusters. Indeed, the 3D1, compared to an IgG used as 
negative control, was able to reduce the C8161 clonogenicity by approximately 
60%.    
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Figure 3.26: 3D1 anti-Nodal antibody affects colony formation of human melanoma cells. (A) A 
representative image of the colony forming assay for C8161 is shown (25 × final magnification).  
(B) A significant reduction in the ability of C8161 cells to form colonies in soft agar was 
observed using 3D1 anti-Nodal antibody 4 μg/mL, compared with no antibody treatment or IgG 
control  (*P < 0.05). 
   
 
c. Vasculogenic mimicry inhibition 
“Vasculogenic mimicry” (VM) describes the functional plasticity of aggressive 
cancer cells able to form de novo matrix-rich vascular networks in three-
dimensional matrices in vitro, mimicking the model of the endothelial vascular 
networks. In this model a perfusion pathway for rapidly growing tumors and 
transporting fluid from leaky vessels and/or connecting with endothelial-lined 
vasculature was proven
 [125]
. The initial morphological and molecular 
characterization of VM was made in human melanoma where it was found that 
the tumor cells co-expressed endothelial and tumor markers, and formed 
channels, networks and tubular structures rich in laminin, collagens IV and VI, 
and heparin sulfate proteoglycans, containing plasma and red blood cells - 
indicating a perfusion pathway for rapidly growing tumors, as well as an escape 
route for metastasis 
[125]
. 
A vasculogenic mimicry assay was performed to evaluate the ability of 3D1 to 
inhibit or reduce the capability of the C8161 to form de novo matrix-rich 
vascular networks. As shown below, C8161 cells, treated with the 3D1 for 24 
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hours, did not complete the formation of networks characteristic of the 
vasculogenic mimicry seen in the control cells (see Fig. 3.27). Indeed 3D1 
remarkably reduced the ability of the C8161 to engage in vasculogenic mimicry 
in vitro compared with no antibody or a non-function-blocking IgG control 
antibody. The effect of 3D1 was similar to that induced by a commercial 
polyclonal anti-Nodal antibody (Nodal Antibody (H-110) : sc-28913, Santa 
Cruz). Thus, 3D1 is able to reduce plasticity and invasiveness of the C8161, 
features that are related to the expression of Nodal protein. 
 
Figure 3.27: Effect of 3D1 mAb on the formation of vascular-like structures by C8161 cells. (2 
x and 10 x final magnification). 
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3.4.2 TARGETING NODAL IN LUNG COLONIZATION INDUCED IN 
MICE BY C8161 MELANOMA CELLS 
After evaluating the in vitro effectiveness of the 3D1 monoclonal antibody on 
C8161 cells, in vivo experiments were performed to assess the effects of 3D1 
treatment on lung colonization induced in nude mice by injecting C8161 
metastatic melanoma cells. Experiments were performed monitoring lung 
colonization by immunohistochemical analyses. 
 
a. Effects on lung colonization 
Histological examination of the lung tissue revealed a significant reduction in 
the number and size of the colonies induced by metastatic C8161 cells in the 
lungs of mice treated with the 3D1 anti-Nodal antibody compared to the mice 
treated with the control IgG antibody (See Fig. 3.28A). As shown in Fig. 3.28A, 
most of the lung surface area (~80) was occupied by tumor burden. By contrast, 
in the Fig. 3.28B, the presence of healthy tissue was predominant, indeed the 
lung tumor burden was approximately only ~10%. 
This evidence showed the remarkable ability of the 3D1 to reduce lung 
colonization induced by metastatic cells. 
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Figure 3.28: Histological examination of a lung section of Nude mice  treated with (A) control 
IgG and (B) the 3D1 anti-Nodal mAb. (C)*Lung tumor burden was determined as the mean 
percentage of lung occupied by C8161 melanoma cell colonies calculated from at least 5 
different lung sections per individual mouse. The effects of 3D1 treatment are expressed as 
Mean% tumour burden (±SEM). 
 
 
b. Effects on the cell cycle 
Immunohistochemical analysis were performed to detect Cyclin B1 and p27 
expression in C8161 lung colonies in Nude mice treated with the 3D1 to 
evaluate the effects of the mAb on the cell cycle. Cyclin B1 is over-expressed in 
several cancers compared to normal cells and tissues; in most tumors the 
expression of cyclin B1 is unrestricted to particular phases of the cycle, whereas 
in normal lymphocytes, the expression of cyclin B1 is restricted to very late S 
and G2 + M phases of the cell cycle. The cyclin-dependent kinase (Cdk) 
inhibitor p27 regulates cell proliferation, cell motility and apoptosis; it blocks 
the entrance of the cell in S phase, binding to the cyclins. Immunohistochemical 
analysis of lung sections of nude mice treated with the 3D1 revealed the ability 
of this mAb to reduce remarkably the progression of cell cycle of cells from 
A
B
C
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mice lungs, as indicated by the reduction in Cyclin B1 staining and on the other 
side the increase in p27 staining (See Fig. 3.29). 
The effects of the 3D1 mAb on Cyclin B1 and p27 expression were confirmed 
by in vitro detection of these markers of the cell cycle, carried out by western 
blot analysis on C8161 treated for three days with either 3D1 or control IgG (See 
Fig. 3.30). 
    
                                      
                                  
                    
                         
Figure 3.29A: Detection of Cyclin B1 expression by IHC in C8161 lung colonies formed in 
Nude mice treated with control IgG or 3D1 anti-Nodal. N = 3 mice. Cyclin B1 positive cells 
(brown stain) detected at high power (63X objective). Mean percent Cyclin B1 positive cells 
representative of 5 different C8161 lung colonies/mouse. (*P = 0.0215; t-test)                                            
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Figure 3.29B: Detection of p27 expression by IHC in C8161 lung colonies formed in Nude mice 
treated with control IgG or 3D1 anti-Nodal. N = 3 mice. p27 positive cells (brown stain) detected 
at high power (63X objective). Mean percent p27 positive cells representative of 5 different 
C8161 lung colonies/mouse. (*P = 0.0215; t-test)                                            
    
     
             
 
 
Figure 3.30: Detection of (A) CycliN B1 and (B) p27 in C8161 melanoma cells treated for 72 
hours with the 3D1 anti-Nodal antibody versus a control IgG antibody (cntl) by western blot 
analysis. 
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c. Immunohistochemical detection of P-Smad2 expression 
 
Immunohistochemical analyses were performed on lung sections also to detect 
P-Smad2 expression. 
As shown by the nuclear staining, a decrease in P-Smad2 expression was 
revealed in the sections of  lungs of mice treated with the 3D1 (See Fig.3.31). 
This evidence confirmed the result obtained in vitro by western blot analysis 
performed on the C8161 cells. 
 
              
 
Figure 3.31: P-Smad2 staining in C8161 lung colonies formed in Nude mice treated with control 
IgG or 3D1 anti-Nodal. N=3 mice/group. Mean percentage of P-Smad2 nuclear staining 
calculated from counts obtained in 8 different fields/lung/mouse. 
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                                 I 4. DISCUSSION 
 
Nodal, a member of the TGF-β superfamily, is a potent morphogen and regulator 
of cell fate in both embryological and adult systems. Nodal expression is largely 
restricted to very early progenitor and reproductive cell types whereas it is 
almost absent in adult tissues and normal cells, including melanocytes. Its re-
expression in the adults is strongly associated with tumorigenesis and protein 
levels are much higher in tumor cells and tissues where it supports uncontrolled 
cell growth, proliferation and differentiation. Several studies reported that Nodal 
expression positively correlates with melanoma tumor progression toward a 
metastatic phenotype; moreover, its over-expression is paralleled by that of the 
co-receptor Cripto-1, suggesting the occurrence of tumor growth mechanisms 
supported by the concomitant presence of both proteins and by their interaction 
with the activin receptor complex. In light of this evidence, Nodal is considered 
a novel diagnostic and prognostic marker other than a very important and 
interesting new therapeutic target. So far, no Nodal inhibitors contrasting its 
anti-apoptotic and tumorigenic activity have been reported. Nodal down-
regulation, which blocks both Cripto-dependent and independent signalling, has 
been only achieved by using the antisense technology, an approach that has 
strongly contributed to the understanding of its functions 
[69]
. We have targeted 
the Cripto-Nodal interaction surface in the attempt to obtain highly specific and 
high affinity Nodal binders, which also inhibit the interaction with Cripto. We 
have privileged an approach based on the generation of monoclonal antibodies, 
since these reagents can be quite easily obtained by the hybridoma technique, 
can be produced in high amount, can be easily purified and characterized by 
current chromatographic techniques and, most importantly, are in most cases 
endowed with a sufficiently high affinity and specificity for the target antigens. 
The target antigen has been the region 43-69 of Nodal, described as part of the 
interaction surface with Cripto. The mAbs have been generated using the 
hybridoma technique and screened following a novel, subtractive approach, 
whereby only those antibodies binding the wild type peptide antigen while not 
binding a mutated variant on specific residues, has been used to identify highly 
selective molecules. The mutant peptide was the one bearing E49 and E50 
mutated to alanines, so as to select mAbs interacting with high specificity with 
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these two residues. Among those with these features, only two of them, named 
3D1 and 1F10, recognized with high affinity the full-length native protein. 3D1 
was chosen for further investigations by virtue of its higher affinity toward the 
full length Nodal (about 1.4 nM compared to about 80 nM). The antibody has 
been produced on large scale (multi-mg) and purified to homogeneity. The 3D1 
mAb is of the IgG1 isotype. The antibody inhibited the binding of Nodal to 
Cripto-1, as demonstrated by competitive SPR assays and, most importantly, 
blocked the Nodal-dependent activation of Smad2/3 in melanoma cancer cells. 
Very importantly, the antibody also blocked the Cripto-independent Nodal 
signalling converging on the MAPKs, as demonstrated by the concomitant 
effective blocking of MAPK activation. This has been demonstrated in the 
highly aggressive human melanoma C8161cell line in the laboratory of Prof. 
Hendrix at Children's Memorial Research Center of Chicago. Given the 
autocrine mechanism of activation of Nodal (Smad2/3 regulate through Smad4 
the expression of Nodal itself), the antibody also showed the ability to reduce 
Nodal expression in the supernatants of C8161 cells and indeed, 3D1 at the 
concentration of 40 and 50 nM reduced the expression of the protein at less than 
a half. In addition, it was also effective in reducing the C8161 clonogenicity and 
the typical vasculature-like phenotype induced by Nodal (vasculogenic 
mimicry), both considered as the mechanisms underlying tumor growth in 
melanoma cells. Remarkably, 3D1 in vivo also showed a potent anti-tumour 
activity.  Indeed, it strongly reduced lung colonization induced by C8161 
metastatic cells, injected in mice. Altogether the 3D1 antibody has many of the 
features needed for developing a new biotherapeutic able to reduce plasticity and 
invasiveness related to the expression of the Nodal protein in cancer cells.  
The antibody has been also fully sequenced on the CDR region to delineate the 
main structural features and to next perform sequence optimization studies 
aimed at further improving the affinity. Such investigations are underway 
together with a study to humanize the antibody, a process required for future 
investigations in vivo on human cells and on human tissues. 
Moreover, immunohistochemical analyses showed the ability of the 3D1 to 
affect the progression of the cell cycle by reducing Cyclin B1 and concurrently 
increasing p27 expression.  
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Given the relevant prognostic meaning of Nodal levels in human tumours and in 
biological fluids of affected individuals, also Nodal detection is of utmost 
importance for the early diagnosis of Nodal-related tumours. The 3D1 mAb, in a 
sandwich ELISA assay, was able to detect as low as 50 pg of rhNodal therefore 
the antibody could be used in this biochemical assay to detect and quantify 
Nodal in human biological fluids, such as urine and serum/plasma because its 
presence and expression are a relevant predictive prognostic marker of tumor 
malignancy (especially in melanomas). 3D1 was finally used also in in vitro 
assays (Western Blotting and FACS analysis) to detect endogenous Nodal in 
melanoma cell lines. 
Collectively analytical and in vitro and in vivo functional data displayed that the 
3D1 is a very promising reagent useful as diagnostic tool and, hence acting as a 
blocking antibody, given its  ability to inhibit the Nodal functions related to its 
tumorigenic activity, it is also a promising novel biotherapeutic agent, as a valid 
alternative to chemotherapic and immunotherapic agents currently employed for 
the treatment of the melanoma. 
In addition, the process of humanization and the generation of smaller functional 
fragments (Fab,ScFv), together with a step of improving the affinity for the 
target protein (antibody maturation) will provide a unique and invaluable reagent 
for use in humans (alone or in combination with other drugs) for the treatment of 
cutaneous melanoma and other relevant cancer diseases. 
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ABSTRACT 
 
We have generated a set of monoclonal antibodies against the region 24-39 of 
human APE1/Ref1 protein, which is supposed to be multiple acetylated on 
lysines 27, 31, 32 and 35. In order to obtain mono- or multi-acetylated-APE1 
specific antibodies, we have immunized mice with a peptides library, containing 
16 different peptide antigens corresponding to all combinations of acetylated 
lysines and, after mAbs generation, we have screened the resulting clones to 
select those producing acetylation-specific mAbs. The screening, performed by 
ELISA, using isolated mono-, di-, tri-, and tetracetylated peptides, allowed to 
isolate four mAbs that bound with very high affinity and specificity to the 
acetylated peptides, while not recognizing the non acetylated variant. All 
selected antibodies displayed a poor selectivity against the differently acetylated 
peptides, being able to only discriminate between mono-acetylated/di-
acetylated/tri-acetylated and tetracetylated variants. Furthemore, all selected 
mAbs were able to specifically recognize the acetylated form of the human 
APE1 protein, as revealed by Western blot analysis, while no detection was 
observed with the non-acetylated form and others acetylated proteins.   
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                        II 1. INTRODUCTION 
 
The introduction of Post-Translational Modifications (PTM) in proteins is a 
major mechanism for regulating their function, localization, stability, 
immunogenicity and other relevant properties. Among these, acetylation of the 
εNH2 of selected lysines, a process regulated by a fine balance between 
acetylases and de-acetylases, is one of the most important, playing a role, among 
the others, in protein-DNA binding, in secondary or higher structures 
modification and sub-cellular localization. Detecting acetylated lysines in 
specific proteins or sets of proteins is thereby a major goal for investigating the 
interplay between the occurrence of PTMs and cell biology. Several very robust 
tools for studying protein acetylation are in the hands of biochemists and cell 
biologists, including mass spectrometry 
[126]
 and batteries of highly specific 
monoclonal antibodies, which allow the detection of either any acetylated lysine 
or acetylated lysines embedded in specific protein sequences 
[127]
. Detecting 
multiple acetylations (di-, tri- or even tetra-acetylations) within short lysine-rich 
protein stretches is however still a challenging task, because of the occurrence of 
highly similar structures with identical molecular mass differences. Only very 
sensitive approaches of tandem mass spectrometry can help to address/unravel 
this issue. Antibodies, on the other hand, are extremely specific and sensitive 
reagents able to recognize in a highly specific manner small as well as large 
macromolecules, and are also able to distinguish among very subtle molecular 
differences.  
 
1.1 HUMAN APURINIC/APYRIMIDINIC ENDONUCLEASE 1  
Apurinic/apyrimidinic endonuclease 1 (APE1), also known as redox effector 
factor-1 (Ref-1), is a multifunctional and essential protein in mammals, acting as 
a key regulator of cellular responses to oxidative stress (redox signalling) and 
contributing to the maintenance of genome stability 
[128-130] 
.  
The human APE1 is a protein of 318 amino acids with a molecular mass of 
approximately 35 kDa (Uniprot P27695); structural investigations revealed that 
the first 42 amino acids are disordered, while the remainder of the protein has a 
globular fold 
[131,132]
. 
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Human APE1 exerts its two most important biological activities, redox and 
repair, through two functionally distinct protein domains, the N-terminal and the 
C-terminal, that act independently each other
[133-135]
. In fact, the non-structured 
N-terminal domain (residues 1–127), containing the nuclear localization signal 
(NLS) sequence, is essential for the redox activity of APE1, whereas the C-
terminal domain (residues 61–318) is essential for the DNA base excision repair 
(BER) activity 
[136]
.  
A third APE1 function, which is regulated by Lys6/Lys7 acetylation 
[137]
, is its 
transcriptional repressor activity through indirect binding to the negative Ca2+-
response elements (nCaRE) 
[138]
 of some promoters (i.e., PTH and APE1 
promoters). 
Furthermore, recent evidences highlighted a novel role for APE1 in RNA 
metabolism, which is modulated by nucleophosmin 1 (NPM1), thus suggesting 
the importance of unstructured N-terminal domain of APE1 as a flexible part of 
protein able to establish protein–protein interaction. The first 35 amino acids in 
the non-structured N-terminal domain of APE1 are required to stabilize 
interaction with rRNA, NPM1 and other proteins involved in ribosome 
biogenesis and RNA processing 
[139,140]
 including pre-mRNA maturation/splicing 
and ribonucleotide catabolism. Moreover, the NPM1-APE1 interaction seems to 
modulate the APE11 subnuclear cellular localization 
[141]
.  
In different mammalian cell types, APE1 is mainly a nuclear protein, however, it 
has been reported that it is even localized into cytoplasm, mitochondria and 
endoplasmic reticulum 
[142]
. Nuclear localization of APE, controlled by the first 
20 amino acids at the N-terminal sequence 
[143]
, is correlated with its functions in 
DNA repair, while cytoplasmic localization may correspond to its role in 
mitochondrial DNA repair or redox regulation of newly synthesized 
transcription factors
[144]
.  
Interestingly, cytoplasmic expression of APE1 has been correlated with 
aggressiveness of different tumors 
[142,144]
, although its role in tumorigenic 
processes is fully unknown. 
In addition, the expression of APE1 is cell cycle dependent and the highest level 
of APE1 is detectable in early or middle S-phase, suggesting a particular 
function of APE1 in this phase of the cell cycle 
[145]
. 
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1.2 REGULATION OF THE ACETYLATION STATUS 
It is well established that APE1 K6/K7 may undergo acetylation during cell 
response to genotoxic treatment 
[146]
 and that the acetylation status of these K 
residues, controlled by the sirtuin 1 (SIRT1) deacetylase activity, may plays a 
key role in modulating protein DNA-repair function by regulating the kinetics of 
its interaction with other enzymes involved in BER.  
Recent studies revealed that five lysine residues K24/K25/K27/K31/K32, 
probably acquired during evolution, located in the region 24–35 of the 
unstructured human APE1 N-terminal domain, are crucial for APE1 interaction 
with rRNA and NPM1 and/or different protein partners and for modulation of its 
catalytic activity on abasic DNA through regulation of product binding. Of 
interest, some of these critical amino acids (K27/K31/K32 and K35) may 
undergo in vivo acetylation under basal conditions 
[147]
, therefore, within cells, 
APE1 is present with different degrees of acetylation on the above mentioned 
lysine residues (Ac-APE1). Since the acetylation at K27/K31/K32/K35 residues 
may favour a transition toward a more organized conformation, this modification 
may significantly modulate the interaction with several protein partners on a 
structural basis 
[123]
.  
Degree of positive charges, modified by acetylation at these residues, may 
modulate Different functions of APE1 can be modulated by the degree of 
positive charges  through its redirection to different substrates and/or stimulation 
of its DNA-repair enzymatic activity 
[141]
, indeed, protein–protein interactions 
and/or posttranslational modifications (PTMs) involving the APE1 N-terminal 
domain may play important roles in vivo in coordinating the protein’s BER 
activity and functions on rRNA metabolism. In particular the positively charged 
residues located in the portion 23–33 of the enzymatic domain plays an active 
role in APE1 catalysis.   
Interestingly, genotoxic stress promotes the acetylated APE1 form, more active 
than the non-acetylated one, is predominat, this is probably due to a decrease in 
affinity for the incised DNA product. Acetylation, in turn, may inhibit binding to 
RNA substrates thus, possibly, this PTM may change the equilibrium of the 
APE1 pool from the RNA-bound to the DNA-bound substrates 
[147]
.  
Moreover, acetylation may also control compartmentalization of APE1 within 
specific subnuclear structures (such as nucleoli), where the enzyme could be 
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stored once bound to interacting partners as NPM1. Whether NPM1 may 
specifically participate in DNA repair inside of nucleoli, or even outside of the 
subnuclear condensed area, is currently unknown. In the first case, the genome 
containing rRNA gene may be a favoured substrate for APE1 in vivo; on the 
other hand, if the latter is the case, stimuli triggering NPM1 to get out of nucleoli 
may affect the cell response in terms of APE1 impact on genome stability. 
Because the protein’s N-terminus is required for the stabilization of APE1 
interaction with NPM1 or rRNA and for the control of the overall endonuclease 
activity 
[147]
, this region-specific multitasking function can provide a “trigger” 
for molecular regulation with important biological significance .  
In addition, the acetylation at K27/K31/K32 and K35 residues may significantly 
affect APE1 protein stability, since such K residues can be also 
polyubiquitinated by UBR3, targeting the protein for degradation by the 
proteasome 
[148]
. Indeed, since acetylation competes with ubiquitination for the 
same K residues, it may represent the switch for controlling protein turnover 
rate. In this context, the acetylation at these residues during cell response to 
genotoxicants may stabilize protein half-life, thus preventing its degradation. 
Remarkably, the acetylation status of these lysine residues is still not well 
understood, as indeed multiple/single specific modifications may occur 
depending on the cell metabolic status and on the presence/absence of different 
stimuli. While the occurrence of one or more acetylations can be easily 
monitored using non-specific pan-acetyl antibodies (Rabbit Anti-Acetyl Lysine 
Polyclonal Antibody Cat. # AB3879, Millipore) the exact array of 
acetylated/free lysines in a specific stretch of aminoacids is instead a much more 
difficult task and implies several steps of protein isolation, digestion by specific 
proteases and fine mapping of modified residues by tandem mass spectrometry.  
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1.3 AIM OF THE PROJECT 
Given the crucial role played by APE1 acetylation on its multiple functions and 
the importance to understand which lysine is acetylated under specific 
conditions, we sought to obtain monoclonal antibodies specific for the region of 
APE1 spanning residues 24-39 and able to discriminate among the differently 
acetylated variants. The final goal was to generate an array of mAbs able to 
discriminate the differently acetylated forms of the 24-39 APE1/Ref1 region.  
The array of mAbs should contain at least one antibody specific for any given 
sub-structure (or group of substructures,  for example the singly monoacetylated 
variants, or the differently di-acetylated variants and so on), so that we could use 
them in western blotting experiments on cell extracts to identify which lysine is 
acetylated and which is not under specific stimulation conditions. To try to 
achieve this goal, we have generated a library of peptides containing all 
acetylated combinations of mono-, di-, tri- and tetra-acetylated variants on 
lysines 27, 31, 32 and 35 (16 different peptides) of the 24-39 segment of 
APE1/Ref1. The pool of peptides has been used to immunize mice and to 
generate monoclonal antibodies by the hybridoma technique. mAbs have been 
then screened to select those recognising specific peptide variants while not 
binding to the others. The screening has been performed by ELISA using 
fractionated small pools of peptides, identified and characterized by mass 
spectrometry and subsequently by a number of different techniques.  
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                    II 2. MATERIALS AND METHODS 
2.1 MATERIALS  
All protected amino acids and resins for peptide synthesis were from either 
Novabiochem (Laufelfingen, Switzerland) or from GL Biochem (Shanghai, 
PRC). Fmoc-L-Lys(Ac)-OH was from Bachem (Bubendorf, Switzerland). 
Solvents for peptide synthesis and purification were from LabScan (Dublin, 
Ireland). Other reagents for peptide synthesis, Bovine Serum Albumin (BSA), 
Keyhole Lympet Hemocyanin (KLH), Ovalbumin (OVA) and glutaraldehyde 
were from Sigma-Aldrich (Milano, Italy). Preparative RP-HPLC were 
performed out on a Shimadzu LC-8A, equipped with a SPD-M10 AV detector 
and with a ONYX monolithic C18 column (100 x 10 mm ID), Phenomenex, 
Torrance, CA, USA). The anti-Acetyl Lysine Polyclonal Antibody (ALPA) was 
from Millipore (Cat. # AB3879). All media for cell culture were from Sigma-
Aldrich (Milan, Italy). The RPMI 1640 medium, containing 10% Fetal Bovine 
Serum (FBS) and 1% Penicillin, Streptomycin and Glutamine (PSG) was used 
for maintaining myeloma cells. The RPMI-GM medium contained RPMI 1640 
with added 1% non-essential amino acids (NEAA). For the fusion of splenocytes 
and myeloma cells we used an RPMI 1640 medium supplemented with 15% 
FBS, 2% HAT (Hypoxantine-Aminoipterine-Thymine), 1% PSG and 10%HES 
(Hybridoma enhancing supplement). The medium for clone selection was RPMI 
1640 supplemented with 15% FBS, 2% HAT, 1% PSG. ELISA data were fitted 
using the software GraphPad Prism 4, ver. 4.02 (GraphPad Software, San Diego, 
CA, USA).  
 
2.2 PEPTIDE SYNTHESIS, PURIFICATION AND IDENTIFICATION 
Antibodies were raised against the 24-39 region of APE1/Ref1, which recently is 
supposed to be acetylated. Since no direct evidences of which lysine is 
acetylated within the protein and to also exploit this molecular system to 
implement a novel mAb generation and screening procedure, we designed and 
prepared a mixture of 16 synthetic peptides containing all combination of 
sequences, whereby lys 27, 31,32 and 35 as potentially acetylated are either 
acetylated or non-acetylated (2
4
 combinations).  
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The peptide mixture can be described by the following single-letter code 
sequence: KKSK*TAAK*K*NDK*EAAG, where K* stands for an acetylated 
or non-acetylated lysine. Peptides were all C-terminally amidated. Two lysines, 
(which are casually located in APE1/Ref1 sequence) were inserted on the N-
terminus to have three additional amino groups, which strongly reduce the 
likelihood of glutaraldehyde conjugation on internal functional lysines. 
The peptide mixture was manually prepared by Fmoc chemical synthesis by the 
solid phase method using a RINK amide resin having a 0.57 mmol/g 
substitution. The synthesis scale was 0.05 mmoles. Canonical coupling and 
deprotection conditions were used to incorporate amino acids into the sequence, 
using a 5-fold excess of protected residues (0.25 mmoles). To generate mixtures, 
in correspondence of K27, K31, K32, and K35, an equimolar mixture of Fmoc-
L-Lys(Boc)-OH and Fmoc-L-Lys(Ac)-OH was used, preactivating the mixture 
as for the other residues. Synthesis progression was tightly monitored during 
chain assembly by removing small resin aliquots and characterizing the products 
by LC-MS, thus assessing identity and distribution of the expected peptides. 
These analytical controls were carried out after incorporation of the first 
Lys/Lys(Ac) incorporation (2 compounds generated), the second Lys/Lys(Ac) 
incorporation (4 compounds generated), the third Lys/Lys(Ac) incorporation (8 
compounds generated) and the fourth Lys/Lys(Ac) incorporation (16 compounds 
generated). These analyses also allowed the determination of relative 
distribution of compounds within the mixtures, by integrating and comparing 
peak areas from UV traces at 214 nm of chromatographically resolved peaks. 
For complex mixtures where not all peaks were chromatographically resolved, 
the relative distribution of compounds was achieved by integrating peaks 
obtained by extracted ions in TIC (Total Ion Current) chromatograms. After 
synthesis completion, peptides were removed from the solid phase using a TFA-
TIS-H2O mixture (90:2.5:2.5, v:v:v), precipitated in cold diethyl ether and 
lyophilized. To remove salts deriving from the cleavage procedure, a 10 mg 
aliquot of the crude material was loaded on a C18 100x10 mm ID monolithic 
column equilibrated at 0.5% CH3CN in H2O, 0.1% TFA. After 10 column 
volume washes with the same solvent at 10 mL/min, the material was eluted by 
changing the solvent to 95% CH3CN in H2O, 0.1% TFA, collected in a single 
fraction and lyophilized. This material was used for conjugation to KLH. 
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Another aliquot of the same material was fractionated by preparative RP-HPLC 
using the same column. For this purpose, a 14.0 mg aliquot of the crude peptide 
mixture was dissolved in 2% CH3CN in H2O, 0.1% TFA (2.0 mL) and injected 
onto a column equilibrated with the same solvent at 20 mL/min. A gradient from 
2% CH3CN in H2O, 0.1% TFA to 30% CH3CN in H2O, 0.1% TFA in 8 minutes 
was applied to separate the components, monitoring the eluate at 214 nm. 16 
fractions (#1 - #16) of 10 mL were manually collected every 0.5 minutes. 
Isolated fractions were lyophilized and characterized by LC-MS using an LCQ 
XP ESI ion trap mass spectrometer (ThermoFisher, Milan, Italy) coupled to a 
Surveyor HPLC system, equipped with a C18 Biobasic 50x2 mm ID, operating 
at 0.25 mL/min. Typical gradients were from 1% CH3CN in H2O, 0.1% TFA to 
30% CH3CN in H2O, 0.1% TFA. Mass spectra were acquired in the positive ion 
mode between m/z 200 and 2000 with the source maintained at 4.0 kV and 300 
°C. Spectra were also acquired by direct infusion at 1 µL/min using a HCT Ultra 
ion trap mass spectrometer (Bruker Daltonics, Macerata, Italy), equipped with a 
nanoESI source maintained at 4.8 kV and 250 °C. Typical spectra were recorded 
between m/z 200 and 2800 in the positive ion mode. Four single peptides of 
sequence KKSKTAAKKNDKEAAG, monoacetylated on either K27, K31, K32, 
or K35, were prepared in a similar way by solid phase synthesis, purified to 
homogeneity by RP-HPLC as described for library fractionation, and 
characterized by LC-MS. The library of c-Myc[119-161] derived acetylated 
peptides and the acetylated cyclized peptide (termed N_1-13) were prepared as 
already described. 
 
2.3 GENERATION AND PRODUCTION OF ANTI-Ac-APE1/Ref1[24-39] 
mAbs 
2.3.1 Antigen preparation: conjugation of antigen peptide to KLH and BSA 
Conjugation reactions were performed mixing 1.0 mg peptide material with 3.0 
mg carrier protein in 1.0 mL PBS containing  0.2% v/v glutaraldehyde in water. 
Mixtures were left under stirring for 3h, then 1.0 mL of 1.0 M glycine in water 
was added and reactions left at room temperature (RT) for 1h. At the end, 
solutions were extensively dialyzed against PBS buffer, pH 7.3 and lyophilized. 
The amount of peptide-protein conjugate was determined by the method of 
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Bradford. The desalted peptide mixture was conjugated to KLH using 
glutaraldehyde and used to prepare the immunogen. 
A mixture of fractions #4 through #8 (thus excluding the non acetylated peptide, 
present only in fraction #1) was prepared by mixing identical amounts (0.2 mg) 
from each fraction. This mixture was subsequently conjugated to BSA as 
described above and named Ac-APE1/Ref1[24-39]-BSA. The isolated fractions 
#1, #4, #5, #6, #7, and #8 were also conjugated under the same conditions to 
BSA. BSA-conjugated fraction #1 was named APE1/Ref1[24-39]-BSA. Ac-
APE1/Ref1[24-39]-BSA and APE1/Ref1[24-39]-BSA were used to monitor 
immunization progression and to perform the first step of hybridoma screening. 
c-Myc peptides described in the previous section, were conjugated to BSA under 
identical experimental conditions and used as control in several ELISA 
experiments. Glutaraldehyde self-conjugated BSA (BSA2) was prepared in a 
similar way, omitting the peptide solution. This reagent was used as control in 
all ELISA tests to exclude those clones producing antibodies binding the BSA-
linked glutaraldehyde or glutaraldehyde alone.  
 
2.3.2  Immunogen preparation 
The immunogen was prepared by mixing 500 µL of KLH-conjugated desalted 
peptide mixture at 4.0 mg/mL in PBS with 500 µL of complete TiterMax Gold 
Adjuvant (Sigma-Aldrich, Milano, Italy). Mixing was achieved using a 3-way 
valve connected with two syringes, one filled with the conjugate and the other 
filled with the adjuvant and allowing the aqueous solution to flow within the oily 
adjuvant solution. 
 
2.3.3 Mice immunization 
Two 5-week old Balb/c mice (from Jackson Lab) were immunized with 50 μL of 
suspension containing about 100 μg of adjuvant emulsified KLH-conjugated 
peptide mixtures. Two independent injections were carried out sub-cutaneously 
with 25 μL immunogen. Before immunization, 250 µL blood samples were 
taken from each mouse from the caudal vein and used as the pre-immune control 
(T0 samples). Mice were again immunized with the same amount of immunogen 
at day 30 after the first immunization (T = 30d), at day 40 (T = 40d) and at day 
60 (T = 60d), and blood samples were taken from the caudal vein (250 µL) 
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before every subsequent immunization and tested by ELISA assay to monitor the 
increase of antibody titer compared to the pre-immune serum (see the section on 
details for the ELISA assays). Mice showing the highest antibody titer were 
sacrificed and splenectomised. 
 
2.3.4 Fusion of myeloma cells and mice splenocytes to generate hybridomas 
The 2 mice showing the highest titer of specific antibodies against the peptide 
mixture, were sacrificed by cervical disarticulation and splenectomised, placing 
the spleens in a 50 mL tube containing 10 mL of RPMI-GM medium (Sigma-
Aldrich, Milano, Italy) pre-warmed at 37 °C. Spleens were then moved to 100 
mm plates containing 10 mL of RPMI-GM medium and grinded using a cell 
filter (BD-Falcon, Milano, Italy). The resulting suspensions were centrifuged at 
800 rpm for 5 minutes at RT, removing the supernatants, then cells were 
suspended in 5 mL of RPMI-GM and counted in the presence of 0.4% Trypan 
Blue (Sigma-Aldrich, Milano, Italy) to exclude dead cells. To perform cell 
fusion, 1/5 of splenocytes in 10 mL RPMI-GM were mixed with 4/5 of SP2/0 
myeloma cells in 5 mL RPMI-GM (ATCC), then 15 mL of RPMI-GM were 
further added. Cells were spun at 600 rpm for 5 minutes at RT. After discarding 
the supernatant, 1 mL of RPMI-GM containing PEG 1300-1600 (Hybri-Max, 
Sigma-Aldrich, Milano, Italy) and 75 µL DMSO (Sigma-Aldrich, Milano, Italy) 
were added. Cell pellets were gently disrupted with a pipette tip, adding at the 
same time 9 mL of RPMI-GM supplemented with 10% FBS. Cells were then 
centrifuged at 500 rpm for 7 minutes at RT, then the pellet was re-suspended in 
200 mL of RPMI-HAT medium and cells seeded in twenty 96-well plates and 
incubated for at least 10 days at 37 °C under 5% CO2. After about 2 weeks, 
supernatants were assayed by ELISA using plates coated with both Ac-
APE1/Ref1[24-39]-BSA and APE1/Ref1[24-39]-BSA to detect the presence of 
antibodies against either the pool of acetylated peptides or the non acetylated 
variant, operating as described in the previous section.  
The most reactive clones, were isolated, sub-cloned by limited dilution and re-
tested by ELISA. By this step, 8 clones lost the productivity; the remaining 
clones were submitted to a stabilization process. 
 
2.3.5 Clone stabilization and adaptation  
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Clones were stabilized by 3 sequential rounds of cloning performed by the 
method of limited dilution. At every round, cells were counted and diluted up to 
about 3 cells/mL; 20 mL of this solution were plated in two 96-well plates, 
dispensing 100 µL/well, thus reaching about 0.3 cells/well. Cells were incubated 
for 2 weeks at 37 °C under 5% CO2, then supernatants from each well were 
again tested for the presence of antibodies against the peptide antigen. 
Supernatants showing the highest antibody titer were isolated and again cloned 
thrice by limited dilution, always testing by ELISA the presence of specific 
antibodies.  
To obtain secreted monoclonal antibodies in absence of serum-derived bovine 
antibodies, selected clones were adapted to grow in serum-free medium. To this 
end, the medium was first changed to OPTIMEM (Sigma-Aldrich, Milano, Italy) 
supplemented with 10% FBS, then FBS was progressively reduced and finally 
eliminated over a time period of about 4 weeks. Productivity was always 
monitored by ELISA assays.  
 
2.4 ELISA ASSAYS 
Titer increase of anti-peptide specific antibodies was monitored by ELISA 
assays performed by coating both Ac-APE1/Ref1[24-39]-BSA and 
APE1/Ref1[24-39]-BSA on 96-well plates (Immunoplate, NUNC Maxisorp,). 
Coating was performed dispensing 100 µL of 1 µg/mL solutions of BSA-
conjugated antigens in PBS and incubating the plate over night at 4 °C in a 
humidified box. After 3 washings with 200 µL/well of PBS-Tween 1% (PBS-T), 
all wells were filled with 200 µL of 3% w/v BSA in PBS (30 mg/mL) and the 
plate incubated for 2h at 37 °C. After 3 washes with 200 µL/well of PBS-Tween 
1% (PBS-T), wells were filled with 100 µL of solutions containing mouse sera 
(both pre-immune and immune samples) at various dilutions (1:100; 1:500, 
1:1000; 1:5000; 1:10000; 1:100000) in PBS. Plates were incubated 1h at 37 °C, 
then were washed again 3 times with 200 µL/well of PBS-T.  
To detect bound antibodies, a secondary goat anti-mouse antibody conjugated to 
horseradish peroxidase (GAM-HRP, Biorad, Milan, Italy), diluted at 1 µg/mL, 
was added to each well (100 µL). After 1h incubation at 37 °C, the plate was 
washed 3 times with 200 µL/well of PBS-T, then 100 µL of a solution of 
peroxidase substrate ABTS (A319, Sigma-Aldrich, Milano, Italy) were added to 
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each well. The reaction was stopped with SDS 1% and the absorbance at 405 nm 
read using a multiwell absorbance reader (Biotek, ). Antibody titers were 
evaluated as sufficiently high when the average absorbance values from 
triplicate wells incubated with immune sera diluted at 1:10000 were at least 
thrice those determined on wells incubated with the pre-immune serum. Clones 
were screened using a similar assay, but utilizing hybridoma supernatants at 
various dilutions instead of sera. BSA2 was used as control in every assay to 
exclude those clones producing antibodies recognizing the BSA-linked 
glutaraldehyde.  
ELISA was also used to compare relative binding of mAbs to different antigens 
(library fractions or single monoacetylated peptides) and to control reagents, 
including the Myc-derived acetylated peptide, cyclized acetylated peptide 1-44 
(coated at 10 µg/mL) , BSA2 and acetylated OVA, BSA and KLH proteins. 
BSA-conjugated antigens were coated at 0.02 µg/mL in PBS and after blocking, 
selected anti-APE antibodies were used at 0.2 µg/mL while the ALPA 
commercial antibody was used at 0.5 µg/mL . Detection of bound antibodies was 
achieved using GAM-HRP 1:2000 (0.5 µg/mL) and OPD 0.4 mg/mL in 0.1 M 
citric acid and 0.2 M Na2HPO4 buffer (pH 4.8) and adding 0.2 μl/mL of 30% 
H2O2 as substrate. The chromogenic reaction was finally stopped adding 2.5 M 
H2SO4. Absorbance at 490 nm was read using a multiwells absorbance reader 
(Synergy 2 Multi-Mode Microplate Reader, Biotek).  
Dose-response bindings of antibodies to immobilized BSA-conjugated peptides 
(0.02 µg/mL) were performed using mAbs at increasing concentrations from 
0.03 µg/mL to 1 µg/mL. (0.2-6.6 nM). In the same experimental conditions 
antigens coated at 0.2 µg/mL were tested using commercially available anti-
acetylated lysine antibody (Polyclonal Antibody Cat. # AB3879, Millipore 
named hereafter ALPA) at 0.5 µg/mL and GAR-HRP diluted 1:500 (1 µg/mL). 
Binding competition assays were performed by coating the tetrapeptide at a 
fixed concentration (0.02 μg/mL) and using the antibody at 0.4nM. Competitors 
were used at the concentration ranging between 0.15 and 118 M. 
In addition, ELISA assay was used to test the reactivity on acetylated and not 
OVA, BSA and KLH proteins. All proteins were coated at 1 µg/mL in PBS and 
all antibodies were tested at the concentration of 0.5 µg/mL. The assays were 
carried out as previously described.  
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2.5 ANTIBODY PURIFICATION 
Antibodies were purified by standard procedures. After centrifugation at 12000 
rpm for 20 minutes at 4°C, hybridoma cell-culture supernatants were filtered on 
a 0.22 μm filter and loaded onto a Protein G Sepharose column (GE, Healthcare) 
using PBS as loading buffer. Elution was performed using 0.1 M glycine pH 2.7. 
Protein G-purified mAbs were dialyzed overnight against 20 mM Tris buffer pH 
7.0 at 4 °C, and then concentrated using Vivaspin™ 500 centrifugal filter (30 
kDa MWCO, Sartorius) by centrifugation at 4000 rpm, at 4°C. Purity of mAbs 
was estimated by size exclusion chromatography (SEC) using a Superdex 200 
Hr 10/30 column (GE, Healthcare) and by 12% SDS-PAGE under reducing and 
non reducing conditions. Concentration was determined using a BIORAD kit. 
 
2.6 ACETYLATION OF PROTEINS 
5mg of OVA, BSA and KLH and wild type pTAC-MAT/hAPE1 (kindly provide 
by Dr. G. Tell) proteins were dissolved in 5ml of 0.1 M Na2CO3 in a 15ml 
Falcon tube. The acetylation procedure was achieved adding slowly drop-wise 
with constant shaking to avoid precipitation 10μl of acetic anhydride and then 
40μl of pyridine. The reactions were incubated at 30°C for 5 h and stopped 
adding 40μl of 1M Tris base. Finally, the proteins were extensively dialyzed 
against 25mM Tris pH=7.5 and 100mM NaCl o.n. 4°C. The acetylated status of 
proteins were assess by SDS-Page analysis. 
 
2.7 WESTERN BLOTTING ANALYSIS 
3µg of wild type and acetylated pTAC-MAT/hAPE1, BSA, OVA and KLH were 
loaded under reducing and denaturing conditions onto a 12% SDS-PAGE gel; 
after electrophoresis, proteins were transferred onto a polyvinylidene difluoride 
(PVDF) membrane (Schleicher & Schuell BioScience, After blocking with 5% 
(w/v) milk (NFDM) in Tris-buffered saline containing 0.1%  (v/v) Tween-20 
(TBS-T) for 1 h at room temperature under shaking, the membrane was 
incubated overnight at 4° C with anti-APE mAbs as primary antibodies at 2 
µg/mL in 2.5% NFDM in TBS-T under shaking. The membrane was then triple-
washed with TBS-T and incubated with GAM-HRP as secondary antibody 
diluted 1:1000 (1 µg/mL) in TBS-T for 1 h at room temperature under agitation. 
The target proteins were detected using the Enhanced Chemi-luminescent 
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Substrate method with the SuperSignal West Pico kit provided by Pierce 
Chemical Co. (Rockford, IL USA). The signals were acquired with the 
ChemiDoc™ system (Bio-Rad, Hercules, CA ), using the Quantity One® 
software.  
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                                     II 3. RESULTS 
 
3.1 ANTIGEN PREPARATION AND CHARACTERIZATION 
A mixture of 16 distinct peptides corresponding to all combinations of four 
acetylated/non acetylated lysines over the sequence 
KKSK*TAAK*K*NDK*EAAG of APE1-Ref1, was prepared by the solid phase 
method incorporating equimolar mixtures of Fmoc-L-Lys(Boc)-OH/Fmoc-L-
Lys(Ac)-OH at the requested positions. Two additional lysines were introduced 
on the N-terminus to facilitate the conjugation of peptides to KLH and reduce 
the likelihood of conjugation on internal lysines. All generated sequences are 
reported in Fig. 3.1.  
Synthesis progression was monitored by removing small resin aliquots after each 
incorporation of lysine mixtures and checking by LC-MS the occurrence of the 
expected products. Following cleavage reactions to free the corresponding 
peptides, resulting compounds were characterized by LC-MS obtaining the 
expected MW and approximate equimolar distributions of molecules (not 
shown).  
After RP-HPLC fractionation (Fig. 3.2) and lyophilisation, the 16 fractions were 
again characterized by LC-MS. Considering the high similarity in structure and 
hydrophobicity, peptides bearing the same number of acetylated lysines were not 
separated and were recovered within the same fractions, except the di-acetylated 
peptides which were retrieved under two well separated fractions. In particular, 
the non acetylated peptide within fraction #1 (flowthrough, MWcalcd/expm: 
1671.96/1672.2 amu) was recovered; in fraction #4 (MWcalcd/expm: 
1716.99/1716.4 amu) all the monoacetylated peptides (four species) were 
recovered; in fraction #5 and #6 (MWcalcd/expm: 1758.02/1758.0 amu) all the di-
acetylated peptides (6 species) were recovered; in fraction #7 (MWcalcd/expm: 
1800.06/1800.1 amu) all the tri-acetylated peptides (4 species) were recovered; 
in fraction #8 (MWcalcd/expm: 1842.10/1841.6 amu) the single tetra-acetylated 
peptide were recovered (Table 1). The remaining fractions did not contain any 
material or contained unrelated side products. After lyophilisation we recovered 
1.5 mg in fraction #1, 1.8 mg in fraction #4, 2.8 mg in fraction #5, 3.6 mg in 
fraction #6, 3.5 mg in fraction #7, and 1.7 mg in fraction #8. Single 
monoacetylated peptides were also prepared by chemical synthesis, obtained in 
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high yield and purified to homogeneity by RP-HPLC. MWs were consistent with 
those expected (Table 1).  
 
                         Figure 3.1: Schematic composition of the acetylated peptides library.                             
                                     
                
           
 
Figure 3.2: RP-HPLC fractionation of  the 16 distinct peptides corresponding to all 
combinations of four acetylated/non acetylated lysines over the sequence 
KKSK*TAAK*K*NDK*EAAG of APE1/Ref1. 
 
                           
Di-Ac
KKSK*TAAK*KNDKEAAG
KKSK*TAAKK*NDKEAAG
KKSK*TAAKKNDK*EAAG
KKSKTAAK*K*NDKEAAG
KKSKTAAK*KNDK*EAAG
KKSKTAAKK*NDK*EAAG
KKSK27TAAK31K32NDK35EAAG 
Mono-Ac
KKSK*TAAKKNDKEAAG
KKSKTAAK*KNDKEAAG
KKSKTAAKK*NDKEAAG
KKSKTAAKKNDK*EAAG
Tetra-Ac
KKSK*TAAK*K*NDK*EAAG
Tri-Ac
KKSK*TAAK*K*NDKEAAG
KKSK*TAAK*KNDK*EAAG
KKSK*TAAKK*NDK*EAAG
KKSKTAAK*K*NDK*EAAG
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3.2 SCREENING OF HYBRIDOMA SUPERNATANTS ON WILD-TYPE 
AND ACETYLATED APE1/Ref1[24-39] PEPTIDES 
Preliminary hybridoma supernatants ELISA assay was carried out coating Ac-
APE1/Ref1[24-39]-BSA, APE1/Ref1[24-39]-BSA and (BSA)2-conjugated at 1 
µg/mL on 96-well plates.  
By this screening we found that four clones (1D4, 1B6, 2E6 and 2G10) exhibited 
high selectivity toward the acetylated variant of the APE1[24-39] peptide while 
five other clones (3G9, 9A12, 4H9, 3G6, 2D9 and 9F11) cross-reacted with both 
antigens; two remaining clones (5E3 and 2A5) showed a very low signal due to 
aspecific binding. Only the four specific clones for the acetylated peptide were 
selected for expansion (see Fig. 3.3). 
                  
Figure 3.3: ELISA-based screening assay of hybridoma supernatants. Peptides were coated at 1 
µg/mL. Hybridoma supernatants were tested at a concentration of 5µg/mL total proteins (33 nM 
assuming the occurrence of purified antibodies). 
 
Table 1. Nomenclature, aminoacidic sequence and MW of Mono-lysine acetylated
Ape1/Ref1[24-39] peptides
Peptide Sequence MW Theor. MW Exp.
APE-K27 KKSK*TAAKKNDKEAAG 1673.95 uma 1672.96 uma
APE-K31 KKSKTAAK*KNDKEAAG 1673.95 uma 1672.96 uma
APE-K32 KKSKTAAKK*NDKEAAG 1673.95 uma 1672.96 uma
APE-K35 KKSKTAAKKNDK*EAAG 1673.95 uma 1672.96 uma
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3.3 PURIFICATION OF ANTI-Ac-APE1/Ref1[24-39] MONOCLONAL 
ANTIBODIES 
 Clones specific for the acetylated peptides (2E6, 2G10, 1D4, 1B6) were adapted 
to grow in serum-free OPTIMEM medium and allowed to produce mAbs. Then 
the mAbs were purified from the supernatants by Protein G affinity 
chromatography (Fig. 3.4A). The elution of the mAb, indicated by the peak B, 
was performed after a few injections of supernatant onto the column, after 
washing away the unbound material (peaks A) with the loading buffer. High 
yield and high purity were achieved for all the four antibodies. As shown by 
12% SDS-PAGE analysis (Fig. 3.4B), a band of 150 kDa under non reducing 
conditions due to the whole antibody and two bands with different mobility 
under reducing conditions, the upper one at 50 kDa corresponding to the heavy 
chains and the lower at 25 kDa corresponding to the light chains were detected. 
Antibody concentration was determined by the Bradford method. 
 
                        
Figure 3.4A: Representative chromatogram of Protein G affinity purification of a mAb from  
hybridoma supernatants.       
                                  
                                 
Figure 3.4B: 12% SDS-PAGE analysis under non-reducing (-) and reducing (+) conditions of 
purified anti-APE mAbs. 
 
 
115 
 
3.4 SCREENING OF SELECTED mAbs WITH LIBRARY FRACTIONS 
TO DETERMINE SELECTIVITY TOWARD DIFFERENTLY 
ACETYLATED PEPTIDES  
To determine whether the selected antibodies had the ability to discriminate the 
different degree of acetylation of the peptides, further ELISA assays were 
performed with BSA-conjugated peptides from the isolated fractions coated at 
0.02 µg/mL. Antibodies 2E6, 2G10, 1D4 and 1B6 were tested at 0.2 µg/mL 
(Fig. 3.5A). In addition the same antigens were tested using as positive control 
the commercially available anti-acetylated lysine antibody (Polyclonal Antibody 
Cat. # AB3879, Millipore, named hereafter ALPA) at two concentrations 
corresponding to 0.5 µg/mL and 1 g/mL (Fig. 3.5B). However, in this case, the 
higher concentration (0.2 g/mL) of the coated antigen peptides and of the 
primary antibody, indicated the lower sensitivity of the commercial antibody 
compared to the anti-Ac-APE1/Ref1 peptides generated from our lab. 
Data obtained from the ELISA binding assay with the different library fractions 
showed that, under these conditions, all antibodies bound very well peptides 
from all fractions with comparable signal. However, the mono-acetylated, the di-
acetylated and the tri-acetylated peptides were bound with same high specificity. 
Interestingly, no significant binding differences were observed among the 
different mAbs and all of them failed to bind to the no-acetylated variant, as 
indicated by the absence of signal. 
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Figure 3.5A: ELISA-based screening assay of selected anti-APE antibodies. Differently BSA-
conjugated acetylated Ape1/Ref1[24-39] peptides were coated at 0.02µg/mL. Antibodies were 
tested at concentration of 0.2µg/mL.  
                                                                              
                                          
Figure 3.5B: Binding of the ALPA antibody to the APE1/Ref1[24-39] acetylated peptides 
coated at 0.2µg/mL. As expected, no binding was detected for the non-acetylated molecule, 
whereas ALPA binding correlated with the degree of peptide acetylation. 
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3.5 DOSE-RESPONSE ELISA ASSAYS 
To more finely investigate the recognition properties between antibodies and the 
different antigens, dose-response binding assays were next performed, using the 
entire set of mAbs and the mono-acetylated, di-acetylated and tri-acetylated 
peptides.  
All antibodies were used at increasing concentrations ranging from 0.2 nM to 
6.7 nM and, as shown, they bound in a dose-dependent and saturable fashion to 
the immobilized peptides. Remarkably, no relevant differences were detected 
among the antibodies for the binding to the mono-acetylated and the tri-
acetylated peptides (Fig. 3.6), whereas small, but measurable differences were 
recorded for the ability of the four antibodies to capture the di-acetylated 
peptide. An estimation of apparent dissociation constants (KD, reported in Table 
2) between the different antigens and the mAbs was derived. As shown, the 
affinity was slightly higher for the di-acetylated peptides, with KDs ranging 
between 70 pM (2E6 and 1B6) and approximately 120 pM (2G10, 1D4). 
Furthermore, the affinities of the four mAbs for the tri-acetylated peptides were 
essentially identical, with KDs between 140 and 170 pM, and were also very 
similar to those exhibited by 1B6, 2G10, 1D4 for the binding to the 
monoacetylated peptides. Of interest, the affinity between 2E6 and the 
monoacetylated molecules was estimated slightly lower (about 400 pM). In 
summary, all the mAbs displayed the highest affinity for the diacetylated 
peptides; a plausible explanation was that the charge localization on the lysine 
residues in the diacetylated form allows favourable interactions with all of the 
mAbs. 
118 
 
 
Figure 3.6A: Dose-dependent binding assay of 2E6 (A), 2G10 (B), 1B6 (C), 1D4 (D) antibodies 
ranging between 0.2 and 6.6 nM to the differently acetylated fractions of APE1/Ref1[24-39] 
BSA-conjugated peptides.                                   
 
                
 
Subsequently, dose-response binding assays were performed between each mAb 
and each of the 4 mono-acetylated peptides to evaluate the ability of mAbs to 
discriminate among the different mono-acetylated lysines. As revealed by the 
estimation of apparent dissociation constants (KD, reported in Table 3) between 
the single acetylated antigens and the mAbs, no significant differences were 
detected.  
Table 2. KD values related to the binding between each mAb and each monoacetylated
APE1/Ref1[24-39] peptide. Data were fitted by Graph pad vers. 4 using a non linear
regression analysis
mAb Mono-Acetylated Di-Acetylated Tri-Acetylated
2E6 0.422*10-9 M ± 0.1815
0.198*10-9 M ± 0.0303
0.127*10-9 M ± 0.0126
0.185*10-9 M ± 0.0326
0.074*10-9 M ± 0.0096
0.115*10-9 M ± 0.0203
0.068*10-9 M ± 0.0067
0.116*10-9 M ± 0.0244
0.144*10-9 M ± 0.0301
0.170*10-9 M ±0.0341
0.159*10-9 M ±0.0231
0.180*10-9 M ± 0.0891
2G10
1B6
1D4
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Figure 3.6B: Dose-dependent binding assay of 2E6 (A), 2G10 (B), 1B6 (C), 1D4 (D) antibodies 
ranging from 0.2 to 6.6 nM to the each APE1/Ref1[24-39] derived monoacetylated peptide. 
 
 
 
3.6 DOSE-DEPENDENT COMPETITION ASSAYS 
In order to explore the difference among various monoclonal antibodies in 
mono-acetylated recognition, competitive ELISA assays were carried out 
coating mono-acetylated mixture and pre-incubating each mAb with every single 
mono-acetylated variant. As expected, all four monoacetylated-lysine peptides 
are competitive (Fig. 3.7A). A detailed analysis of data suggested that the 
peptide bearing acetylation on K35 residue is slightly more competitive for the 
binding only to 2G10, 1B6 and 2E6 antibodies, exhibiting a similar IC50 around 
7*10
-6
 M, compared to other mono-acetylated peptides. In addition, 2G10 and 
1B6 displayed a very comparable behaviour, showing the capability to similarly 
recognize the peptides K32, K31, K27 and K35, with an increasing affinity, 
respectively. By contrast, 2E6 mAb seems to bind preferentially to the peptide 
Table 3. KD values related to the binding between each mAb and each monoacetylated
APE1/Ref1[24-39] peptide. Data were fitted by Graph pad vers. 4 using a non linear regression
analysis
mAb APE- K27 APE- K31 APE- K32 APE- K35
2E6 0.283*10-9 M+ 0.038 0.335*10-9 M+ 0.042 0.303*10-9 M+ 0.049 0.325*10-9 M+ 0.079
2G10 0.448*10-9 M+ 0.016 0.508*10-9 M+ 0.068 0.456*10-9 M+ 0.046 0.562*10-9 M+ 0.057
1B6 0.445*10-9 M+ 0.020 0.554*10-9 M+ 0.070 0.545*10-9 M+ 0.022 0.616*10-9 M+ 0.090
1D4 0.760*10-9 M+ 0.093 0.505*10-9 M+ 0.098 0.714*10-9 M+ 0.064 0.523*10-9 M+ 0.132
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containing the acetylated K35. Furthermore, no significant differences of 
bindings were detected between various monoacetylated peptides and 1D4. 
Finally, the same competitive assays were carried out using the reconstituted 
library achieving a similar result (Figure 3.7B).  
These data are relevant because confirm the ability of selected mAbs to 
recognize the mono-acetylated variant of APE1/Ref1.  
 
 
Figure 3.7A: Dose-dependent Competitive ELISA assay. Monoacetylated mixture was coated at 
0.02 mg/mL. Competition solutions were set up by incubation of each antibody [2E6 (A), 2G10 
(B), 1B6 (C), 1D4 (D)], at pre-saturation concentration (0.4nM), with single and free APE1/Ref1 
[24-39] monoacetylated peptides at a concentration ranging between 0.15 and 118 µM. The 
signal was expressed as % of relative absorbance measured  at 490nm and  calculated as  
B/B0*100. 
          
 
 
Table 4. IC50 values obtained by data fitting of  ELISA competitive assays
mAb APE- K27 APE- K31 APE- K32 APE- K35
2E6 1.89* 10-5 M + 0.026 1.84*10-5 M + 0.053 1.67*10-5 M + 0.029 0.61*10-5 M + 0.033
2G10 3.87*10-5 M + 0.056 1.61*10-5 M + 0.058 1.73*+10-5 M 0.031 6.78*10-5 M + 0.054
1B6 3.27* 10-5 M + 0.043 1.93*10-5 M + 0.056 1.75*10-5 M + 0.059 7.00*10-5 M + 0.065
1D4 2.11*10-5 M + 0.056 3.18*10-5 M + 0.012 2.25*10-5 M + 0.048 1.19*10-5 M + 0.037
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Figure 3.7B: Dose-dependent competitive ELISA assay. Each antibody (2E6, 2G10, 1B6, 1D4) 
at pre-saturation concentration 0.4nM was pre-incubated with reconstituted Ac-APE1/REf1[24-
39] library peptides at a concentration ranging between 0.15 and 118 µM. The solutions were 
added on 96-wells plate. The coating solution composed of tetracetylated mixture was fixed at 
0.02mg/mL. Data were reported as % of relative absorbance, calculated as  B/B0*100. 
                                            
                   
 
                                         
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5. IC50 values obtained by data fitting of competitive ELISA assays between each mAb
and the peptides library
2E6 2G10 1B6 1D4
2.12*10 -5 M ± 0.055 3.19*10 -5M ± 0.012 2.25*10 -5M ± 0.048 1.2*10 -5M ± 0.037
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3.7 SELECTIVITY ASSAYS  
The specificity of anti APE1/ Ref1 antibodies was investigated evaluating their 
capability to bind to c-Myc[119-161] derived acetylated peptides and to an 
acetylated unrelated cyclic peptide (termed N_1-13) as well as to different 
acetylated classic carriers proteins BSA, OVA and KLH, that is the specific 
antigen used to generate ALPA antibody. (See Fig.7) 
The library of c-Myc[119-161] derived acetylated peptides containing 8 distinct 
molecules and N_1-13 peptide (Table 4) were synthetized and characterized as 
described in the section 2.2 of Methods. The acetylation of carrier proteins, 
carried out as described in the Methods section, was detected by SDS-PAGE. As 
can be seen in Fig. 3.8, the acetylated proteins showed different migration 
because the mobility is retarded by acetylation.  
           
                                   
                 
 
Figure 3.8: 10% SDS-PAGE analysis of non-acetylated and acetylated BSA and OVA proteins. 
Marker Precision Plus Protein Prestained Standards 15-150kDa. Acetylated proteins have a 
higher molecular weight compared to the wild-type form. 
 
                a. ELISA assays 
To assess the specificity of anti-APE1-ref antibodies toward the acetylated 
lysine residues of the APE protein, ELISA assays were set up using both 
unrelated peptides at a concentration of 10 g/mL (Fig. 3.9A) as well as coating 
all proteins at 1 g/mL (Fig. 3.9B). All anti-APE mAbs were used at 1 g/mL 
while the ALPA was used at 0.5 g/mL. As shown in Fig. 3.9, ALPA was able 
Table 6. Nomenclature, aminoacidic sequence and MW of un-related acetylated peptides
Peptide Sequence MW Theor. MW Exp.
c-Myc [119-161] DDETFIKNIIIQDCMWSGFSAAAK*LVSEK*LASYQAARK*DSGS 5006.147 uma 5006.05 uma
N_1-13 CLIKLKDGRKVEC 1544.842 uma 1544.05 uma
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to detect both the unrelated peptides and all three acetylated proteins with a very 
similar signal whereas the monoclonal antibodies were inactive. As expected, no 
reactivity for proteins, used as negative control, was observed for all antibodies 
also using peptides at high concentrations. 
In summary, these findings suggested that the recognition of the acetylation by 
our antibodies was not mediated by isolated acetyl-lysines, but it was due to 
acetyl-lysine residues in the context of the APE1/Ref1 sequence.                       
                        
 
Figure 3.9A: Binding of four anti-APE and ALPA antibodies to cMyc-derived and N_1-13 
acetylated peptides. As expected, ALPA bound to acetylated peptides while no binding was 
detected for anti-APE antibodies. 
                                  
                      
Figure 3.9B: Binding of four anti-APE1 and ALPA antibodies to acetylated proteins. As 
expected, no binding was detected for anti-APE1 antibodies. ALPA bound its proper antigen 
acetylated KLH as well as Ac_BSA  and Ac_OVA.  
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b. Western blotting analysis 
Finally the specificity of the mAbs to recognize the APE1/Ref1 proteins in 
acetylation status, even under reducing and denaturing conditions, was 
confirmed by western blotting analysis.  
The wild type recombinant human APE1 [1-318 residues, Uniprot P27695- 
APE1_HUMAN-Ref1)] was kindly provided by Dr. G.Tell (University of 
Udine), expressed in pTAC-MAT-Tag-2 Vector. 
The aminoacidic sequence of protein is reported below and the lysine residues 
involved in their biological activity are red and underline.  
  
        10         20         30         40         50         
60  
MPKRGKKGAV AEDGDELRTE PEAKKSKTAA KKNDKEAAGE GPALYEDPPD 
HKTSPSGKPA  
 
        70         80         90        100        110        
120  
TLKICSWNVD GLRAWIKKKG LDWVKEEAPD ILCLQETKCS ENKLPAELQE 
LPGLSHQYWS  
 
       130        140        150        160        170        
180  
APSDKEGYSG VGLLSRQCPL KVSYGIGDEE HDQEGRVIVA EFDSFVLVTA 
YVPNAGRGLV  
 
       190        200        210        220        230        
240  
RLEYRQRWDE AFRKFLKGLA SRKPLVLCGD LNVAHEEIDL RNPKGNKKNA 
GFTPQERQGF  
 
       250        260        270        280        290        
300  
GELLQAVPLA DSFRHLYPNT PYAYTFWTYM MNARSKNVGW RLDYFLLSHS 
LLPALCDSKI  
 
       310        320  
RSKALGSDHC PITLYLALEH NHRHKH 
 
 
Molecular weight: 36639.6 
 
 
Figure 3.10: Aminoacidic sequence of hAPE 1-318. Molecular weight is reported. An additional 
linker sequence derived from the vector is reported as underline and bold. 
 
 
To preliminarily investigate whether the mAbs could be used to detect the 
acetylated protein in cellular extracts by western blot analysis, the APE1/Ref1 
recombinant protein was acetylated, as already described. The acetylation 
reaction was successfully achieved as confirmed by 12% SDS-PAGE analysis 
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Fig. 3.11A, that showed the different apparent migration of the wild-type and 
acetylated proteins as indicated by the band at 35 kDa corresponding to the wild 
type form and the slower one at approximately 45 kDa. Western blotting 
analyses were performed using wild-type and acetylated OVA, BSA e 
recombinant APE1/Ref1 proteins 2 g/mL and probing the membranes with the 
four anti-APE antibody at concentration of 2 g/mL. The detection was carried 
out using Femto chemilumiscence Kit. All mAbs were able to detect only the 
acetylated APE1/Ref1 form, while and no detection was observed with the wild-
type protein and for other proteins. A representative western blotting analysis 
using 2E6 mAb is reported in Fig. 3.11B. 
               
 
 
Figure 3.11: (A) 12% SDS-PAGE and (B) Western blot analysis on 15% SDS-PAGE, 
representative of one mAb, of  wild-type and acetylated APE1/Ref1. Western blot analysis was 
carried out on the acetylated and the wild type form of OVA, BSA and rAPE1; as expected, anti-
APE1/Ref1 mabs were able to detect only the acetylated APE1/Ref1 protein; OVA and BSA 
were not detectable. 
  
A B 
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                           II 4. DISCUSSION  
       
Apurinic/apyrimidinic endonuclease 1 (APE1), also known as redox effector 
factor-1 (Ref-1), is a multifunctional and essential protein in mammals, acting as 
a key regulator of cellular responses to oxidative stress and contributing to the 
maintenance of genome stability. 
Human APE1 exerts its two most important biological activities, redox and 
repair, through two functionally distinct protein domains, the N-terminal and the 
C-terminal, that act in a completely independent way, in fact, the non-structured 
N-terminal domain (residues 1–127) is essential for the redox activity, while the 
C-terminal domain (residues 61–318) is essential for the DNA base excision 
repair (BER) activity. APE1 is a protein that undergoes several post-translational 
modifications (PTMs); of interest charged K residues, located within the 
unstructured APE1 N-terminal domain (K24/K25/K27/K31/K32), are crucial for 
APE1 interaction with rRNA and NPM1 and for regulation of its catalytic 
activity on abasic DNA through modulation of product binding. Interestingly, 
some of these critical amino acids (K27/K31/K32 and K35) may undergo in vivo 
acetylation under basal conditions. 
Recent results highlight the emerging role of acetylation of critical Lys residues 
in regulating APE1 functions. They also suggest the existence of cross-talk 
between different Lys residues of APE1, occurring upon genotoxic damage, 
which may modulate APE1 subnuclear distribution and enzymatic activity in 
vivo. Since the actual acetylation status of this protein region following different 
cell stimulations is currently unknown, we have explored the possibility of 
generating monoclonal antibodies which could specifically recognize the 
differently acetylated variants of the protein, so as to perform quick and very 
sensitive western blotting assays to monitor the protein modification under 
different conditions. The use of monoclonal antibodies is of particular interest in 
the context of the target antigen here considered, because the lysines potentially 
acetylated occur within a peptide segment of nine residues (K27->K35), which 
is the typical length of mAbs peptide antigens. This could imply that all the 
peptide combinations, at least the peptide sequence covering residues from 
Lys27 to Lys35, have the potential to be fully captured by the antibody CDR, 
thus recognition could be very specific with a particular antibody. 
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We used a pool of 16 differently acetylated peptides to immunize mice 
and to generate the mAbs, which were subsequently screened for their ability to 
interact with the different pool components. One major problem with 
immunizations with multiple immunogens (or mixtures) could arise with the 
difference in antigenicity of the different components and the consequent 
distribution of antibody population. However, this would not be the case, 
because the peptidic portion of the molecules is conserved so the overall 
antigenicity is largely preserved and should ensure an almost equal 
representation of the stimulated antibody population. This should also ensure 
that the resulting antibodies are at least specific for the APE1 primary sequence 
(as such residues are included in all the library components) and have as 
secondary recognition element, the variable acetylation. Following a screening 
approach based on the exclusion of mAbs binding the non-acetylated peptide 
variant, we isolated a set of monoclonal antibodies all recognizing with 
comparable affinity all the library components (at least when tested as sub-pools 
as we did in our work). Only the single tetra-acetylated peptide bound less well 
all the four selected mAbs. While this could be true, such an effect could instead 
likely be the result of a partial molecule insolubility that leads to an 
overestimation of the actual concentration. Importantly, all selected antibodies 
only bind the acetylated peptides while being completely inactive toward the 
non-acetylated variant. This strongly suggest that they bind with high affinity at 
least one acetylated lysine and a second, specific site on the peptide chain, far 
from acetylation sites. This is supported by the observation that all the four 
singly acetylated peptides tested against the antibodies had very strong binding 
affinities (in the sub-nM range) and is further supported by the lack of antibody 
recognition by both the non-acetylated and chemically acetylated proteins BSA, 
OVA and KLH and the strong binding observed with the acetylated recombinant 
APE1 protein. 
However, as demonstrated, antigen recognition by our antibodies is strictly 
dependent on amino acid sequence surrounding the acetylated lysines.  
Altogether, the data support the conclusion that monoclonal antibodies specific 
for the singly o multi-acetylated variants of the region 24-39 can be generated 
with our approach, but they are not sufficiently specific to detect the differently 
acetylated forms of the peptide and of the protein with enough selectivity. 
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Further, since the selected mAbs bind the monoacetylated variants at different 
positions, they also detect the poliacetylated variants. Therefore, our approach 
has demonstrated the feasibility of generating monoclonal antibodies (given the 
length of the antigen) with polyclonal features and combines the advantages of 
targeting multiple antigenic determinants (high avidity, low likelihood of antigen 
'escape variants’) with the advantages of obtaining monoclonal antibodies 
characterized by very high affinity. The idea reported here provided a rapid 
method for the generation of site-specific multi and monoacetyl-lysine 
antibodies which could be applicable to a protein acetylation studies in other 
tissues and organisms. For the first time, here we reported a new method for the 
high-throughput generation of monoclonal antibody suitable to generate 
diagnostic and/or therapeutics tools. 
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               ABBREVIATIONS 
Abs : Absorbance 
ABTS : 2,2-Azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) 
amu : atomic mass unit 
APS : Ammonium persulfate 
BSA : Bovine serum albumin 
CDR : Complemetarity determining region 
CM5 : Carboxy-methylated dextran sensor chip 
DIEA : N,N-Diisopropylethylamine 
DMEM : Dulbecco's modified Eagle's medium 
DMF : Dimethylformamide  
DMSO : Dimetilsulphoxide 
DTT : Dithiothreitol  
ECL : Enhanced Chemiluminescence 
EDC : 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide 
EDTA : Ethylenediaminetetraacetic acid 
ELISA : Enzyme-Linked Immunosorbent Asssay  
Fab : Fragment antigen-binding  
FACS : Fluorescence-activated cell sorting 
Fc : Fragment cystallizable 
FCS : Foetal calf serum  
Fmoc : Fluorenylmethyloxycarbonyl chloride 
FPLC : Fast Protein Liquid Chromatography 
GAM-HRP : Goat anti mouse-Horseradish peroxidase 
GAR-HRP : Goat anti rabbit-Horseradish peroxidise 
h : hours 
HATU:1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium-3-oxid 
hexafluorophosphate 
HEPES : 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HPLC : High performance liquid chromatography 
IAM : Iodoacetamide 
IgG : Immunoglobulin G 
kDa : kiloDalton 
KLH : Keyhole Hemocyanin Limpet 
LC- MS : Liquid Chromatography- Mass Spectrometry 
mAb : Monoclonal antibody 
MBHA : resin 4-Methylbenzhydrylamine Hydrochloride Salt Resin 
min : minutes 
MW : Molecular Weight 
MWCO : Molecula Weight Cut Off 
NaAc : Sodium Acetate  
NFDM : Not Fat Dry Milk 
NHS : N-hydroxysuccinimide ester  
OD : Optical Density 
o.n. overnight 
OPD : o-Phenylenediamine dihydrochloride 
PBS : Phosphate-Buffered Saline 
PBS-T : Phosphate-Buffered Saline-Tween 20 
PDA : Photodiode Array 
PEG : Polyetilen gycole 
PNGase F : Peptide-N-Glycosidase F 
PVDF : Polyvinylidene fluoride 
rhNodal : recombinant human Nodal 
rhCripto-1 : recombinant human Cripto-1 
RFU : Relative Fluorescence Units 
RP-HPLC : Reverse phase-high performance liquid chromatography 
rpm : Revolutions per minute 
RPMI : Roswell Park Memorial Institute 
r.t. : room temperature 
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RU : Resonance Unit 
SDS : Sodium Dodecyl Sulphate 
SDS-PAGE : Sodium Dodecyl Sulphate - PolyAcrylamide Gel Electrophoresis 
SEC : Size-exclusion chromatography 
SPR : Surface Plasmon Resonance 
TBS-T : Tris-Buffered Saline-Tween 20 
TEMED : Tetramethylethylenediamine  
TFA : Trifluoroacetic Acid 
TIS : Triisopropylsilane 
U/ml :  Unit/ml 
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Nodal belongs to the transforming growth factor-β (TGF-β) super-
family and plays essential roles in regulating embryonic develop-
ment [1] and cell fate determination [2,3]. As with other growth
factors, its late re-expression in adult tissues contributes to tumor
development and progression. Nodal overexpression is indeed im-
plicated in tumorigenesis, metastasis and cancer vascularization
and has been associated to various cancers [4], including ovarian
[5], pancreatic [6,7], endometrial [8], breast [9–11], prostate
[12,13], testicular [14], brain [15,16], colon [17], melanoma [18,19]
and hepatocellular carcinoma [20]. Because the TGF-β roles in tu-
morigenesis frequently reflect their function in embryonic develop-
ment, in the current literature, their signaling pathways are
observed with a special regard as possible therapeutic targets
[10,16,21–24]. The overexpression of Nodal in numerous cancers,
as well as its low abundance in normal tissues, makes Nodal a
potential biomarker or antitumor target. In order to achieve this
goal, many efforts have been made to fully understand how Nodal
works in both normal and neoplastic conditions [4].
As for other TGF-βs, Nodal triggers the signaling functions
through the interaction with the extracellular domains (ECD) of
type I and type II serine/threonine kinase receptors. In particular,
Nodal can signal via ActRIIB type II receptor and ALK7 or ALK4 type
I receptors [25,26]. Effective signaling through ALK4 requires theCopyright © 2014 European Peptide Society and John Wiley & Sons, Ltd.
CALVANESE ET AL.additional interaction of Nodal with the co-receptor Cripto [27].
Cripto is a membrane protein bound to the extracellular surface
via glycosylphosphatidylinositol linkages [28]. It belongs to the
Epidermal Growth Factor - Cripto_FRL-1_Cryptic (EGF-CFC) family
and contains two cysteine-rich domains: the EGF-like domain,
highly homologous to epidermal growth factor domains, and the
prototypical CFC domain. Both domains are compact structural
modules held together by three disulfide bridges and likely fur-
ther stabilized by reciprocal interactions. Cripto is required for
the formation of the multimeric complex involving Nodal and
the ALK4/ActRIIB receptors. Indeed, Cripto binds ALK4 by means
of its CFC domain while it interacts with Nodal via the EGF-like
domain [27] (Figure 1). It is worth remembering that Nodal is
absent in most normal adult tissues, but, like its cognate co-
receptor Cripto, is expressed in many different tumors where
they potently promote cell proliferation and growth through
the phosphorylation of Smads [4]. These findings make the
Nodal–Cripto signaling pathway a very attractive target for tumor
therapy [24]. Indeed, many efforts are currently made to develop
specific Nodal inhibitors, mostly antibodies, which can interfere
with one of the several interactions established by Nodal with
Cripto or with ALK7 and efficiently interrupt the downstream
Smad signaling [4]. Several groups have proposed anti-Nodal
antibodies that potentially target its interaction with Cripto and
block tumor growth in models of metastatic melanoma cells [29].
However, developing effective and selective inhibitors remains a
very challenging task in absence of a more comprehensive view
of the network of interactions established by these proteins and,
more importantly, in absence of a detailed understanding of theFigure 1. Schematic representation of ALK4/Cripto/Nodal/ActRIIB complex.
wileyonlinelibrary.com/journal/jpepsci Copyright © 2014 Europstructural features underlying mutual recognition. For these pur-
poses, we have investigated the structural aspects underpinning
the Nodal–Cripto binding and have reported the first molecular
models of Nodal in complex with its receptors [30,31].
Nodal is a homodimer consisting of two subunits, eachwith three
disulfidebonds, linkedbyanadditional inter-chaincovalentdisulfide
bond,highly conserved in theTGF-β superfamily [32] . Thehomology
model of Nodal, we previously reported [30], shows the canonical,
symmetric and elongated TGF-β topology (Figure 2). Each Nodal
monomer is characterized by two pairs of antiparallel β-strands
stretching out from the cysteine core-like fingers and by an α-helix
(H3 helix). The typical curvature of these fingers creates concave
andconvexsurfaces,namelywristandknuckleregions,whichenable
the interaction of Nodal with type I and type II receptor binding epi-
topes, respectively. Inparticular, tothewrist regionparticipate, the in-
ner concave surface of the fingers of one monomer and the α-helix
(H3 helix) and the pre-helix loop of the other monomer [33–35].
The molecular models of Nodal in complex with the ECDs of its
type I receptors (ALK4 and ALK7), as well as with Cripto, were ob-
tained by homology modeling and docking simulations. Also, po-
tential binding epitopes were identified [30,31]. These comprise
residues belonging to the Nodal wrist region. To validate such hy-
pothesis, a series of new Nodal fragments has been now designed
and synthesized. This series includes peptides from the pre-helix
loop and the H3 helix of Nodal (residues 44–67) (Figure 2), and
bears somemutations that will help to evaluate the role of selected
hot spots in receptors binding, as discussed in the Results section.
Peptides have been synthesized, and their conformational fea-
tures have been analyzed in solution by CD and NMR. To evaluate
their binding affinity toward ALK4 and ALK7 receptors, as well as to-
ward Cripto co-receptor, surface plasmon resonance (SPR) assays
have been carried out. Also, a comparative binding analysis of
Nodal to the ECD of recombinant human rhCripto, rhALK4 and
rhALK7 has been performed to assess that the reagents used are
fully active in terms of recognition and that interacting surfaces
are properly exposed.
The set of data, resulting from conformational analyses and bind-
ingmeasurements, provide useful information that confirms the re-
liability of the theoretical models. On these grounds, the design of
new molecules, acting as antagonists in the Nodal-receptors com-
plex formation, can be improved with the outlook to their thera-
peutic and diagnostic applications.Materials and Methods
Reagents
Reagents for peptide synthesiswere fromNovabiochem (Laufelfingen,
Switzerland), Inbios (Napoli, Italy) and GL Biochem (Shanghai, China).
Solvents for peptide synthesis and purification, including ACN, DMF,
DCM and MeOH were from Romil (Dublin, Ireland). Recombinant
proteins were purchased from R&D system (MN, USA).
Peptides Synthesis and Purification
Peptides were prepared by stepwise solid-phase synthesis as
C-terminally amidated molecules following standard Fmoc chem-
istry protocols. To increase the polypeptide’s stability, the
N-terminal and C-terminal ends were acetylated and amidated,
respectively. A Rink-amide resin (substitution 0.53mmol/g) and
amino acid derivatives with standard protections were used in
the synthesis [36]. The syntheses were performed underean Peptide Society and John Wiley & Sons, Ltd. J. Pept. Sci. 2014
Figure 2. Ribbon representation of Nodal dimer model, with the twomonomers colored in green and gray, respectively. The disulfide bridges are shown as
yellow sticks. The Nodal wrist and knuckle regions, responsible for the binding to the type I and II receptors, are schematically indicated. At the bottom, both
the primary and secondary structures of the Nodal monomer are reported. The Nodal fragment selected in this study is circled in orange.
CONFORMATIONAL AND BINDING PROPERTIES OF NODAL SYNTHETIC FRAGMENTScanonical conditions of peptide synthesis (HATU/DIEA pre-
activation, fivefold excess of Fmoc-protected amino acids).
Coupling and deprotection times were kept at 30 and 20min, re-
spectively. Finally, N-terminal acetylation was performed on the
resin using acetic anhydride at 0.5M in DMF with 5% DIEA,
20min at room temperature. The cleavage of peptides from
the solid support was performed by treatment with a TFA/TIS/
water (90 : 5 : 5, v/v/v) mixture for 3 h at room temperature,
affording the crude peptides after precipitation in cold diethyl-
ether. The precipitates were dissolved in water and were lyoph-
ilized. Products were purified to homogeneity by RP-HPLC using
an ONYX monolithic C18 column (100×10mm ID) applying a
linear gradient of 0.05% TFA in ACN from 5% to 70% over
10min (flow rate 20mL/min). The purity and integrity of all pep-
tides were estimated by LC-MS analyses using an LCQ mass
spectrometer (ThermoFisher, Milano, Italy) coupled to a Surveyor
system HPLC or an HCT Ultra ESI Ion Trap mass spectrometer
(Bruker), coupled to a Waters Alliance HPLC system (Milford,
MA, USA). LC-MS analyses were performed under conditions
standardized for the detection of peptides in the positive mode.
Typical gradients applied to elute the peptides were as follows:
flow 0.2mL/min; gradients from 5% solvent B (ACN, 0.05% TFA)
to 70% solvent B in 10min. Solvent A was H2O, 0.08% TFA.
Biobasic C18 50×2mm ID columns (ThermoFisher, Milano, Italy)
were used to separate peptides during LC-MS analyses.
Peptides were all prepared in amounts sufficient for the CD and
NMR analyses and for the binding assays. Purities were >95% as
determined by LC-MS analysis (Table 1).Table 1. Sequences of Nodal fragments investigated in this study
Peptide name Sequence
Nodal[44-67] Ac-PNPVGEEFHPTNHAYIQSLLKRYQ–NH2
Nodal[44-67]EE-AA Ac-PNPVGAAFHPTNHAYIQSLLKRYQ–NH2
Nodal[44-67]PV-AA Ac-PNAAGEEFHPTNHAYIQSLLKRYQ–NH2
Nodal[44-67]Y-A Ac-PNPVGEEFHPTNHAAIQSLLKRYQ–NH2
J. Pept. Sci. 2014 Copyright © 2014 European Peptide Society and JohCircular Dichroism Analysis
All CD analyses were performed using a JASCO J-710 spectropolar-
imeter (Halifax, Canada), equipped with a Peltier system for
changing the temperature in a controlled way and quartz cuvettes
110-QS with 1.0mm path length. Experiments were performed in
10mM phosphate, pH 8.0 at a concentration of 0.5×105M. In ad-
dition, spectra in the same buffer with added 20% of TFE were col-
lected to increase the α-helix structure.
Spectra were collectedwithin thewavelength range 250–190nm
at a scan rate of 50 nm/min, with a data pitch of 0.2nm, a band-
width of 1 nm and a response time of 4 s.
On every sample, five independent spectra were recorded, aver-
aged and smoothed using the Spectra Manager software, version
1.53 (Easton, MD, USA). Buffer scans were recorded under the same
conditions and subtracted.NMR Analysis
NMR characterization of Nodal fragments was performed in a
water/deuterated trifluoethanol TFE-d3/H2O 20 : 80 (v/v) mixture at
298K. Samples were prepared by dissolving weighted amounts of
each peptide in water (spectroscopic purity) and adding TFE-d3
(Sigma-Aldrich Chemicals, St. Louis, MO, USA, 99.9% D) up to a final
ratio of 80/20 v/v. Final concentrations were about 3mM.
One-dimensional and two-dimensional NMR spectra were ac-
quired on a Varian Inova spectrometer (Agilent Technologies, Palo
Alto, California, USA), operating at a proton frequency of 500MHz,Molecular Weight theor. Molecular Weight exp.
2880.2 2880.0
2764.1 2764.2
2826.1 2826.6
2788.1 2788.2
n Wiley & Sons, Ltd. wileyonlinelibrary.com/journal/jpepsci
CALVANESE ET AL.located at the ‘Centro Interdipartimentale di Metodologie Chimico-
Fisiche (CIMCF)’ of the University Federico II of Naples. Two-
dimensional (2D) experiments, such as total correlation spectroscopy
(TOCSY) [37], nuclear Overhauser effect spectroscopy (NOESY) [37],
and double quantum-filtered correlated spectroscopy (DQFCOSY)
were recorded by the phase-sensitive States-Haberkorn method
[38]. The data file generally consisted of 512 and 2048 (4096 for
DQFCOSY) data points in the ω1 and ω2 dimensions, respectively.
TOCSY experiments were acquired with a 70ms mixing time, while
NOESY experiments were acquired with 300ms mixing time. The
water resonance was suppressed by using gradients [37]. Chemical
shifts were referred to internal sodium 3-(trimethylsilyl) propionate
2,2,3,3-d4.
Spectra were analyzed by using the CARA program [39,40]. Pro-
ton sequential assignments of the amino acid spin systems are re-
ported as Supporting Information (Tables S1–S3). NOE intensities,
evaluated by integration of cross-peaks in the 300ms NOESY spec-
tra, were converted into inter-proton distances by use of the
CALIBA program [41]. Geminal protons were chosen as reference
with a distance of 2.2 Å.
Computational Methods
Structure calculations for Nodal[44-67], Nodal[44-67]EE-AA and
Nodal[44-67]Y-A started from 100 randomized conformers and
used the standard CYANA-simulated annealing schedule [42] with
20 000 torsion angle dynamics steps per conformer. Three-
dimensional structures were obtained by using inter-proton dis-
tances evaluated from NOEs as upper limits without the use of ste-
reospecific assignments. All the conformers showed a fair
agreement with experimental constraints showing no violations.
The 40 conformers with the lowest final CYANA target function
(TF) [43] values (TF average value= 0.42± 0.12Å2, 4.02E-02
± 3.03E-02Å2, and 4.41E-02±4.40E-02Å2 for Nodal[44-67], Nodal
[44-67]EE-AA and Nodal[44-67]Y-A, respectively; mean global back-
bone RMSD=3.51±0.97Å, 3.15± 0.65Å, and 3.44± 0.69Å for
Nodal[44-67], Nodal[44-67]EE-AA and Nodal[44-67]Y-A) were sub-
jected to restrained energy minimization by use of the SANDER
module of the AMBER 6.0 package [44].
The 40 minimized structures were subjected to the program CHI-
MERA [45] that divided them, based on structural similarity
(RMSD< 0.5), into 7 clusters for Nodal[44-67], 7 clusters for Nodal
[44-67]EE-AA and 6 clusters for Nodal[44-67]Y-A. The structures
present in the first cluster (13 for Nodal[44-67], 17 for Nodal
[44-67]EE-AA and 12 for Nodal[44-67]Y-A) were chosen as represen-
tative of the conformational space accessible to the peptide. The
molecular graphics program MOLMOL [46] was employed to per-
form the structural statistics analysis. Statistical data are reported
as Supporting Information (Tables S4 and S5).
SPR Analyses
All analyses were performed on a Biacore 3000 instrument from
GE Healthcare (Little Chalfont, UK) using certified HEPES
Buffered Saline (HBS) buffer (20mM Hepes, 0.15M NaCl, pH 7.2,
P20 at 0.005%), at 25 °C.
Human ALK4 (rhALK4-ECD) and ALK7 (rhALK7-ECD) and Cripto
(rhCripto) recombinant proteins were purchased from R&D system.
Proteins immobilization was carried out on the flow cells of CM5 sen-
sor chips at 5.0μg/mL following the canonical EDC/HOSu (amine cou-
pling) method, operating at 5μL/min. In detail, human ALK7-ECD
bearing as fusion protein Fc fragment human and Criptowileyonlinelibrary.com/journal/jpepsci Copyright © 2014 Europrecombinant proteins were efficiently immobilized in NaAc pH=4.5.
For human ALK4-ECD bearing as fusion Fc fragment and the Fc frag-
ment alone derived from an unrelated IgG1 of the same isotype, the
immobilization procedure was performed in sodium acetate (NaAc)
pH=4.0. An underivatized and Fc-derivatized (IgG1) surfacewere pre-
pared and used as control blank. Analyses were carried out at a flow
rate of 20μL/min, injecting a constant volume of 60μL of peptides so-
lutions at concentrations ranging between 0.1 and 1.0mM. Regener-
ations were performed by injecting 20μL of a solution of 10mM
glycine, pH2.7. The proteins were immobilized at a similar level
(around 3000 RU), using the wizard procedure. All binding experi-
ments were performed at 20μL/min with a total contact time of
180 s (60μL injected for every run) and the samples opportunely di-
luted in the HBS running buffer. For every single analysis, experimen-
tal sensorgrams were aligned, subtracted of blank signals and
overlapped. The binding of synthetic peptides to ALK4, ALK7 and to
Cripto was performed by injecting peptide solutions (60μL injected
for every run) at increasing concentrations, between 25μΜ and
1mM. All mathematical manipulations and fitting were performed
using the BIA evaluation software, version 4.1 from GE Healthcare.Results
Peptide Preparation
All peptides were obtained in yields ranging from about 20–30%.
After purification, homogeneous products were isolated. Molecular
weights were consistent with the expected values as assessed by
LC-MS analyses (Table 1).
Binding of Nodal to the Immobilized Receptors
Before testing the binding of synthetic peptides to the different re-
ceptors, we first probedwhether the interaction of full-length Nodal
was productive under the chosen experimental conditions. To this
end, we injected the recombinant protein at increasing concentra-
tions over the three channels where the proteins were immobilized.
As shown in Figure 3, Nodal binds in a dose-dependent manner to
both Cripto and ALK7 and exhibiting KDs of 5.8nM and 1.6 nM,
respectively (Table 2). These values were indicative of very strong
interactions and suggested that protein surfaces required for
interaction were properly and well exposed. Surprisingly, Nodal
was found to bind with high affinity (1.8nM, Table 2) also the
immobilized ALK4 (Figure 3B). That result was unexpected because,
according to the accepted literature, Nodal/ALK4 binding occurs
in vivo only in the presence of the co-receptor Cripto.
Computational Analysis
Through a computational analysis of the complex containing
ALK4/Cripto/Nodal (Figure 4), and ALK7/Nodal (Figure 5), obtained
by homology modeling and docking simulations [30], we identified
Nodal residues potentially involved in the interaction with Cripto
and ALK7.
In the ternary complex containing ALK4/Cripto/Nodal (Figure 4),
the EGF-like domain of Cripto was predicted to form, with G87, T88,
N79, T82 and G92 residues, a polar groove in which Nodal Y58 can
pocket. Furthermore, favorable electrostatic interactions are ob-
served between E49 and E50 lying on the pre-helix loop of Nodal
and the Cripto R80 residue [30].
In the ALK7/Nodal complex (Figure 5), the binding is driven by
hydrophobic interactions and hydrogen bonds. Of note, majorean Peptide Society and John Wiley & Sons, Ltd. J. Pept. Sci. 2014
Table 2. KDs, Kas and Kds for the interaction of soluble Nodal with the
ECD of Cripto, ALK7 and ALK4
KD (M) Ka (1/Ms) Kd (1/s)
Cripto 5.79 * 109 3.20 * 105 6.11 * 104
ALK7 1.58 * 109 1.48 * 106 7.68 * 104
ALK4 1.82 * 109 1.49 * 106 5.80 * 104
Figure 3. SPR dose–response binding sensorgrams between rhNodal and (A) rhCripto; (B) rhALK4-ECD; and (C) rhALK7-ECD, immobilized on CM5
sensor chips.
CONFORMATIONAL AND BINDING PROPERTIES OF NODAL SYNTHETIC FRAGMENTSbinding interactions are driven by a single Nodal monomer and the
residues involved belong to the α-helix H3 (Y58 and L62) and pre-
helix loop of Nodal (P46 and V47) and to loop 23 of ALK7 (V51
and F52) [30].
In a previous study, we demonstrated that the entire 43–69
sequence of Nodal, encompassing the α-helix H3 and pre-helix
loop region, is able to bind to Cripto, while peptides reproducing
the helix H3 alone do not. Moreover, the substitution of the E49J. Pept. Sci. 2014 Copyright © 2014 European Peptide Society and Johand E50 pre-helix loop residues with alanine negatively affects
the binding to Cripto, confirming their involvement in the inter-
action [30].
On this basis, we have now designed a set of Nodal-derived
peptides comprising residues 44–67, still reproducing the helix
H3 and pre-helix loop region of the protein but shorter than
the first published ones [30] (Table 2). Indeed, the N-terminal cys-
teine (C43) and the C-terminal proline (P68) and histidine (H69)
have been removed as not influencing the peptide structural
and binding properties.
Single or double point Ala-mutated peptides have been synthe-
sized, purified and characterized by mass spectrometry together
with the unmodified molecule. A structural characterization by
NMR and circular dichroism has been then carried out in the at-
tempt of correlating binding and structural data. Binding to Cripto,
ALK4 and ALK7 receptors has been analyzed for all the peptides by
SPR assays.n Wiley & Sons, Ltd. wileyonlinelibrary.com/journal/jpepsci
Figure 4. (A) Cartoon representation of the Nodal (green)/Cripto (orange)/ALK4-ECD (pink) complexmodel. (B) Cripto co-receptor is represented as Connolly
surface (orange). Residues at the binding interface are colored by type.
CALVANESE ET AL.Nodal[44-67] reproduces the 44–67 region of native human
Nodal, while the first mutant, Nodal[44-67]EE-AA, bears Ala residues
in place of E49 and E50; it was designed and prepared to confirm
the role of the two acidic residues in the binding with Cripto [30]
and a potential involvement in the interaction with ALK receptors.
In the second mutant, Nodal[44-67]PV-AA, the P46 and V47 resi-
dues were replaced with alanines to verify the influence of the
two hydrophobic residues of the pre-helix loop in the binding to
Cripto and to ALKs. In the last mutant, Nodal[44-67]Y-A, the Y58 res-
idue was substituted by alanine. Indeed, by analyzing the
ALK7/Nodal [31] and ALK4/Cripto/Nodal molecular complexes,
Y58 should be one of the residues mostly involved in the binding
with the Nodal helix H3.CD and NMR of Nodal Fragments
As shown, CD spectra (Figure 6) of peptides analyzed at 20° C in H20
or buffer exhibited a negative band at 201nm, typical of random
coil structures. However, in presence of TFE, 20% all peptides
adopted α-helical structures as suggested by the two negative
bands at 207nm and 223nm and a positive band at 192 nm.
NMR characterization of Nodal fragments (Nodal[44-67],
Nodal[44-67]EE-AA and Nodal[44-67]Y-A) was performed in a
trifluoethanol/water TFE-d3/H2O 20 : 80 (v/v) mixture at 298 K.wileyonlinelibrary.com/journal/jpepsci Copyright © 2014 EuropProton assignment was carried out with the procedure sug-
gested by Wuthrich [47], and the chemical shifts are reported in
Tables S1–S3 of the Supporting Information.
Negative deviations of the αCH proton chemical shift of each res-
idue from random coil values [48] are observed for all the peptides
from Y58 to R65 residues, indicating the presence of helical struc-
tures in this region (see Figure S1 of the Supporting Information).
Positive deviations observed in the remaining parts suggest ex-
tended conformations.
These structural diagnoses were consistent with the NOE pat-
terns. NOE long-range effects, such as (αi, NHi+3), (αi, βi+3) and (αi,
NHi+4) contacts (Figure 7), confirmed the occurrence of helical con-
formations in the 59–65 segment of all the three examined
peptides.
A set of 153 (87 intra-residual, 48 sequential and 18 long-range),
204 (115 intra-residual, 65 sequential and 24 long-range) and 181
(129 intra-residual, 32 sequential and 20 long-range) experimental
NOE constraints for Nodal[44-67], Nodal[44-67]EE-AA and Nodal
[44-67]Y-A, respectively, was used as upper limits of inter-proton
distances for structure calculations by CYANA program [43].
For all the peptides, the 40 CYANA structures with the lowest
values of target function were subjected to restrained energy min-
imization by use of the AMBER 6.0 package [44] and then clustered
by CHIMERA program [45]. The structures contained in the first and
most-populated cluster (13 structures for Nodal[44-67], 17 forean Peptide Society and John Wiley & Sons, Ltd. J. Pept. Sci. 2014
Figure 5. (A) Cartoon representation of the Nodal (green)/ALK7-ECD (pink) complex model. (B) ALK7 receptor is represented as Connolly surface (orange).
Residues at the binding interface are colored by type.
CONFORMATIONAL AND BINDING PROPERTIES OF NODAL SYNTHETIC FRAGMENTSNodal[44-67]EE-AA and 12 for Nodal[44-67]Y-A) were chosen as
representative of the conformational space accessible to the pep-
tide. The statistics of the structural analysis are reported in Tables
S4 and S5 of the Supporting Information.
For all the peptides, the representative clusters show struc-
tures characterized by an α-helix conformation in the 58–65 seg-
ment, where the backbone RMSD are 0.24± 0.12Å, 0.26± 0.17Å
and 1.15± 0.41Å for Nodal[44-67], Nodal[44-67]EE-AA, and
Nodal[44-67]Y-A and a C-terminal flexible segment. It is worth
noticing that the helical structure characterizing all three pep-
tides reproduces the same secondary structure in the
corresponding region of wild-type Nodal. In Figure 8, a superpo-
sition of the Nodal homology model (HM) [30] with the repre-
sentative NMR structures of Nodal[44-67], Nodal[44-67]EE-AA
and Nodal[44-67]Y-A, well represents this structural similarity.
The backbone RMSD values, obtained by superimposing Nodal
[44-67], Nodal[44-67]EE-AA and Nodal[44-67]Y-A NMR structures
in the 58–65 segment of Nodal HM, are 0.41Å, 0.60Å and
0.30Å, respectively.J. Pept. Sci. 2014 Copyright © 2014 European Peptide Society and JohThe molecular model of Nodal[44-67]PV-AA was not computed,
as it contains modifications that, occurring in the loop region,
would not expectedly alter the helical conformation in the 58–65
tract, common to the other analogs. This hypothesis is corroborated
by its CD spectrum that shows a profile similar to the others
(Figure 6).
Surface Plasmon Resonance Analysis
Wehave studied the interaction between peptides reproducing the
Nodal region 44–67 and the ECDs of ALK4, ALK7 and Cripto, evalu-
ating the effect of specific substitutions of hot-spot residues within
the pre-helix loop and helix H3 in protein recognition. SPR dose-
dependent binding assays between each Nodal peptide and every
single protein were carried out.
All sensorgrams obtained for the binding of Nodal peptides to
immobilized Cripto, ALK4 and ALK7 recombinant proteins showed
a similar kinetics profile with both fast association and dissociation
rates resulting in typical ‘square-pulse’ sensorgrams (Figure 9 andn Wiley & Sons, Ltd. wileyonlinelibrary.com/journal/jpepsci
Figure 7. (A) NOE contacts graph for Nodal[44-67], Nodal[44-67]EE-AA and Nodal[44-67]Y-A. (B) Backbone superposition in the I59–Y66 segment of the
structures constituting the first cluster. The representative structure of the cluster is shown with blue cartoon for Nodal[44-67], green cartoon for Nodal
[44-67]EE-AA and red cartoon for Nodal[44-67]Y-A.
Figure 6. CD spectra of the Nodal fragments within the range 190–250 nm. (A) Nodal[44-67]: in water (blue line) and in water containing 20% TFE (v/v) (red
line). (B) Nodal[44-67]EE-AA: in water (green line) and in water containing 20% TFE (v/v) (light green line). (C) Nodal[44-67]PV-AA: in water (violet line) and in
water containing 20% TFE (v/v) (pink line). (D) Nodal[44-67]Y-A: in water (blue line) and in water containing 20% TFE (v/v) (cyan line).
CALVANESE ET AL.Figures S2 and S3 of the Supporting Information). Comparative
binding data were extrapolated by curve fitting. Remarkably, al-
though we could achieve good-fitting data for the binding of mostwileyonlinelibrary.com/journal/jpepsci Copyright © 2014 Europpeptides to Cripto (except for Nodal[44-67]Y-A), all calculations per-
formed on binding and dissociation curves to ALK4 and ALK7 did
not converge to significant values (data are summarized in Table 3).ean Peptide Society and John Wiley & Sons, Ltd. J. Pept. Sci. 2014
Figure 8. Structural overlap in the 58–65 segment of Nodal HM (green) [30]
and the representative NMR structures of Nodal[44-67] (blue), Nodal[44-67]
EE-AA (light blue) and Nodal[44-67]Y-A (red).
Table 3. Affinity constant values of Nodal[44-67] and related Ala-mu-
tated peptides to immobilized rhCripto
KD
Peptide Cripto ALK4 ALK7
Nodal[44-67] 1.39 * 106M nf nf
Nodal[44-67]EE-AA 13.3 * 106M nf nf
Nodal[44-67]PV-AA 3.42 * 106M nf nf
Nodal[44-67]Y-A nf nf nf
The KD values were extrapolated by data fitting of dose-dependent
binding curves using the BIA evaluation analysis package (version
4.1, Pharmacia Biosensor).
No fitting (nf) means that fitting of binding and association curves did
not converge to any value.
CONFORMATIONAL AND BINDING PROPERTIES OF NODAL SYNTHETIC FRAGMENTSAccording to this analysis and in agreement with previous findings
[30], we concluded that replacing the two glutamic acids (E49 and
E50) with alanines in Nodal[44-67] reduced the affinity by about ten
times (KD=13.3μM) compared with that obtained with the unmod-
ified Nodal fragment (KD=1.39μM). Conversely, the affinity con-
stant (KD=3.42μM) for Cripto of Nodal[44-67]PV-AA, in which P46
and V47 were substituted with alanines, resulted very close to that
of the wild-type peptide, suggesting a relatively weak contribution
of these residues to the binding with Cripto and to the stability of
the overall complex. Nodal[44-67]Y-A very poorly associated with
immobilized Cripto (Figure 9D), and, furthermore, attempts to fit
the association and dissociation curves to derive the binding pa-
rameters were all unfruitful (Table 3). The results therefore suggest
that the binding of Nodal to Cripto could be mediated by tyrosine
on position 58 (Y58) and is further stabilized by the upstream
glutamic acid pair (E49–E50). Following the same procedure, we
found that none of the peptides tested displayed sufficient binding
capacity for either ALK4 and ALK7. Kinetic data, reported in Table 4,
show that the Nodal peptides exhibit very similar Koffs (NodalFigure 9. SPR sensorgrams obtained for the binding of Nodal peptides to im
ranging between (A) 25–500μM for Nodal[44-67]; (B) 100–500μM for Nodal[4
Nodal[44-67]Y-A.
J. Pept. Sci. 2014 Copyright © 2014 European Peptide Society and Joh[44-67]: Koff = 2.86*10
3 s1; Nodal[44-67]EE-AA: Koff = 2.44*10
3 s1;
Nodal[44-67]PV-AA: Koff = 2.40*10
3 s1) and that the differences
in affinity constants (KD) for Cripto arise mainly from changes in
the association rates (Nodal[44-67]: 2.51*103M1 s1; Nodal[44-67]
PV-AA: 2.15*103M1 s1; Nodal[44-67]EE-AA: 3.23*102M1 s1). Such
observations support the hypothesis that E49 and E50 positively
affect the binding to Cripto by enhancing the association speed.
To try to further rationalize the data obtained and to gain a more
comprehensive overview of the interaction between peptide frag-
ments and target proteins, we also made a comparison of the
RUmax values obtained for all molecules at a given concentration
(0.1mM). Data are reported in the Supporting Information as Figure
S4 and reflect the values from sensorgrams reported in Figure 9
(A–D) and Figures S2 and S3. As shown, the most intense values
are observed for the interaction between Nodal[44-67] with Cripto
whereas the samemolecule only very poorly binds the other recep-
tors. Unexpectedly, peptides Nodal[44-67]EE-AA and Nodal[44-67]
PV-AA were somehow captured by ALK4 and ALK7, although themobilized rhCripto. Dose–response curves were recorded at concentrations
4-67]EE-AA; (C) 100–1000μM for Nodal[44-67]PV-AA; (D) 100–1000μM for
n Wiley & Sons, Ltd. wileyonlinelibrary.com/journal/jpepsci
Table 4. Kinetic constants extrapolated for the binding of Nodal
[44-67] and related Ala-mutated peptides to immobilized rhCripto
Peptide Kon (M
1 s1) Koff (s
1) KD (M)
Nodal[44-67] 2.51 * 103 2.86 * 103 1.39 * 106
Nodal[44-67]EE-AA 3.23 * 102 2.44 * 103 13.3 * 106
Nodal[44-67]PV-AA 2.15 * 103 2.40 * 103 3.42 * 106
Nodal[44-67]Y-A nf nf nf
The KD values were obtained as the ratio between Koffs and Kons.
Data were obtained using the BIA evaluation analysis package
(version 4.1, Pharmacia Biosensor).
No fitting (nf) means that fitting of binding and association curves did
not converge to any value.
CALVANESE ET AL.kinetic parameters could not be determined (Tables 2 and 3). Thus,
it seems that replacement of two glutamic acids (E49 and E50) or of
proline 47 (P47) and valine 48 (V48) with alanine residues may favor
the binding to the ALK receptors. These data could be explained by
looking at the ALK7/Nodal complex binding epitope (Figure 5). In-
deed, the model suggests that the Nodal E49–E50 residues are close
to the ALK7 hydrophobic interface; therefore, when they are changed
to alanine, the hydrophobic interactions could be enhanced. The
same explanation could hold true also for ALK4, assuming that the
theoretical ALK4/Nodal complex adopts the same topological struc-
ture as the ALK7/Nodal complex. Strikingly, the substitution of Y58
with alanine in Nodal[44-67]Y-A completely abolishes the binding
to ALK4 and ALK7, indicating a possible role of such residue in
the Nodal binding with these proteins.Discussion
In this work, we have investigated some structural properties of the
binding of Nodal with its type I receptors, ALK4 and ALK7, and with
the co-receptor Cripto. An approach based on homologymodeling,
CD, NMR and SPR binding assays has been applied to design and
study a set of synthetic peptides reproducing the pre-helix loop
and the H3 α-helix region of Nodal. Nodal is reported to establish
direct interactions with ALK7 and with Cripto, whereas the interac-
tion with ALK4 was so far believed to be only mediated by Cripto.
We find here for the first time that, at least in vitro, Nodal can di-
rectly and strongly interact with ALK4 too. However, whether this
interaction occurs also in vivo or has a functional relevance remains
to be established. We also evaluated for the first time the KD for the
Nodal/ALK7 interaction (1.58 nM). These strong interactions, to-
gether with that underlying the binding of Nodal with Cripto [30],
also in the low nanomolar range, suggest that the members of
the resulting molecular complex are very tightly associated, and
their dissociation is a very difficult task. Using the synthetic pep-
tides, we have further investigated the Nodal main residues in-
volved in the binding with Cripto. Nodal binding residues have
been identified using the previously published ALK4/Cripto/Nodal
[30] and ALK7/Nodal [31] molecular models. On this basis, a series
of Nodal fragments, which include residues 44–67 of the pre-helix
loop and the H3 α-helix, have been synthesized with selected resi-
due replacements to evaluate their putative role in receptor bind-
ing. The conformational NMR and CD analyses of Nodal peptides
show their propensity to adopt α-helix structures, at least in the
N-terminal tract reproducing the H3 α-helix of the parent protein.
Remarkably, substitution of residues on positions 47–50 withwileyonlinelibrary.com/journal/jpepsci Copyright © 2014 Europalanines does not seem to affect the overall propensity of the pep-
tide C-terminal tail to adopt the helical structure. Also, changing
Y58 within the helix with an alanine poorly alters the structural fea-
tures of the molecule.
The ability of Nodal fragments to bind to ALK4, ALK7 receptors
and Cripto, evaluated by SPR assays, has shown a preferential rec-
ognition of the wild-type Nodal 44–67 fragment for Cripto. Indeed,
changing the key residues E49, E50 and Y58 to alanines interferes
with and strongly impairs the recognition with this protein. Our
data are also suggestive of aminor role of P47 and V48. Remarkably,
the mutated synthetic peptides Nodal[44-67]EE-AA and Nodal
[44-67]PV-AA, likely because of an increase of the local hydropho-
bicity, are also attracted to some extent by the ALK4 and the
ALK7 receptors, while the substitution of Y58 abolishes the binding.
All together, these data suggest that the part of the molecular sur-
face corresponding to this region of Nodal could be shared with the
other two protein partners.
In conclusion, the results reported here confirm that the binding
of Nodal to the receptor complex, comprising the type I receptors
ALK7 and ALK4 via the co-receptor Cripto, is influenced by glutamic
acid residues (E49 and E50) and by tyrosine 58 (Y58). Such residues
appear crucial tomodulate Nodal specificity for one or the other re-
ceptor, thus altering also its function.
Considering the outstanding implications of Nodal in cancer, elu-
cidation of the structural features underlying its interaction with re-
ceptors and co-receptors is fundamental in the perspective of
planning strategies aimed at targeting the Nodal/Cripto-ALK
receptors–Smad axis for therapeutic purposes.
Although further structural studies are required to confirm in vivo
our observations, the identification of such hot-spot residues is a
primary step to develop new inhibitors, especially neutralizing
antibodies and small high-affinity peptides reproducing the bind-
ing interfaces on both Nodal and ALK7. The finding that Nodal
can bind directly ALK4, if confirmed by other studies, could suggest
the existence of a new Cripto-independent axis, which could be,
independently or in combination with, targeted for developing
specific antagonists that disrupt the Nodal–receptor complex(es)
and block the growth and proliferation of many cancer cells.
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Abstract Intravenous immunoglobulin are important bio-
therapeutics used in the replacement therapy for primary
and secondary immunodeficiencies, chronic inflammatory
disorders and several autoimmune haematologic disorders.
Currently, a number of immunoglobulin intravenous
(IVIG) products have been approved by the Food and Drug
Administration (FDA) and are available commercially. It is
known that small differences in the manufacturing pro-
cesses as well as in the formulations may affect their
clinical efficacy and tolerability. Therefore, given the
complexity of the multi-step process required for the iso-
lation of IVIG from human plasma, it is necessary to ensure
a rigorous quality control of final products. We show here
that a set of different bioanalytical techniques can be
conveniently used to comparatively characterize, at a
quantitative and qualitative level, different lots of IVIG
preparations and to unveil randomly occurring impurities
which can also affect the overall product stability. We have
used circular dichroism, surface plasmon resonance and
two-dimensional electrophoresis (2DE), and have demon-
strated that this combination of bioanalytical approaches is
very useful to improve the quality control of antibodies and
to monitor the reliability of the IVIG manufacturing
process.
Keywords IVIG  Circular dichroism  SPR  Biacore 
Protein A  Thermal denaturation
Introduction
Intravenous immunoglobulin (IVIG) preparations have
become the major plasma-derived product with increas-
ingly important bio-therapeutic applications. Indeed, IVIG
have been successfully employed for the treatment of
several immunological and inflammatory diseases includ-
ing replacement therapies for primary immunodeficiencies,
such as X-linked agammaglobulinemia, hypogammaglob-
ulinemia, some acute graft-versus-host diseases and
chronic B cell lymphocytic leukaemia [1, 2]. In addition,
IVIG preparations are also employed for the therapy of
humoral immunodeficiencies related to several patho-
physiological diseases. In this context, infusion of IVIG has
been widely applied for the treatment and prevention of
infectious and inflammatory diseases such as the coronary
artery aneurysms in Kawasaki disease, the idiopathic
thrombocytopenic purpura and the Guillain–Barre` syn-
drome. Moreover, minor neurologic and dermatologic
pathologies are also treated off-label with IVIG.
Except for the replacement therapy, the IVIG mecha-
nism of action is not yet fully understood. However, clin-
ical evidences suggest their involvement in the modulation
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of multiple networks related to the expression and function
of Fc receptors, the activation of the complement and
cytokine pathways and the regulation of cell growth. Some
effects on the activation, differentiation and effector
functions of dendritic, T and B cells have been also
hypothesized [3, 4].
Intravenous immunoglobulin preparations contain a
pool of polyclonal IgG antibodies extracted from the
plasma derived from a high number of healthy blood
donors. Although manufacturing processes have been sig-
nificantly improved in the last two decades to increase
purity and yield of IVIG molecules, almost all the purifi-
cation strategies include an initial step based on the Cohn–
Oncley ethanol fractionation. Additional procedures (e.g.
ion exchange chromatography, ultrafiltration, enzymatic
digestion, pH and ion strength variations and organic sol-
vent–detergent partitioning) may be applied for removing
proteins and other minor contaminants, for minimizing the
formation of IgG aggregates and for inactivating and
removing viral contaminants such as hepatitis B virus,
hepatitis C virus and human immunodeficiency virus [5].
In this framework, critical issues in the pharmaceutical
production of active products, such as antibodies, are
mainly related to the reproducibility and safety of the
industrial-scale manufacturing processes and to the cost
optimization measures. Increasingly stringent legislation at
national and international level ensures the quality and
safety of drugs and the materials used in their production.
Therefore, given the wide use of IVIG as bio-therapeutics
in a broad range of applications, there is a growing demand
of powerful and reliable methodologies for the control of
the IVIG production process aimed to guarantee the con-
sistency, the quality and safety of the final drug. Although
different commercial IVIG preparations are available and
equivalent by a therapeutic point of view, an intrinsic
variability may be present amongst different commercial
products and different lots of the same products.
In this study, a set of bioanalytical methods have been
used to characterize and comparatively analyse IVIG from
different preparations to evaluate their application for the
routine analysis of IVIG lots.
The experimental protocol for monitoring commercial
IVIG preparations includes structural investigations carried
out by circular dichroism (CD), protein denaturation
studies, surface plasmon resonance (SPR) binding assays
and two-dimensional electrophoresis (2DE).
The approach has proven to be very sensitive and reli-
able for the evaluation of full antibody, as well as of sep-
arate Fc and Fab, stability and integrity and for the
monitoring of lot-to-lot consistency of different IVIG
preparations. To demonstrate its applicability, we have
analyzed in a comparative way, six different 10 % IVIG
lots deriving from two distinct sets: one starting from
cryosupernatant 1 and one from fraction II–III, both puri-
fied by chromatographic methods.
Materials and Methods
Circular Dichroism Analysis
The six lots of 10 % IVIG, comprising 3 lots prepared from
cryosupernatant 1 (lots A1, A2, A3) and 3 lots prepared
from fraction II ? III (lots B1, B2, B3) are produced by
Kedrion S.p.A. 10 % solutions were used as starting
material and properly diluted in the indicated buffers prior
analysis. All CD analyses were performed using a JASCO
J-710 spectropolarimeter, equipped with a Peltier system
for changing the temperature in a controlled way and
quartz cuvettes 110-QS with 1.0 mm path length. Experi-
ments were performed in 10 mM phosphate, pH = 8.0 at a
concentration of 0.20 mg/mL [6]. Spectra were collected
within the wavelength range 250–190 nm at a scan rate of
20 nm/min, with a data pitch of 0.2 nm, a band width of
1 nm and a response of 4 s. In order to compare the dif-
ferent protein lots, far UV CD spectra were recorded at 20,
55, 60, 65, 70, 75, and 85 C and then again at 20 C
(‘after cooling’ condition). The ‘after cooling’ spectrum
was required to assess whether proteins were able to
recover original structures or had undergone irreversible
aggregation. Thermal denaturation experiments were per-
formed by monitoring changes in ellipticity at 209 nm by
exposure to increasing temperatures between 40 and 90 C,
at a speed of 60 C/h (1 C/min). The melting point was
determined by the method of the first derivative.
On every sample, five independent spectra were recor-
ded, averaged and smoothed using the Spectra Manager
software, version 1.53. Buffer scans were recorded under
the same conditions and subtracted. The analysis of sec-
ondary structure content was performed using the online
server named Dichroweb [7, 10].
2D-PAGE Analysis
IVIG preparations at 100 mg/mL (10 %) were used without
any further manipulation except dilution. Immobilized pH
gradient (IPG) buffers, IPG strips and electrophoresis apparatus
were purchased from GE Healthcare (Italy). Electrophoresis
reagents, including acrylamide, N,N,N,N-methylenebisacryla-
mide, N,N,N,N-tetramethylethylenediamine, ammonium per-
sulfate and sodium dodecylsulfate (SDS), were from BioRad
(Milano, Italy). Chemical reagents were from Sigma-Aldrich
(Milano, Italy). Gels were scanned using a Molecular
Dynamics densitometer, model 375–557, from Amersham
Biosciences (USA). Image analysis was performed using the
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ImageJ software (Image processing and analysis in Java),
available on-line on the National Institutes of Health website
(Bethesda, Maryland, USA, http://rsbweb.nih.gov/ij). All other
reagents were of analytical grade.
An extensive reduction of IgG disulphide bonds was
performed on aliquots of IgG samples (50 mg/mL) by
adding DTT 2.3 % in aqueous solution containing SDS
10 % (final volume: 15 lL). Following an incubation of
5 min at 95 C, samples were directly diluted in the
rehydration solution to a final concentration of 2 mg/mL.
A total amount of 200 lg of IgG were loaded on
each gel, reduced as reported above, was analyzed by
2D-PAGE. Samples to be processed by isoelectrofocusing
(IEF) were diluted with the rehydration buffer (8 M urea,
0.5 % CHAPS, 0.2 % DTT, 0.5 % IPG ampholytes and
0.002 % bromophenol blue) to a final volume of 125 lL.
The precast IPG strips (3–10 linear pH gradient, 7 cm
long), used for the first dimension, were passively rehy-
drated and loaded with the sample at room temperature for
12 h under low-viscosity paraffin oil. IEF was then per-
formed using an IPGphor isoelectric focusing cell,
according to the following protocol: 50 V for 3 h, 100 V
for 2 h, 500 V for 2 h, 1,000 V for 2 h, 3,000 V for 2 h,
4,000 V for 2 h, 5,000 V for 2 h, 6,000 V for 2 h, 8,000 V
until about 25,000 V h total. Strips were then equilibrated
twice for 15 min with gentle shaking in the equilibration
solution (6 M urea, 50 mM Tris–Cl buffer pH 8.8, 30 %
glycerol, 2 % SDS, 0.002 % bromophenol blue) containing
1 % DTT to reduce disulphide bonds, in the first equili-
bration step, and 2.5 % iodoacetamide to alkylate thiols, in
the second. The second-dimension separation was per-
formed in a 12 % polyacrylamide (7 9 8 cm). The strips
were fixed with 0.5 % agarose and 0.002 % bromophenol
blue dissolved in SDS/Tris running buffer. The run was
carried out at constant power (10 mA/gel for 15 min;
20 mA/gel until the end of the run). At the end of the
electrophoresis, the protein spots were visualized by Coo-
massie Blue R250 staining.
After staining, 2D-gels were scanned using a Molecular
Dynamics densitometer. Gel images were then processed
for background subtraction and analysed for spot identifi-
cation and matching using image analysis Image J software
(http://rsbweb.nih.gov/ij). Quantification of relative band
intensities to determine IgG purity was performed using the
same software.
SPR Analyses
All analyses were performed on a Biacore 3,000 instrument
from GE Healthcare, using certified HBS buffer (20 mM
Hepes, 0.15 M NaCl, pH 7.2, P20, 0.005 %), at 25 C.
Protein A (Sigma-Aldrich, Milano) was dissolved in
deionized water at a concentration of 1.0 mg/mL. Protein
immobilization was efficiently performed on the flow cells
(FC) of CM5 sensor chips at 5.0 lg/mL in sodium acetate
10 mM pH 4.5 following the canonical EDC/NHS (amine
coupling) method, operating at 5 lL/min [8]. An underiv-
atized surface was prepared and used as control blank.
Analyses were carried out at a flow rate of 20 lL/min,
injecting a constant volume of 60 lL of IVIG solutions at
the following concentration: 1.0, 2.5, 5.0, 10.0, 50.0, 100,
250, 500, 1,000, 1,500, 2,500, 3,000 nM. Dissociations
were monitored for at least 600 s, performing at the end a
regeneration step by injecting 20 lL of a solution of
10 mM glycine, pH 2.7.
The immobilization of the anti-k-chain monoclonal
antibody (mAb K4377, Sigma-Aldrich, Milano) was
achieved in 10 mM sodium acetate pH 5, operating at a
flow rate of 5 lL/min. In this case, three flow channels
were derivatized with the mAb at different immobilization
levels: low density on FC2, 613 RU; medium density on
FC3, 1813 RU; high density on FC4, 4718 RU. On FC1,
used as reference, no protein was immobilized. Experi-
ments were performed at 20 lL/min with a total contact
time of 180 s (60 lL injected for every run). Dissociations
were monitored for at least 600 s, regenerating at the end
with a 20 mM solution of HCl with added 0.005 % v/v of
surfactant P20. The concentrations of IgGs used for the
binding experiments were: 10, 25, 50, 100, 500, 1,000,
1,500 and 2,000 nM. For every single analysis, experi-
mental sensorgrams were aligned, subtracted of blank
signals and overlapped. All mathematical manipulations
and fitting were performed using the BiaEvaluation soft-
ware, version 4.1 from GE Healthcare. Analyses were
carried out using the six samples opportunely diluted in the
HBS running buffer.
Fragment Crystallizable (Fc) Function
Because most of the anti-inflammatory properties of IVIG
are mediated by the Fc antibody portion, evaluation of the
Fc functional integrity of IgG is an indirect way to measure
their therapeutic potential. This has been determined by Fc
function in accordance with Eu. Ph., 2.7.9, method A [9],
using haemolytic complement-fixation assay. This test is
based on the haemolysis of antigen-coated fresh human red
blood cells in the presence of guinea pig complement.
Rubella antigen is used in the reference method. Results
are reported as a ratio to an IgG standard (biological ref-
erence preparation—BRP—batch 3). For experimental
details see also: British Pharmacopoeia Volume IV,
Appendix XIV J. Blood and Related Products.
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Results and Discussion
Comparative Evaluation of the Structural Stability
Properties of Different Lots of IgG Preparations
by Circular Dichroism
The thermal stability of the different IVIG lots analysed in
this study, was first evaluated by CD. In Fig. 1a–f, an
overlay of the far UV–CD spectra recorded for the six
different samples at increasing temperatures from 20 to
85 C and then back at 20 C (‘after cooling’ condition), is
reported. As shown, CD spectra of IVIG analyzed at 20 C
exhibited the canonical positive band at 202 nm, the neg-
ative band at 216–218 nm and an intensity equal to zero at
208–210 nm, typical of proteins with a high b-sheet con-
tent. Although the occurrence of several other positive and
negative bands in the near UV, at around 260–300 nm is
reported [6], these bands have not been considered in our
analysis, because they are much less intense and poorly
diagnostic. During thermal denaturation, the canonical
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Fig. 1 a–f CD spectra of samples A1, A2, A3, B1, B2, B3 between 195 and 250 nm at the indicated temperatures
Fig. 2 a–f a-helix, b-sheet and random coil content determined for
samples A1, A2, A3, B1, B2, B3 at the different temperatures using
the Dichroweb server. Normalized root mean square deviation
(NRMSD), expressed as percentage, have also been determined for
all analyses (not shown)
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b-sheet spectrum was maintained up to 60 C for all
samples, confirming the high stability of antibodies. For
temperatures below this threshold, the minimum at
216–218 nm was maintained more or less at the same
intensity, between about -6 and -8 mdegrees.
Afterwards, starting from 65 C, spectra varied consid-
erably, suggesting severe structural changes. As shown in
Fig. 1c, sample A3 exhibited a different behavior at shorter
wavelengths, with the maximum shifting from about 205 to
195 nm. Such changes are suggestive of a general reduced
stability of proteins present in this preparation. By further
temperature increase, a progressive denaturation was
observed for all samples, witnessed by the large changes in
the CD spectra. In particular, the band at 209 nm was
progressively lost, leading to spectra resembling more
those of proteins having a large content of a-helix (see for
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Fig. 3 a Curves of thermal denaturation between 40 and 95 C for all samples analyzed in this study. b The corresponding first derivative for the
curves are reported. Spectra were collected between 195 and 250 nm
Fig. 4 a–f 2D-PAGE analysis
of immunoglobulin preparations
on 7 cm strips (linear gradient
pH 3–10). The basic isoelectric
points are to the right and acidic
to the left. Red squares three-
dimensional magnifications are
reported in 4g–n. g–n Three-
dimensional profiles of
2D-maps of IgG preparations
obtained using the ‘interactive
3D-surface plot’ application of
ImageJ software.
Magnifications of regions
indicated by red squares in
Fig. 1 are shown. Red arrows
indicate streaks not detected in
S220611, 270711 and S280911
2D-maps. (Color figure online)
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example spectra at 85 C). For all samples, except A3, also
a shift of the point at zero millidegrees was observed (from
208 up to about 197 nm). The shift observed by analyzing
sample A3 was instead less intense, and the overall signal
below 200 nm strongly changed with the temperature,
certainly due to premature protein precipitation. After
cooling to record again the spectra at 20 C, original bands
were not restored and white precipitates were observed in
the cuvettes for all samples. In Fig. 2a–f, the global
changes in a-helix, b-sheet and random coil contents, at all
temperatures, obtained using the software Dichroweb, are
reported [8, 9]. According to the changes observed in
spectra, a progressive and remarkable reduction of the
b-sheet content was noticed, paralleled by an increase in
Fig. 4 continued
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the a-helix character and a less intense increase of the
random coil content. As shown, changes in the samples
from cryosupernatant 1 were less intense; furthermore, one
of the these samples, A3, exhibited a decrease of the ran-
dom coil character and a more marked change of the a-
helix and b-sheet contents, in agreement with the spectral
changes below 200 nm described before.
To further unveil possible differences in stability,
melting curves were recorded following signal change at
209 nm as a function of the temperature increase. Since
proteins were essentially very stable up to about 60 C,
melting curves were recorded only between 40 and 95 C.
In Fig. 3a, an overlay of melting curves for all samples is
shown, and as can be seen, except that referred to as sample
A3, which yet declined at 65 C, all exhibited a sudden
drop of signal starting at about 70 C. This difference is
also reflected in the graph of Fig. 3b reporting the first
derivatives of all spectra, where the minimum of sample
A3 is clearly shifted some 5 towards lower temperatures
compared to those of other samples. Altogether, data
indicate that all IVIG samples behave in a similar way in
terms of resistance to thermal denaturation, with a slightly
higher stability exhibited by lots deriving from cryosu-
pernatant 1 fraction. Amongst these, sample A3, more
rapidly aggregated and precipitated upon heating, thus
showing unique properties, presumably deriving by the
occurrence of pre-existing random aggregates.
Analysis of IVIG Preparations by 2D-PAGE
Immunoglobulins (Igs) are a heterogeneous population of
proteins (polyclonal immunoglobulins), whose basic
structure consists of two identical halves connected by
disulphide bonds. Each half is made up of a heavy chain of
*55 kDa and a light chain of *25 kDa, joined together
by a disulphide bond near the carboxyl terminus of the light
chain. The heterogeneity of Igs is not detectable using
monodimensional SDS-PAGE, which only resolves the
most abundant protein bands at 55 and 25 kDa. An
extensive bioanalytical characterization of all samples was
thus performed by 2D-PAGE followed by densitometric
analysis, in order to assess the occurrence of low-abun-
dance impurities and a possible correlation with the dif-
ferent physico-chemical properties evidenced by the CD
analysis. After extensive reduction, aliquots of proteins
(200 lg) were separated by 2D-PAGE using, for the first
dimension, IPG strips with a linear 3–10 pH gradient. The
second dimension was carried out on 12 % polyacrylamide
gel, following further reduction and alkylation steps. At the
end of the run, 2D-gels were stained with Coomassie Blue
R250 and the resulting gels are reported in Fig. 4a–f. As
expected, multiple protein spots were visualized in the
regions with molecular mass of about 25 and 55 kDa,
corresponding to the light and heavy chains of IgG,
respectively. These profiles attested the IgG polyclonal
nature with many isoforms with the same molecular weight
but differing in their isoelectric point. However, though all
samples appeared highly homogeneous, 2D-maps corre-
sponding to the A group, comprising A1, A2 and A3,
showed a set of streaks having MW between about 70 and
150 kDa and pIs comprised between about 4 and 7;
remarkably, the most intense streaks were visible on the gel
corresponding to sample A3.
A more detailed comparison of the 2D-gels of the dif-
ferent IgG preparations was also performed following gel
images acquisition and quantitative analysis. Three-
dimensional profiles of the gel image sections boxed in
Fig. 4a–f are reported in Fig. 4g–n and Fig. S1a–f in the
supporting material, and provide a more quantitative view
of the impurities (indicated by arrows). In Table 1, the
level of purity of samples studied is reported and as shown,
A lots contain detectable levels of impurities (1.12, 1.15
and 1.30 %, respectively), whereas B lots appear 100 %
pure. Remarkably, lot A3 has the highest content of
impurities, which could account for the difference in sta-
bility observed during the CD analysis.
Table 1 Impurities detected on the six samples of IVIGs. Both absolute and percentage values are reported
Intensity IgG samples
A1 A2 A3 B1 B2 B3
IgG light chain 6,174.52 9,175.93 6,372.33 3,483.64 4,229.45 3,700.35
IgG heavy chain 17,293.27 19,822.25 18,559.78 12,689.34 12,496.99 11,052.83
IgG total 23,467.79 28,998.18 24,932.11 16,172.98 16,726.44 14,753.18
Impurities 262.85 334.38 324.01 0.00 0.00
% impurities 1.12 1.15 1.30 0.00 0.00 0.00
% IgG 98.88 98.85 98.70 100.00 100.00 100.00
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Fig. 5 a–c Envelope of
sensorgrams for the IgG lots A1,
A2 and A3. Concentrations are
reported below each group of
curves. d–f Envelope of
sensorgrams for the IgG lots B1,
B2 and B3. Concentrations are
reported below each group of
curves
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Comparative Binding Analysis of the Different Lots
of IVIG to Protein A (pA) by SPR
To have a measure of the integrity of the Fc portion of
IVIG, we performed binding analyses of the different IgG
preparation to pA. pA is a bacterial protein largely used to
purify Igs of different classes from complex matrices. It is
known to bind on a region of the Fc portion that comprises
residues from the Cc2 and Cc3, therefore comparative
binding analyses can provide information on the relative
integrity of this IgG region.
pA is a protein of 42 kDa which binds with high affinity
and selectivity at least two distinct IgG molecules [11],
however the exact stoichiometry is at present not known
and generally is dependent on experimental conditions and
technique used. In solution the stoichiometry can be higher
than 2:1 and also binding sites on the IgGs are two,
therefore the mathematical models for studying this inter-
action can be complex [11].
Analyses were carried out by SPR, using sensor chips
with immobilized pA. Optimal concentrations for these
analyses were between 1 and 2,500 nM.
The envelopes of sensorgrams referred to the six IVIG
lots, reported in Fig. 5a–f, show as all curves have essen-
tially the same shape and trend, reaching the saturation for
concentrations higher than 2,500 nM. Since the binding
stoichiometry between pA and IgGs is not well-defined,
especially for interactions occurring on solid surfaces, to
derive kinetic and thermodynamic binding parameters
Kons, Koffs and KDs, we tried with different mathematical
A B
C D
E F
Fig. 6 a–f Correlation curves
between RUmax values at each
concentrations and
concentrations itself for IgG lots
A1, A2, A3 and B1, B2, B3
expressed as Log M. For each
single plot the EC50 value
calculated by this method is also
reported. Correlation curves
between RUmax values at each
concentrations and
concentrations itself for IgG lots
A1, A2, A3 and B1, B2, B3
expressed as Log M. For each
single plot the EC50 value
calculated by this method is also
reported
Table 2 Values of the EC50 values determined for all IgG lots and the relative standard errors
IgG samples A1 A2 A3 B1 B2 B3
EC50 (M) 3.7 ± 2.0 9 10
-7 1.5 ± 0.8 9 10-7 1.7 ± 0.7 9 10-7 7.7 ± 1.0 9 10-7 11.4 ± 0.7 9 10-7 7.5 ± 0.7 9 10-7
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models of interactions (including 1:1, 1:2 stoichiometries
or even higher). However, all attempts to fit the curves
failed or gave inaccurate results (see Fig. S2a, b in the
supporting material as an example of failed fitting).
Therefore, in order to compare the analyses, we built plots
reporting RUmax values versus analyte concentration, as
reported in Fig. 6a–f. Next, using an algorithm of nonlinear
regression and assuming a 1:1 stoichiometry, we derived a
measure of global affinities, expressed as EC50 which could
be seen as the resultant of multiple interactions [12, 13].
EC50s values determined by this method are summarized in
Table 2. As expected, values are all very similar, being
comprised between 1.5 9 10-7 and 3.9 9 10-7 M, how-
ever EC50s for the B lots are slightly higher (about dou-
bled), not only suggesting a higher consistency among lots
within the same group, but also measurable differences
among lots coming from different starting material.
A further comparison was performed by comparing
RUmax values observed at a given concentration. Data are
plotted in Fig. S3 in supporting material, whereby for each
distinct lot, RUmax values at all concentrations are reported.
It can be reasonably assumed that, the more similar are
RUmax values, the more is expected that IgG samples are
similar each other. By analyzing data, it emerged that the
set of B samples comprising lots B1, B2 and B3, appears
more homogeneous with almost identical values at the
same concentrations. This holds not true for samples A1,
A2 and A3 which indeed showed varying RUmax values at
the same concentration. This effect, negligible at low
concentrations, is more evident for concentrations higher
than 10 nM. It should be also noticed that RUmax values are
a little bit higher for IgGs lots from set A, as compared to
those obtained with IgGs from the other one. This differ-
ence could be due to the presence of small amounts of
aggregates in set A, which could form (or be retained after
dilution) at higher concentrations and over time. Aggre-
gates, being bigger than monomeric IgG, provide more
intense SPR signals.
Comparative Analysis of Different Lots of IVIG
to Anti-k-chain mAb by SPR
The study performed with pA was paralleled by another
comparative study carried out using an anti-k-chain
monoclonal antibody, in order to obtain a global evaluation
of the Fab integrity.
Fig. 7 a–c Sensorgrams
obtained for the interaction
between the immobilized Mab
anti-k-chain and IgGs from the
lot A1 on FC4 (high density, a),
on FC3 (medium density, b) and
on FC2 (low density, c)
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Binding experiments were performed in parallel on three
channels with different immobilization levels. In Fig. 7a–c,
the envelopes of sensorgrams obtained for one of the six
samples (sample A1) at three different immobilization
levels, are reported. In the supporting material Fig. S4–S8,
sensorgrams corresponding to the remaining five analyses
are reported. In all plots, time and RU scales were kept at
the same values to visualize at best differences in RUs
achieved on the distinct channels by varying ligand density.
As expected, lower bindings were recorded for lower
ligand density and curves were all very similar. As with the
pA, bindings were analyzed by determining the global KDs
plotting the RUmax values derived from every single
injection on distinct flow channels versus the concentration
of Igs. Data were then best fitted by a nonlinear regression
analysis and are reported in Fig. 8a–f. KDs determined by
this method are instead reported in Table 3. As can be seen,
values are very similar for the same IgG lot on channels at
different immobilization levels, thus suggesting that the
analyses are very reproducible and reliable. It should be
pointed out that KDs are also very similar amongst different
lots with values ranging between about 136 and 288 nM,
suggesting that the population of Igs present in the different
lots are highly comparable in terms of Fab homogeneity.
Fragment Crystallizable (Fc) Function
The functional integrity of the Fc fragment of all analysed
lots was evaluated using a well-established method sug-
gested by the European Pharmacopeia. Data for all six
samples are presented in Table 4 and show that results are
in compliance, therefore proving the full functionality of
the analysed IgGs. Despite large differences in function are
observed between the diverse IVIG lots, they do not cor-
relate with the slight discrepancies emerged at the bioan-
alytical level.
Fig. 8 a–f Plots reporting RUmax values versus IgGs concentration for all lots analyzed
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Conclusions
We have undertaken a comparative evaluation of the
macroscopic physico-chemical properties of six different
lots of IVIG coming from two distinct preparations. Three
lots, A1–A3, came out from a chromatographic purification
from a cryosupernatant fraction, whereas three other lots
were obtained from fraction II–III, using the same chro-
matographic purification procedure. The study has been
carried out using different bioanalytical techniques to gain
a global view of antibody properties, to assess lot-to-lot
consistency and to point out possible differences arising
from the different starting material. For this purpose we
have conducted on all samples: (i) a macroscopic structural
analysis by CD, also evaluating IgG resistance to thermal
denaturation; (ii) an evaluation of purity by 2D-gel analy-
ses and (iii) a macroscopic evaluation of Fc and Fab
integrity by SPR, carrying out comparative binding studies
to pA and to an anti-k chain monoclonal antibody.
As expected, samples displayed quite identical proper-
ties and it was difficult to unveil macroscopic dissimilari-
ties, however subtle but measurable differences emerged
amongst the different lots during the investigation, espe-
cially amongst lots coming from different starting material
(lots A vs. lots B). Since the different lots have the same
age and have been purified all by the same method, the
presence of such impurities or degradation components
demonstrates that side products occurring in these experi-
mental IVIG lots can only arise from the diverse raw
material. The reason for this has not been investigated here;
we can however hypothesize that small impurities are
either co-purified with the main component or generated
during the purification steps or during storage. Irrespective
of the way they are generated, these impurities can be
detected and quantified by 2DE and, looking retrospec-
tively at our CD data, could also be predicted to some
extent by a CD analysis, which seems to be qualitatively
affected by such low levels of contaminants.
Data show that IgGs purified from Fraction II-III are
generally homogeneous compared to those obtained from
cryosupernatant 1, but also that IgGs extracted from the
same starting material have a higher lot-to-lot consistency,
thus suggesting that also the very initial steps of plasma
manipulation can affect final products. Furthermore, we
have observed that one lot (lot A3), showed reduced
resistance to thermal denaturation and, at the same time,
also contained sensibly higher amounts of undetermined
impurities (presumably immunoglobulin fragments), as
detected by 2DE. Remarkably, lots A1 and A2, coming
from the same raw material (cryosupernatant 1) also con-
tained detectable levels of impurities (see Table 1; Fig. 4),
but the resistance to thermal denaturation was comparable
to that of the purer lots B1–B3. In order to further unravel
differences between lots, an extensive characterization by
SPR was also performed. In our experimental setting, the
SPR approach would allow to dissect differences deriving
from the Fab and/or the Fc antibody portions, however it
proved generally less sensitive, being able to measure
subtle differences only for the binding to pA and not to the
anti-k-chain K4377 mAb. While confirming that samples
coming from the same set of lots are more homogeneous,
we also noticed that lots A are less comparable in terms of
relative binding to pA in respect to B lots (see the sup-
plementary Fig. S3).
Altogether, our results show that this set of bioanalytical
techniques is useful and complementary to the analytical
tests provided in the European Pharmacopeia for a better
global view of IVIG purity, stability and integrity of full
antibodies, as well as of separate Fc and Fab fragments.
Table 3 KD values for the binding between IgGs and the immobi-
lized anti-k-chain mAb K4377, as obtained by nonlinear regression
analyses of curves reported in Fig. 8a–f
Low
density
Medium
density
High
density
Average SD
A1
KD (nM) 380.9 251.0 232.4 288.1 80.9
A2
KD (nM) 347.1 254.2 203.8 264.4 73.7
A3
KD (nM) 269.4 171.7 170.6 203.9 56.7
B1
KD (nM) 303.2 176.3 159.5 213.0 78.5
B2
KD (nM) 110.3 141.1 158.4 136.6 24.4
B3
KD (nM) 1,149** 185.5 182.3 183.9 23**
SD standard deviation
** This value has not been considered for calculating the average KD,
therefore the corresponding SD is also meaningless, being derived by
only two values
Table 4 Fragment crystallizable function
Limit From
cryosupernatant 1
From Fr II ? III
Lot
A1
Lot
A2
Lot
A3
Lot
B1
Lot
B2
Lot
B3
Fragment
crystallizable (Fc)
function (%)
[60 82 116 90 79 87 85
Limits are defined in accordance with EU pharmacopoeia: the value is
stated in the leaflet accompanying the reference preparation (BRP—
batch 3)
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